

(19) **DANMARK**

(10) **DK/EP 3837263 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 07 D 498/04 (2006.01)** **A 61 K 31/5365 (2006.01)** **A 61 P 25/06 (2006.01)**
A 61 P 25/08 (2006.01) **A 61 P 25/16 (2006.01)** **A 61 P 25/24 (2006.01)**
A 61 P 25/28 (2006.01) **A 61 P 35/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-09-09**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2024-07-03**
- (86) Europæisk ansøgning nr.: **19755855.4**
- (86) Europæisk indleveringsdag: **2019-08-12**
- (87) Den europæiske ansøgnings publiceringsdag: **2021-06-23**
- (86) International ansøgning nr.: **EP2019071520**
- (87) Internationalt publikationsnr.: **WO2020035424**
- (30) Prioritet: **2018-08-13 EP 18188681**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz**
- (72) Opfinder: **BELL, Charles, 86 Bramhall Lane , South Bramhall, Stockport Cheshire SK7 2EA, Storbritannien**
BENZ, Joerg, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
GOBBI, Luca, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
GRETHER, Uwe, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
GROEBKE ZBINDEN, Katrin, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
HORNSPERGER, Benoit, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
KOCER, Buelent, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
KROLL, Carsten, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
KUHN, Bernd, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
LUTZ, Marius Daniel Rinaldo, Friedheimstrasse 15, 8057 Zuerich, Schweiz
O'HARA, Fionn, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
RICHTER, Hans, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
RITTER, Martin, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
ROMBACH, Didier, c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Schweiz
KURATLI, Martin, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Schweiz
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **Nye heterocykliske forbindelser som monoacylglycerollipasehæmmere**
- (56) Fremdragne publikationer:
EP-A1- 3 279 191
**PATEL JAYENDRA Z ET AL: "Loratadine analogues as MAGL inhibitors", BIOORGANIC & MEDICINAL
CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 25, no. 7, 24 February 2015 (2015-02-24), pages**

Fortsættes ...

1436-1442, XP029148590, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.02.037

JAE?WON CHANG ET AL: "Highly Selective Inhibitors of Monoacylglycerol Lipase Bearing a Reactive Group that Is Bioisosteric with Endocannabinoid Substrates", CHEMISTRY & BIOLOGY, vol. 19, no. 5, 1 May 2012 (2012-05-01), pages 579-588, XP055153225, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2012.03.009

PATEL JAYENDRA Z ET AL: "Loratadine analogues as MAGL inhibitors", BIOORGANIC & MEDICINAL

CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 25, no. 7, 24 February 2015 (2015-02-24), pages 1436 - 1442, XP029148590, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.02.037

JAE?WON CHANG ET AL: "Highly Selective Inhibitors of Monoacylglycerol Lipase Bearing a Reactive Group that Is Bioisosteric with Endocannabinoid Substrates", CHEMISTRY & BIOLOGY, vol. 19, no. 5, 1 May 2012 (2012-05-01), pages 579 - 588, XP055153225, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2012.03.009

DESCRIPTION

Description

Field of the Invention

[0001] The present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to monoacylglycerol lipase (MAGL) inhibitors for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine and/or depression in a mammal.

Background of the Invention

[0002] Endocannabinoids (ECs) are signaling lipids that exert their biological actions by interacting with cannabinoid receptors (CBRs), CB1 and CB2. They modulate multiple physiological processes including neuroinflammation, neurodegeneration and tissue regeneration (Iannotti, F.A., et al., Progress in lipid research 2016, 62, 107-28.). In the brain, the main endocannabinoid, 2-arachidonoylglycerol (2-AG), is produced by diacylglycerol lipases (DAGL) and hydrolyzed by the monoacylglycerol lipase, MAGL. MAGL hydrolyses 85% of 2-AG; the remaining 15% being hydrolysed by ABHD6 and ABDH12 (Nomura, D.K., et al., Science 2011, 334, 809.). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes and microglia cells (Chanda, P.K., et al., Molecular pharmacology 2010, 78, 996; Viader, A., et al., Cell reports 2015, 12, 798.). 2-AG hydrolysis results in the formation of arachidonic acid (AA), the precursor of prostaglandins (PGs) and leukotrienes (LTs). Oxidative metabolism of AA is increased in inflamed tissues. There are two principal enzyme pathways of arachidonic acid oxygenation involved in inflammatory processes, the cyclo-oxygenase which produces PGs and the 5-lipoxygenase which produces LTs. Of the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at sites of inflammation, e.g. in the cerebrospinal fluid of patients suffering from neurodegenerative disorders and are believed to contribute to inflammatory response and disease progression. Mice lacking MAGL (Mgll^{-/-}) exhibit dramatically reduced 2-AG hydrolase activity and elevated 2-AG levels in the nervous system while other arachidonoyl-containing phospho- and neutral lipid species including anandamide (AEA), as well as other free fatty acids, are unaltered. Conversely, levels of AA and AA-derived prostaglandins and other eicosanoids, including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly decreased. Phospholipase A₂ (PLA₂) enzymes have been viewed as the principal source of AA, but cPLA₂-deficient mice have unaltered AA levels in their brain, reinforcing the key role of MAGL in the brain for AA production and regulation of the brain inflammatory process.

[0003] Neuroinflammation is a common pathological change characteristic of diseases of the brain including, but not restricted to, neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy and mental disorders such as anxiety and migraine). In the brain, production of eicosanoids and prostaglandins controls the neuroinflammation process. The pro-inflammatory agent lipopolysaccharide (LPS) produces a robust, time-dependent increase in brain eicosanoids that is markedly blunted in Mgll^{-/-} mice. LPS treatment also induces a widespread elevation in pro-inflammatory cytokines including interleukin-1-a (IL-1-a), IL-1b, IL-6, and tumor necrosis factor-a (TNF-a) that is prevented in Mgll^{-/-} mice.

[0004] Neuroinflammation is characterized by the activation of the innate immune cells of the central nervous system, the microglia and the astrocytes. It has been reported that anti-inflammatory drugs can suppress in preclinical models the activation of glia cells and the progression of disease including Alzheimer's disease and multiple sclerosis (Lleo A., *Cell Mol Life Sci.* 2007, 64, 1403.). Importantly, genetic and/or pharmacological disruption of MAGL activity also blocks LPS-induced activation of microglial cells in the brain (Nomura, D.K., et al., *Science* 2011, 334, 809.).

[0005] In addition, genetic and/or pharmacological disruption of MAGL activity was shown to be protective in several animal models of neurodegeneration including, but not restricted to, Alzheimer's disease, Parkinson's disease and multiple sclerosis. For example, an irreversible MAGL inhibitor has been widely used in preclinical models of neuroinflammation and neurodegeneration (Long, J.Z., et al., *Nature chemical biology* 2009, 5, 37.). Systemic injection of such inhibitor recapitulates the *Mgll*^{-/-} mice phenotype in the brain, including an increase in 2-AG levels, a reduction in AA levels and related eicosanoids production, as well as the prevention of cytokines production and microglia activation following LPS-induced neuroinflammation (Nomura, D.K., et al., *Science* 2011, 334, 809.), altogether confirming that MAGL is a druggable target.

[0006] Consecutive to the genetic and/or pharmacological disruption of MAGL activity, the endogenous levels of the MAGL natural substrate in the brain, 2-AG, are increased. 2-AG has been reported to show beneficial effects on pain with, for example, anti-nociceptive effects in mice (Ignatowska-Jankowska B. et al., *J. Pharmacol. Exp. Ther.* 2015, 353, 424.) and on mental disorders, such as depression in chronic stress models (Zhong P. et al., *Neuropsychopharmacology* 2014, 39, 1763.).


[0007] Furthermore, oligodendrocytes (OLs), the myelinating cells of the central nervous system, and their precursors (OPCs) express the cannabinoid receptor 2 (CB2) on their membrane. 2-AG is the endogenous ligand of CB1 and CB2 receptors. It has been reported that both cannabinoids and pharmacological inhibition of MAGL attenuate OLs's and OPCs's vulnerability to excitotoxic insults and therefore may be neuroprotective (Bernal-Chico, A., et al., *Glia* 2015, 63, 163.). Additionally, pharmacological inhibition of MAGL increases the number of myelinating OLs in the brain of mice, suggesting that MAGL inhibition may promote differentiation of OPCs in myelinating OLs in vivo (Alpar, A., et al., *Nature communications* 2014, 5, 4421.). Inhibition of MAGL was also shown to promote remyelination and functional recovery in a mouse model of progressive multiple sclerosis (Feliu A. et al., *Journal of Neuroscience* 2017, 37 (35), 8385.).


[0008] Finally, in recent years, metabolism is talked highly important in cancer research, especially the lipid metabolism. Researchers believe that the de novo fatty acid synthesis plays an important role in tumor development. Many studies illustrated that endocannabinoids have antitumorigenic actions, including anti-proliferation, apoptosis induction and anti-metastatic effects. MAGL as an important decomposing enzyme for both lipid metabolism and the endocannabinoids system, additionally as a part of a gene expression signature, contributes to different aspects of tumourigenesis (Qin, H., et al., *Cell Biochem. Biophys.* 2014, 70, 33; Nomura DK et al., *Cell* 2009, 140(1), 49-61; Nomura DK et al., *Chem. Biol.* 2011, 18(1), 846-856).

[0009] In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.

Summary of the Invention

[0010] In a first aspect, the present invention provides a compound of formula (I)







or a pharmaceutically acceptable salt thereof, wherein wherein A, L, X, m, n, R¹ and R² are as described herein.

[0011] In one aspect, the present invention provides a process of manufacturing the urea compounds of formula (I) described herein, comprising:

reacting a first amine of formula **1**, wherein R¹ is as described herein, preferably wherein R¹ is hydrogen,



with a second amine **2**, wherein A, L, m, n, X and R² are as described herein



in the presence of a base and a urea forming reagent,

to form said compound of formula (I).

[0012] In a further aspect, the present invention provides a compound of formula (I) as described herein, when manufactured according to the processes described herein.

[0013] In a further aspect, the present invention provides a compound of formula (I) as described herein, for use as therapeutically active substance.

[0014] In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

[0015] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

[0016] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0017] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0018] In a further aspect, the present invention provides a compound of formula (I) as described herein or a pharmaceutical composition described herein for use in a method of inhibiting monoacylglycerol lipase in a mammal.

[0019] In a further aspect, the present invention provides a compound of formula (I) as described herein or a pharmaceutical composition described herein for use in the treatment or prophylaxis of neuroinflammation,

neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0020] In a further aspect, the present invention provides a compound of formula (I) as described herein or a pharmaceutical composition described herein, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0021] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein for the preparation of a medicament for inhibiting monoacylglycerol lipase in a mammal.

[0022] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0023] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0024] In a further aspect, the present invention provides a method for inhibiting monoacylglycerol lipase in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein or of a pharmaceutical composition described herein to the mammal.

[0025] In a further aspect, the present invention provides a method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein or of a pharmaceutical composition described herein to the mammal.

[0026] In a further aspect, the present invention provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein or of a pharmaceutical composition described herein to the mammal.

Detailed Description of the Invention

Definitions

[0027] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the

details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

[0028] The term "alkyl" refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In some preferred embodiments, the alkyl group contains 1 to 6 carbon atoms ("C₁₋₆-alkyl"), e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. In other embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, isobutyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. Particularly preferred, yet non-limiting examples of alkyl are methyl and tert-butyl.

[0029] The term "alkoxy" refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some preferred embodiments, the alkoxy group contains 1 to 6 carbon atoms ("C₁₋₆-alkoxy"). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy.

[0030] The term "halogen" or "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I). Preferably, the term "halogen" or "halo" refers to fluoro (F), chloro (Cl) or bromo (Br). Particularly preferred, yet non-limiting examples of "halogen" or "halo" are fluoro (F) and chloro (Cl).

[0031] The term "cycloalkyl" as used herein refers to a saturated or partly unsaturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms. In some preferred embodiments, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. "Bicyclic cycloalkyl" refers to cycloalkyl moieties consisting of two saturated carbocycles having two carbon atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms, and to spirocyclic moieties, i.e., the two rings are connected via one common ring atom. Preferably, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., of 3, 4, 5 or 6 carbon atoms. Some non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0032] The terms "heterocyclyl" and "heterocycloalkyl" are used herein interchangeably and refer to a saturated or partly unsaturated mono- or bicyclic, preferably monocyclic ring system of 3 to 10 ring atoms, preferably 3 to 8 ring atoms, wherein 1, 2, or 3 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Preferably, 1 to 2 of said ring atoms are selected from N and O, the remaining ring atoms being carbon. "Bicyclic heterocyclyl" refers to heterocyclic moieties consisting of two cycles having two ring atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms, and to spirocyclic moieties, i.e., the two rings are connected via one common ring atom. Some non-limiting examples of monocyclic heterocyclyl groups include azetidin-3-yl, azetidin-2-yl, oxetan-3-yl, oxetan-2-yl, 1-piperidyl, 2-piperidyl, 3-piperidyl, 4-piperidyl, 2-oxopyrrolidin-1-yl, 2-oxopyrrolidin-3-yl, 5-oxopyrrolidin-2-yl, 5-oxopyrrolidin-3-yl, 2-oxo-1-piperidyl, 2-oxo-3-piperidyl, 2-oxo-4-piperidyl, 6-oxo-2-piperidyl, 6-oxo-3-piperidyl, morpholino, morpholin-2-yl and morpholin-3-yl.

[0033] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 14 ring members, preferably, 6 to 12 ring members, and more preferably 6 to 10 ring members, and wherein at least one ring in the system is aromatic. Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g. 9H-fluoren-9-yl). A particularly preferred, yet non-limiting example of aryl is phenyl.

[0034] The term "heteroaryl" refers to a mono- or multivalent, monocyclic or bicyclic ring system having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein

at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms. Preferably, "heteroaryl" refers to a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. Most preferably, "heteroaryl" refers to a 5-10 membered heteroaryl comprising 1 to 2 heteroatoms independently selected from O, S and N. Some preferred, yet non-limiting examples of heteroaryl include thiazolyl (e.g. thiazol-2-yl); oxazolyl (e.g. oxazol-2-yl); 5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl; 1,2,4-oxadiazol-5-yl; pyridyl (e.g. 2-pyridyl); pyrazolyl (e.g. pyrazol-1-yl); imidazolyl (e.g. imidazole-1-yl); benzoxazolyl (e.g. benzoxazol-2-yl) and oxazolo[5,4-c]pyridin-2-yl.

[0035] The term "hydroxy" refers to an -OH group.

[0036] The term "cyano" refers to a -CN (nitrile) group.

[0037] The term "haloalkyl" refers to an alkyl group, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a halogen atom, preferably fluoro. Preferably, "haloalkyl" refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms of the alkyl group have been replaced by a halogen atom, most preferably fluoro. Particularly preferred, yet non-limiting examples of haloalkyl are trifluoromethyl (CF₃) and trifluoroethyl (e.g. 2,2,2-trifluoroethyl).

[0038] The term "haloalkoxy" refers to an alkoxy group, wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by a halogen atom, preferably fluoro. Preferably, "haloalkoxy" refers to an alkoxy group wherein 1, 2 or 3 hydrogen atoms of the alkoxy group have been replaced by a halogen atom, most preferably fluoro. A particularly preferred, yet non-limiting example of haloalkoxy is trifluoromethoxy (-OCF₃).

[0039] The term "hydroxyalkyl" refers to an alkyl group, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a hydroxy group. Preferably, "hydroxyalkyl" refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms, most preferably 1 hydrogen atom of the alkyl group have been replaced by a hydroxy group. Preferred, yet non-limiting examples of hydroxyalkyl are hydroxymethyl and hydroxyethyl (e.g. 2-hydroxyethyl). A particularly preferred, yet non-limiting example of hydroxyalkyl is hydroxymethyl.

[0040] The term "haloaryl" refers to an aryl group, wherein at least one of the hydrogen atoms of the aryl group has been replaced by a halogen atom. Preferably, "haloaryl" refers to an aryl group wherein 1, 2 or 3 hydrogen atoms, more preferably 1 or 2 hydrogen atoms, most preferably 1 hydrogen atom of the aryl group have been replaced by a halogen atom. A particularly preferred, yet non-limiting example of haloaryl is chlorophenyl, in particular 4-chlorophenyl.

[0041] The term "aryloxy" refers to an aryl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. A preferred, yet non-limiting example of aryloxy is phenoxy.

[0042] The term "haloaryloxy" refers to a haloaryl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. A preferred, yet non-limiting example of haloaryloxy is 4-fluorophenoxy.

[0043] The term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition these salts may be prepared by addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts

derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like. Particular pharmaceutically acceptable salts of compounds of formula (I) are hydrochloride salts.

[0044] The term "pharmaceutically acceptable ester" refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Representative examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. Examples of pharmaceutically acceptable prodrug types are described in Higuchi and Stella, *Pro-drugs as Novel Delivery Systems*, Vol. 14 of the A.C.S. Symposium Series, and in Roche, ed., *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987.

[0045] The term "protective group" (PG) denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.

[0046] Protective groups can be removed at the appropriate point. Exemplary protective groups are amino-protective groups, carboxy-protective groups or hydroxy-protective groups. Particular protective groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn). Further particular protective groups are the tert-butoxycarbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc). More particular protective group is the tert-butoxycarbonyl (Boc). Exemplary protective groups and their application in organic synthesis are described, for example, in "Protective Groups in Organic Chemistry" by T. W. Greene and P. G. M. Wuts, 5th Ed., 2014, John Wiley & Sons, N.Y.

[0047] The term "urea forming reagent" refers to a chemical compound that is able to render a first amine to a species that will react with a second amine, thereby forming an urea derivative. Non-limiting examples of urea forming reagents include bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole. The urea forming reagents described in G. Sartori et al., *Green Chemistry* 2000, 2, 140 are incorporated herein by reference.

[0048] The compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. In a preferred embodiment, the compound of formula (I) according to the invention is a *cis*-enantiomer of formula (Ia) or (Ib), respectively, as described herein.

[0049] According to the Cahn-Ingold-Prelog Convention, the asymmetric carbon atom can be of the "R" or "S" configuration.

[0050] The abbreviation "MAGL" refers to the enzyme monoacylglycerol lipase. The terms "MAGL" and "monoacylglycerol lipase" are used herein interchangeably.

[0051] The term "treatment" as used herein includes: (1) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (2) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the

outcome may not always be effective treatment.

[0052] The term "prophylaxis" as used herein includes: preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal and especially a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition.

[0053] The term "neuroinflammation" as used herein relates to acute and chronic inflammation of the nervous tissue, which is the main tissue component of the two parts of the nervous system; the brain and spinal cord of the central nervous system (CNS), and the branching peripheral nerves of the peripheral nervous system (PNS). Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. Acute neuroinflammation usually follows injury to the central nervous system immediately, e.g., as a result of traumatic brain injury (TBI).

[0054] The term "traumatic brain injury" ("TBI", also known as "intracranial injury"), relates to damage to the brain resulting from external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile.

[0055] The term "neurodegenerative diseases" relates to diseases that are related to the progressive loss of structure or function of neurons, including death of neurons. Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

[0056] The term "mental disorders" (also called mental illnesses or psychiatric disorders) relates to behavioral or mental patterns that may cause suffering or a poor ability to function in life. Such features may be persistent, relapsing and remitting, or occur as a single episode. Examples of mental disorders include, but are not limited to, anxiety and depression.

[0057] The term "pain" relates to an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Examples of pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain including chemotherapy induced neuropathy, phantom pain and psychogenic pain. A particular example of pain is neuropathic pain, which is caused by damage or disease affecting any part of the nervous system involved in bodily feelings (i.e., the somatosensory system). In one embodiment, "pain" is neuropathic pain resulting from amputation or thoracotomy. In one embodiment, "pain" is chemotherapy induced neuropathy.


[0058] The term "neurotoxicity" relates to toxicity in the nervous system. It occurs when exposure to natural or artificial toxic substances (neurotoxins) alter the normal activity of the nervous system in such a way as to cause damage to nervous tissue. Examples of neurotoxicity include, but are not limited to, neurotoxicity resulting from exposure to substances used in chemotherapy, radiation treatment, drug therapies, drug abuse, and organ transplants, as well as exposure to heavy metals, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances.

[0059] The term "cancer" refers to a disease characterized by the presence of a neoplasm or tumor resulting from abnormal uncontrolled growth of cells (such cells being "cancer cells"). As used herein, the term cancer explicitly includes, but is not limited to, hepatocellular carcinoma, colon carcinogenesis and ovarian cancer.

[0060] The term "mammal" as used herein includes both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines. In a particularly preferred embodiment, the term "mammal" refers to humans.

Compounds of the Invention

[0061] In a first aspect, a compound of formula (I) is provided



or a pharmaceutically acceptable salt thereof,

wherein:

1. (i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from - (CH₂)_p-, -O-, -OCH₂-, -CH₂O-, -CH₂OCH₂-, -CF₂CH₂-, and -CH₂CF₂-; or
2. (ii) X is N; m is 1; n is 1 or 2; and L is -(CH₂)_p- or -CF₂CH₂-;

p is selected from 1, 2 and 3;

A is selected from:

1. (i) aryl substituted with R⁴, R⁵ and R⁶;
2. (ii) heteroaryl substituted with R⁷, R⁸ and R⁹; and
3. (iii) heterocycloalkyl substituted with R¹⁰, R¹¹ and R¹²;

R¹ is hydrogen or C₁₋₆-alkyl;


R² is selected from hydrogen, C₁₋₆-alkyl and hydroxy-C₁₋₆-alkyl;

R³ is selected from hydrogen, halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkyl and halo-C₁₋₆-alkyl;

each of R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² is independently selected from hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, halo-C₁₋₅-alkyl-CH(OH)-, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, SF₅, CH₃SO₂, C₃₋₁₀-cycloalkyl, C₃₋₁₀-cycloalkyl substituted with R¹³, heterocycloalkyl, heterocycloalkyl substituted with R¹⁴, heteroaryl, aryl and haloaryl; and


each of R¹³ and R¹⁴ is independently C₁₋₆-alkyl, halo-C₁₋₆-alkyl or hydroxy.


[0062] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ia):



wherein A, L, X, m, n, R¹ and R² are as defined herein. Preferably, said compound of formula (Ia) has an enantiomeric excess (ee) of >80%, more preferably >90%, in particular >99%.


[0063] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ib):






wherein A, L, X, m, n, R¹ and R² are as defined herein. Preferably, said compound of formula (Ib) has an enantiomeric excess (ee) of >80%, more preferably >90%, in particular >99%.

[0064] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ic):



wherein A, L, X, m, n, R¹ and R² are as defined herein. Preferably, said compound of formula (Ic) has an enantiomeric excess (ee) of >80%, more preferably >90%, in particular >99%.

[0065] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Id):



wherein A, L, X, m, n, R¹ and R² are as defined herein. Preferably, said compound of formula (Id) has an enantiomeric excess (ee) of >80%, more preferably >90%, in particular >99%.

[0066] In one embodiment, there is provided a compound of formula (I) as described herein, wherein when X is C-R³ and R³ is hydroxy or halogen, L is not -O- or -CH₂O-.

[0067] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from -(CH₂)_p-, -O-, -OCH₂-, -CH₂O- and -CH₂OCH₂-; or
2. (ii) X is N; m and n are both 1; and L is -(CH₂)_p-.

[0068] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1; and

L is selected from -(CH₂)_p-, -O-, -OCH₂- and -CH₂O-.

[0069] In another preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

R^3 is selected from hydrogen, C_{1-6} -alkyl and halogen; and

p is 1 or 2.

[0070] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

R^3 is hydrogen; and

p is 1 or 2.

[0071] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2.

[0072] In one embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

1. (i) aryl substituted with R^4 , R^5 and R^6 ; and
2. (ii) heteroaryl substituted with R^7 , R^8 and R^9 .

[0073] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

1. (i) phenyl substituted with R^4 , R^5 and R^6 ; and
2. (ii) oxazolyl substituted with R^7 , R^8 and R^9 .

[0074] In another preferred embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is aryl substituted with R^4 , R^5 and R^6 .

[0075] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as

described herein, or a pharmaceutically acceptable salt thereof, wherein A is phenyl substituted with R⁴, R⁵ and R⁶.

[0076] In one embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) aryl substituted with R⁴, R⁵ and R⁶, and
2. (ii) heteroaryl substituted with R⁷, R⁸ and R⁹;

R⁴

is selected from hydrogen, halogen, halo-C₁₋₆-alkoxy and halo-C₁₋₆-alkyl;

R⁵

is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, heterocycloalkyl, C₃₋₁₀-cycloalkyl, heteroaryl and haloaryl;

R⁶

is hydrogen or halogen;

R⁷

is selected from hydrogen, C₁₋₆-alkyl, aryl and halo-C₁₋₆-alkyl;

R⁸

is hydrogen or C₁₋₆-alkyl; and

R⁹

is hydrogen.

[0077] In a preferred embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) aryl substituted with R⁴, R⁵ and R⁶, and
2. (ii) heteroaryl substituted with R⁷, R⁸ and R⁹;

R⁴

is selected from halogen, halo-C₁₋₆-alkoxy and halo-C₁₋₆-alkyl;

R⁵

is selected from hydrogen, cyano, halogen, heterocycloalkyl, C₃₋₁₀-cycloalkyl and haloaryl;

R⁶

is hydrogen;

R⁷

is C₁₋₆-alkyl;

R⁸

is hydrogen; and

R⁹

is hydrogen.

[0078] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as

described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) phenyl substituted with R⁴, R⁵ and R⁶; and
2. (ii) oxazolyl substituted with R⁷, R⁸ and R⁹;

R⁴

is selected from chloro, OCF₃ and CF₃;

R⁵

is selected from hydrogen, cyano, fluoro, chloro, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R⁶

is hydrogen;

R⁷

is *tert*-butyl;

R⁸

is hydrogen; and

R⁹

is hydrogen.

[0079] In a further particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from phenyl, 4-*tert*-butylthiazol-2-yl, 4-*tert*-butyloxazol-2-yl, 2-chloro-4-fluoro-phenyl, 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 4-chlorophenyl, 5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl, 3-phenyl-1,2,4-oxadiazol-5-yl, 5-(trifluoromethyl)-2-pyridyl, 4-(trifluoromethyl)pyrazol-1-yl, 2-fluoro-4-(trifluoromethyl)phenyl, 2,4-difluorophenyl, 4-chloro-3-fluoro-phenyl, 4-cyanophenyl, 4,4-difluoro-1-piperidyl, 5-*tert*-butyloxazol-2-yl, 4-methoxy-2-fluoro-phenyl, 2-chloro-4-(trifluoromethyl)phenyl, 6-(trifluoromethyl)-3-pyridyl, 3-(trifluoromethyl)phenyl, 2-chloro-4-(trifluoromethoxy)phenyl, 4-chloro-2-fluoro-phenyl, 4-fluoro-2-(trifluoromethyl)phenyl, 2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl, 4-fluoro-2-cyanophenyl, 2-cyclopentyl-4-(trifluoromethyl)phenyl, 2-chloro-4-cyanophenyl, 4-(trifluoromethyl)imidazol-1-yl, 4-fluoro-2-methyl-phenyl, 4-*tert*-butylpyrazol-1-yl, 1,3-benzoxazol-2-yl, 4-chloro-3-(4-chlorophenyl)phenyl, 2-(1H-pyrazol-4-yl)-4-(trifluoromethyl)phenyl, 2,4-dichlorophenyl, 3-methoxy-4-(trifluoromethyl)phenyl, 5-methyl-6-(trifluoromethyl)-3-pyridyl, 3-chlorophenyl, 2-chlorophenyl, 2-cyclopropyl-4-(trifluoromethyl)phenyl, 2-methyl-4-(trifluoromethyl)phenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 2-fluoro-6-(trifluoromethyl)phenyl, 3-chloro-4-(trifluoromethyl)phenyl, 2,4-difluoro-5-(trifluoromethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 2-methoxy-4-(trifluoromethyl)phenyl, 4-chloro-2-(trifluoromethyl)phenyl, 4-chloro-3-(trifluoromethyl)phenyl, 4-chloro-3-cyclopropyl-phenyl, 4-chloro-3-morpholino-phenyl, 2-cyano-4-(trifluoromethyl)phenyl, oxazolo[5,4-c]pyridin-2-yl, 4-Methyl-3-(trifluoromethyl)phenyl, 3-cyclopropyl-4-(trifluoromethyl)phenyl, 2-fluoro-4-methyl-phenyl, 4-methoxy-2-(trifluoromethyl)phenyl, 4-methyl-2-(trifluoromethyl)phenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 5-methyl-6-(trifluoromethyl)-3-pyridyl, 4,5-bis(trifluoromethyl)-2-pyridyl, 2-fluoro-4-(trifluoromethyl)-phenyl, 2-fluoro-4-(pentafluoro-lambda6-sulfanyl)phenyl, 2,4-bis(trifluoromethyl)phenyl, 2-methyl-3-(trifluoromethyl)phenyl, 2-methyl-4-(trifluoromethoxy)phenyl, 3-chloro-4-(trifluoromethyl)phenyl, 3-cyclopropyl-4-chloro-phenyl, 2-chloro-3-(trifluoromethyl)phenyl, 2-chloro-3-cyclopropyl-phenyl, 3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenyl, 2-chloro-3-(2-azaspiro[3.3]heptan-2-yl)-phenyl, 2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 2-fluoro-4-methylphenyl, 2-fluoro-6-(trifluoromethyl)phenyl, and 2-(trifluoromethyl)-4-methyl-phenyl.

[0080] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a

pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen or methyl.

[0081] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.

[0082] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen or C_{1-6} -alkyl.

[0083] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen or methyl.

[0084] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from hydrogen, halogen, C_{1-6} -alkyl and halo- C_{1-6} -alkyl.

[0085] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl.

[0086] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from hydrogen, fluoro and methyl.

[0087] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from hydrogen, methyl, fluoro and trifluoromethyl.

[0088] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from hydrogen, halogen, halo- C_{1-6} -alkoxy and halo- C_{1-6} -alkyl.

[0089] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from halogen, halo- C_{1-6} -alkoxy and halo- C_{1-6} -alkyl.

[0090] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from chloro, OCF_3 and CF_3 .

[0091] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from hydrogen, chloro, fluoro, OCF_3 and CF_3 .

[0092] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, heterocycloalkyl, C_{3-10} -cycloalkyl, heteroaryl and haloaryl.

[0093] In a preferred embodiment, the present invention provides a compound of formula (I) as described

herein, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from hydrogen, cyano, halogen, heterocycloalkyl, C_{3-10} -cycloalkyl and haloaryl.

[0094] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from hydrogen, cyano, fluoro, chloro, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl.

[0095] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from hydrogen, methyl, methoxy, cyano, fluoro, chloro, pyrrolidinyl, morpholinyl, pyrazolyl, cyclopentyl, cyclopropyl and 4-chlorophenyl.

[0096] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydrogen or halogen.

[0097] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydrogen or fluoro.

[0098] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydrogen.

[0099] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^7 is selected from hydrogen, C_{1-6} -alkyl, aryl and halo- C_{1-6} -alkyl.

[0100] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^7 is C_{1-6} -alkyl.

[0101] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^7 is *tert*-butyl.

[0102] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^7 is selected from hydrogen, *tert*-butyl, phenyl and CF_3 .

[0103] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^8 is hydrogen or C_{1-6} -alkyl.

[0104] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^8 is hydrogen or methyl.

[0105] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^8 is hydrogen.

[0106] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^9 is hydrogen.

[0107] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{10} is halogen.

[0108] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{10} is fluoro.

[0109] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{11} is halogen.

[0110] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{11} is fluoro.

[0111] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{10} and R^{11} are both fluoro.

[0112] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{12} is hydrogen.

[0113] In one embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is $C-R^3$; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$, $-CH_2O-$ and $-CH_2OCH_2-$; or
2. (ii) X is N; m and n are both 1; and L is $-(CH_2)_p-$;

p is 1 or 2;

A is selected from:

1. (i) aryl substituted with R^4 , R^5 and R^6 ;
2. (ii) heteroaryl substituted with R^7 , R^8 and R^9 ; and
3. (iii) heterocycloalkyl substituted with R^{10} , R^{11} and R^{12} ;

R^1 is hydrogen or C_{1-6} -alkyl;

R^2 is selected from hydrogen or C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen, C_{1-6} -alkyl and halo- C_{1-6} -alkyl;

R^4 is selected from hydrogen, halogen, halo- C_{1-6} -alkoxy and halo- C_{1-6} -alkyl;

R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, heterocycloalkyl, C_{3-10} -cycloalkyl, heteroaryl and haloaryl;

R^6 is hydrogen or halogen;

R^7 is selected from hydrogen, C_{1-6} -alkyl, aryl and halo- C_{1-6} -alkyl;

R^8 is hydrogen or C_{1-6} -alkyl;

R^9 is hydrogen;

R^{10} is halogen;

R¹¹ is halogen, and

R¹² is hydrogen.

[0114] In a preferred embodiment, the present description provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1;

L is selected from -(CH₂)_p-, -O-, -OCH₂- and -CH₂O-;

p is 1 or 2;

A is selected from:

1. (i) aryl substituted with R⁴, R⁵ and R⁶, and
2. (ii) heteroaryl substituted with R⁷, R⁸ and R⁹;

R¹ is hydrogen;

R² is selected from hydrogen or C₁₋₆-alkyl;

R³ is selected from hydrogen, halogen and C₁₋₆-alkyl;

R⁴ is selected from halogen, halo-C₁₋₆-alkoxy and halo-C₁₋₆-alkyl;

R⁵ is selected from hydrogen, cyano, halogen, heterocycloalkyl, C₃₋₁₀-cycloalkyl and haloaryl;

R⁶ is hydrogen;

R⁷ is C₁₋₆-alkyl;

R⁸ is hydrogen; and

R⁹ is hydrogen.

[0115] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1;

L is selected from -(CH₂)_p-, -O-, -OCH₂- and -CH₂O-;

p is 1 or 2;

A is selected from:

1. (i) phenyl substituted with R^4 , R^5 and R^6 ; and
2. (ii) oxazolyl substituted with R^7 , R^8 and R^9 ;

R^1 is hydrogen;

R^2 is selected from hydrogen or methyl;

R^3 is selected from hydrogen, fluoro and methyl;

R^4 is selected from chloro, OCF_3 and CF_3 ;

R^5 is selected from hydrogen, cyano, fluoro, chloro, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R^6 is hydrogen;

R^7 is *tert*-butyl;

R^8 is hydrogen; and

R^9 is hydrogen.

[0116] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is $C-R^3$; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$, $-CH_2OCH_2-$, $-CF_2CH_2-$, $-CH_2=CH_2-$, $-(CR^{16}R^{17})_q-CH_2O-$, and $-CH_2CF_2-$; or
2. (ii) X is N; m is 1; n is 1 or 2; and L is $-(CH_2)_p-$ or $-CF_2CH_2-$;

p is selected from 1, 2 and 3;

q is 0 or 1;

A is selected from:

1. (i) C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ;
2. (ii) 5- to 14-membered heteroaryl substituted with R^7 , R^8 and R^9 ; and
3. (iii) 3- to 14-membered heterocycloalkyl substituted with R^{10} , R^{11} and R^{12} ;

R^1 is hydrogen or C_{1-6} -alkyl;

R^2 is selected from hydrogen, C_{1-6} -alkyl and hydroxy- C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkyl and halo- C_{1-6} -alkyl;

each of R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently selected from hydrogen, halogen, cyano, hydroxy, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkanoyl, halo- C_{1-5} -alkyl-CH(OH)-, C_{1-6} -alkoxy,

halo-C₁₋₆-alkoxy, SF₅, CH₃SO₂, C₃₋₁₀-cycloalkyl, C₃₋₁₀-cycloalkyl substituted with R¹³, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, C₆-C₁₄-aryl, C₆-C₁₄-aryloxy, halo-C₆-C₁₄-aryl, and halo-C₆-C₁₄-aryloxy;

each of R¹³, R¹⁴, and R¹⁵ is independently selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, halogen, and hydroxy; and

R¹⁶ and R¹⁷, taken together with the carbon atom to which they are attached, form a C₃₋₁₀-cycloalkyl.

[0117] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from - (CH₂)_p-, -O-, -OCH₂-, -CF₂CH₂-, -CH₂=CH₂-, -(CR¹⁶R¹⁷)_q-CH₂O-, and -CH₂OCH₂-; or
2. (ii) X is N; m and n are both 1; and L is -(CH₂)_p-.

[0118] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein p is 2.

[0119] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein q is 0 or 1.

[0120] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein q is 0.

[0121] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

1. (i) C₆-C₁₄-aryl substituted with R⁴, R⁵ and R⁶; and
2. (ii) 5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹.

[0122] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

1. (i) phenyl substituted with R⁴, R⁵ and R⁶;
2. (ii) oxazolyl substituted with R⁷, R⁸ and R⁹; and
3. (iii) pyridyl substituted with R⁷, R⁸ and R⁹.

[0123] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from hydrogen, halogen, hydroxy, cyano, C₁₋₆-alkyl, C₁₋₆-alkanoyl, SF₅, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, 3- to 14-membered heterocyclyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl,

C₆-C₁₄-aryloxy, and halo-C₆-C₁₄-aryl.

[0124] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from halogen, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, and 3-to 14-membered heterocycloalkyl.

[0125] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from chloro, SF₅, methyl, methoxy, OCF₃, CF₃, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl.

[0126] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl, 5- to 14-membered heteroaryl, and halo-C₆-C₁₄-aryl.

[0127] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl and halo-C₆-C₁₄-aryl.

[0128] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, fluoro, chloro, methyl, CF₃, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl.

[0129] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁷ is selected from hydrogen, C₁₋₆-alkyl, C₆-C₁₄-aryl, halo-C₆-C₁₄-aryl, halo-C₆-C₁₄-aryloxy, and halo-C₁₋₆-alkyl.

[0130] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁷ is C₁₋₆-alkyl or halo-C₁₋₆-alkyl.

[0131] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁷ is *tert*-butyl or CF₃.

[0132] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁸ is selected from hydrogen, halogen, C₁₋₆-alkyl, and halo-C₁₋₆-alkyl.

[0133] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁸ is hydrogen or halo-C₁₋₆-alkyl.

[0134] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R⁸ is hydrogen or CF₃.

[0135] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R¹⁴ is selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, and halogen.

[0136] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R^{15} is hydrogen or halogen.

[0137] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is $C-R^3$; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$, $-(CR^{16}R^{17})_q-CH_2O-$, $-CH_2OCH_2-$, $-CF_2CH_2-$, and $-CH_2=CH_2-$; or
2. (ii) X is N; m and n are both 1; and L is $-(CH_2)_p-$;

p is 1 or 2;

q is 0 or 1;

A is selected from:

1. (i) C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ;
2. (ii) 5- to 14-membered heteroaryl substituted with R^7 , R^8 and R^9 ; and
3. (iii) 3- to 14-membered heterocycloalkyl substituted with R^{10} , R^{11} and R^{12} ;

R^1 is hydrogen or C_{1-6} -alkyl;

R^2 is hydrogen or C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen, C_{1-6} -alkyl and halo- C_{1-6} -alkyl;

R^4 is selected from hydrogen, halogen, cyano, SF_5 , C_{1-6} -alkyl, C_{1-6} -alkanoyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R^{14} and R^{15} , 5- to 14-membered heteroaryl, halo- C_6-C_{14} -aryl, and C_6-C_{14} -aryloxy;

R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, C_{1-6} -alkoxy, 3- to 14-membered heterocycloalkyl, C_{3-10} -cycloalkyl, 5- to 14-membered heteroaryl and halo- C_6-C_{14} -aryl;

R^6 is hydrogen or halogen;

R^7 is selected from hydrogen, C_{1-6} -alkyl, C_6-C_{14} -aryl, halo- C_6-C_{14} -aryl, halo- C_6-C_{14} -aryloxy, and halo- C_{1-6} -alkyl;

R^8 is selected from hydrogen, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl;

R^9 is hydrogen;

R^{10} is halogen;

R^{11} is halogen;

R^{12} is hydrogen;

R^{14} is selected from halogen, C_{1-6} -alkyl, and C_{1-6} -alkoxy;

R^{15} is hydrogen or halogen; and

R^{16} and R^{17} , taken together with the carbon atom to which they are attached, form a C_{3-10} -cycloalkyl.

[0138] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

p is 1 or 2;

A is selected from:

1. (i) C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ; and
2. (ii) 5- to 14-membered heteroaryl substituted with R^7 , R^8 and R^9 ;

R^1 is hydrogen;

R^2 is hydrogen or C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl;

R^4 is selected from halogen, SF_5 , C_{1-6} -alkyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, and 3- to 14-membered heterocycloalkyl;

R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, 3- to 14-membered heterocycloalkyl, C_{3-10} -cycloalkyl and halo- C_6-C_{14} -aryl;

R^6 is hydrogen;

R^7 is C_{1-6} -alkyl or halo- C_{1-6} -alkyl;

R^8 is hydrogen or halo- C_{1-6} -alkyl; and

R^9 is hydrogen.

[0139] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

p is 1 or 2;

A is selected from:

1. (i) phenyl substituted with R^4 , R^5 and R^6 ;
2. (ii) oxazolyl substituted with R^7 , R^8 and R^9 ; and
3. (iii) pyridyl substituted with R^7 , R^8 and R^9 ;

R^1 is hydrogen;

R^2 is hydrogen or methyl;

R^3 is selected from hydrogen, fluoro and methyl;

R^4 is selected from chloro, SF_5 , methyl, methoxy, OCF_3 , CF_3 , cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl;

R^5 is selected from hydrogen, cyano, fluoro, chloro, methyl, CF_3 , pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R^6 is hydrogen;

R^7 is selected from tert-butyl, methyl, and CF_3 ;

R^8 is hydrogen or CF_3 ; and

R^9 is hydrogen.

[0140] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$; and

R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl.

[0141] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$; and

R^3 is selected from hydrogen, fluoro and methyl.

[0142] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

1. (i) X is $C-R^3$; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$, $-(CR^{16}R^{17})_q-CH_2O-$, $-CH_2OCH_2-$, $-CF_2CH_2-$, and $-CH_2=CH_2-$; or

2. (ii) X is N; m and n are both 1; and L is $-(CH_2)_p-$;

p is 1 or 2;

q is 0 or 1;

R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl; and

R^{16} and R^{17} , taken together with the carbon atom to which they are attached, form a C_{3-10} -cycloalkyl.

[0143] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

p is 1 or 2; and

R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl.

[0144] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

p is 1 or 2; and

R^3 is selected from hydrogen, fluoro and methyl.

[0145] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ;
2. (ii) 5- to 14-membered heteroaryl substituted with R^7 , R^8 and R^9 ; and
3. (iii) 3- to 14-membered heterocycloalkyl substituted with R^{10} , R^{11} and R^{12} ;

R^4 is selected from hydrogen, halogen, cyano, SF_5 , C_{1-6} -alkyl, C_{1-6} -alkanoyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy,

halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, halo-C₆-C₁₄-aryl, and C₆-C₁₄-aryloxy;

R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl, 5- to 14-membered heteroaryl and halo-C₆-C₁₄-aryl;

R⁶ is hydrogen or halogen;

R⁷ is selected from hydrogen, C₁₋₆-alkyl, C₆-C₁₄-aryl, halo-C₆-C₁₄-aryl, halo-C₆-C₁₄-aryloxy, and halo-C₁₋₆-alkyl;

R⁸ is selected from hydrogen, halogen, C₁₋₆-alkyl, and halo-C₁₋₆-alkyl;

R⁹ is hydrogen;

R¹⁰ is halogen;

R¹¹ is halogen;

R¹² is hydrogen;

R¹⁴ is selected from halogen, C₁₋₆-alkyl, and C₁₋₆-alkoxy; and

R¹⁵ is hydrogen or halogen.

[0146] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) C₆-C₁₄-aryl substituted with R⁴, R⁵ and R⁶; and
2. (ii) 5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹;

R⁴ is selected from halogen, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, and 3- to 14-membered heterocycloalkyl;

R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl and halo-C₆-C₁₄-aryl;

R⁶ is hydrogen;

R⁷ is C₁₋₆-alkyl or halo-C₁₋₆-alkyl;

R⁸ is hydrogen or halo-C₁₋₆-alkyl; and

R⁹ is hydrogen.

[0147] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

1. (i) phenyl substituted with R^4 , R^5 and R^6 ;
2. (ii) oxazolyl substituted with R^7 , R^8 and R^9 ; and
3. (iii) pyridyl substituted with R^7 , R^8 and R^9 ;

R^4 is selected from chloro, SF_5 , methyl, methoxy, OCF_3 , CF_3 , cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl;

R^5 is selected from hydrogen, cyano, fluoro, chloro, methyl, CF_3 , pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R^6 is hydrogen;

R^7 is tert-butyl, methyl, and CF_3 ;

R^8 is hydrogen or CF_3 ; and

R^9 is hydrogen.

[0148] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-H;

m and n are both 0;

L is $-CH_2O-$;

A is C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ;

R^1 , R^2 , and R^6 are all hydrogen;

R^4 is halo- C_{1-6} -alkyl; and

R^5 is halogen or C_{1-6} -alkyl.

[0149] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-H;

m and n are both 0;

L is $-CH_2O-$;

A is C_6-C_{14} -aryl substituted with R^4 , R^5 and R^6 ;

R^1 , R^2 , and R^6 are all hydrogen;

R⁴ is halo-C₁₋₆-alkyl; and

R⁵ is halogen.

[0150] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-H;

m and n are both 0;

L is -CH₂O-;

A is phenyl substituted with R⁴, R⁵ and R⁶;

R¹, R², and R⁶ are all hydrogen;

R⁴ is CF₃; and

R⁵ is fluoro or methyl.

[0151] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

X is C-H;

m and n are both 0;

L is -CH₂O-;

A is phenyl substituted with R⁴, R⁵ and R⁶;

R¹, R², and R⁶ are all hydrogen;

R⁴ is CF₃; and

R⁵ is fluoro.

[0152] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, selected from the compounds disclosed in Table 1.

[0153] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, selected from:

(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4',6'-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1-carbonyl)hexahydro-2H-

pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR, 8aS)-6-[3-((2,4-Dichlorophenyl)methoxy) azetidine-1-carbonyl]-4,4a, 5,7, 8, 8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR, 8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3 (4H)-one;

(4aR, 8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR, 8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-16-sulfaneyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; and

(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one.

[0154] In one embodiment, the present invention provides pharmaceutically acceptable salts or esters of the compounds of formula (I) as described herein. In a particular embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein, especially hydrochloride salts. In a further particular embodiment, the present invention provides pharmaceutically acceptable esters of the compounds according to formula (I) as described herein. In yet a further particular embodiment, the present invention provides compounds according to formula (I) as described herein.

[0155] In some embodiments, the compounds of formula (I) are isotopically-labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number. Such isotopically-labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of this disclosure. Examples of isotopes that can be incorporated into the compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but not limited to, ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I , and ^{125}I , respectively. Certain isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ^3H , and carbon-14, i.e., ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. For example, a compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99 percent of a given isotope.

[0156] Substitution with heavier isotopes such as deuterium, i.e. ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.

[0157] Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the nonlabeled reagent previously employed.

Processes of Manufacturing

[0158] The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those persons skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein, unless indicated to the contrary.

[0159] If one of the starting materials, intermediates or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protective groups (as described e.g., in "Protective Groups in Organic Chemistry" by T. W. Greene and P. G. M. Wuts, 5th Ed., 2014, John Wiley & Sons, N.Y.) can be introduced before the critical step applying methods well known in the art. Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature.

[0160] If starting materials or intermediates contain stereogenic centers, compounds of formula (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes

by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates. Using such diastereomerically/enantiomerically enriched starting materials and intermediates in the synthesis of compounds of formula (I) will typically lead to the respective diastereomerically/enantiomerically enriched compounds of formula (I).

[0161] A person skilled in the art will acknowledge that in the synthesis of compounds of formula (I) - insofar not desired otherwise - an "orthogonal protection group strategy" will be applied, allowing the cleavage of several protective groups one at a time each without affecting other protective groups in the molecule. The principle of orthogonal protection is well known in the art and has also been described in literature (e.g. Barany and R. B. Merrifield, J. Am. Chem. Soc. 1977, 99, 7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl. 1996, 35, 2056).

[0162] A person skilled in the art will acknowledge that the sequence of reactions may be varied depending on reactivity and nature of the intermediates.

[0163] In more detail, the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Also, for reaction conditions described in literature affecting the described reactions see for example:

Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999). It was found convenient to carry out the reactions in the presence or absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The described reactions can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and compounds. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered.

[0164] If starting materials or intermediates are not commercially available or their synthesis not described in literature, they can be prepared in analogy to existing procedures for close analogues or as outlined in the experimental section.

[0165] The following abbreviations are used in the present text:

AcOH = acetic acid, ACN = acetonitrile, Bn = benzyl, Boc = tert-butyloxycarbonyl, CAS RN = chemical abstracts registration number, Cbz = benzyloxycarbonyl, Cs₂CO₃ = cesium carbonate,

CO = carbon monoxide, CuCl = copper(I) chloride, CuCN = copper(I) cyanide, CuI = copper(I) iodide, DAST = (diethylamino)sulfur trifluoride, DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene,

DCM = dichloromethane, DEAD = diethyl azodicarboxylate, DIAD = diisopropyl azodicarboxylate, DMAP = 4-dimethylaminopyridine, DME = dimethoxyethane, DMEDA = N,N'-dimethylethylenediamine, DMF = N,N-dimethylformamide, DIPEA = N,N-diisopropylethylamine, dppf = 1,1 bis(diphenyl phosphino)ferrocene, EDC.HCl = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, EI = electron impact, ESI = electrospray ionization, EtOAc = ethyl acetate, EtOH = ethanol, h = hour(s), FA = formic acid,


H₂O = water, H₂SO₄ = sulfuric acid, HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HBTU = O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-

phosphate, HCl = hydrogen chloride, HOBT = 1-hydroxy-1H-benzotriazole; HPLC = high performance liquid chromatography, iPrMgCl = isopropylmagnesium chloride, I₂ = iodine, IPA = 2-propanol, ISP = ion spray positive (mode),

ISN = ion spray negative (mode), K₂CO₃ = potassium carbonate, KHCO₃ = potassium bicarbonate, KI = potassium iodide, KOH = potassium hydroxide, K₃PO₄ = potassium phosphate tribasic, LiAlH₄ or LAH = lithium aluminium hydride, LiHMDS = lithium bis(trimethylsilyl)amide, LiOH = lithium hydroxide, MgSO₄ = magnesium sulfate, min = minute(s), mL = milliliter, MPLC = medium pressure liquid chromatography, MS = mass spectrum, nBuLi = n-butyllithium, NaBH₃CN = sodium cyanoborohydride, NaH = sodium hydride, NaHCO₃ = sodium hydrogen carbonate, NaNO₂ = sodium nitrite, NaBH(OAc)₃ = sodium triacetoxyborohydride, NaOH = sodium hydroxide, Na₂CO₃ = sodium carbonate,

Na₂SO₄ = sodium sulfate, Na₂S₂O₃ = sodium thiosulfate, NBS = N-bromosuccinimide, nBuLi = n-butyllithium, NEt₃ = triethylamine (TEA), NH₄Cl = ammonium chloride, NMP = N-methyl-2-pyrrolidone, OAc = Acetoxy, T₃P = propylphosphonic anhydride, PE = petroleum ether, PG = protective group, Pd-C = palladium on activated carbon, PdCl₂(dppf)-CH₂Cl₂ = 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex, Pd₂(dba)₃ = tris(dibenzylideneacetone)dipalladium(0), Pd(OAc)₂ = palladium(II) acetate, Pd(OH)₂ = palladium hydroxide, Pd(PPh₃)₄ = tetrakis(triphenylphosphine)palladium(0), PTSA = p-toluenesulfonic acid, R = any group, RT = room temperature, SFC = Supercritical Fluid Chromatography, S-PHOS = 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, TBAI = tetra butyl ammonium iodide, TEA = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, TMEDA = N,N,N',N'-tetramethylethylenediamine, ZnCl₂ = zinc chloride, Hal = halogen.


[0166] Compounds of formula I wherein A, L, X, m, n, R¹ and R² are as described herein can be synthesized in analogy to literature procedures and/or as depicted for example in [Scheme 1](#).



[Scheme 1](#)

[0167] Accordingly, 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-ones **1** are reacted with intermediates **2** in the presence of a urea forming reagent, such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM, to give compounds of formula I ([step a](#)). Further urea forming reagents include but are not limited to phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate or 1,1'-carbonyldiimidazole. Reactions of this type and the use of these reagents are widely described in literature (e.g. G. Sartori et al., Green Chemistry 2000, 2, 140). A person skilled in the art will acknowledge that the order of the addition of the reagents can be important in this type of reactions due to the reactivity and stability of the intermediary formed carbamoyl chlorides, as well as for avoiding formation of undesired symmetrical urea by-products.

[0168] Intermediates **1** may be synthesized as depicted for example in Scheme 2 and/or in analogy to methods described in literature.



3

5

6

1


Scheme 2

[0169] Thus, 3-aminopiperidin-4-ol derivatives **3** in which "PG" signifies a suitable protective group such as a Cbz or Boc protective group can be acylated for example with acyl chlorides **4** in which R^1 is as defined herein and "LG" signifies a suitable leaving group (e.g., Cl or Br), using a suitable base such as sodium or potassium carbonate, sodium hydroxide or sodium acetate in an appropriate solvent such as THF, water, acetone or mixtures thereof, to provide intermediates **5** (step a). Intermediates **4** are either commercially available or can be prepared according to literature methods in achiral ($R^1 = H$), racemic (R^1 not H) or enantiomerically pure form (R^1 not H).

[0170] Intermediates **5** can be cyclized to intermediates **6** using methods well known in the art, for example by treatment of **5** with sodium hydride in THF or potassium tert-butoxide in IPA and water (step b). Reactions of that type are described in literature (e.g. Z. Rafinski et al., J. Org. Chem. 2015, 80, 7468; S. Dugar et al., Synthesis 2015, 47(5), 712; WO2005/066187).


[0171] Removal of the protective group in intermediates **6**, applying methods known in the art (e.g., a Boc group using TFA in DCM at temperatures between 0°C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)₂ on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates **1** (step c).

[0172] Intermediates **1** can be obtained as mixtures of diastereomers and enantiomers, respectively, or as single stereoisomers depending on whether racemic mixtures or enantiomerically pure forms of cis- or trans-3-aminopiperidin-4-ol derivatives **3** or intermediates **4** are employed in their syntheses. Intermediates **3** are commercially available and their synthesis has also been described in literature (e.g. WO2005/066187; WO2011/0059118; WO2016/185279). Optically pure cis-configured intermediates **1B** and **1C** can be obtained for example according to Scheme 3 by chiral separation of commercially available rac-(4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (**1A**) (optionally in form of a salt such as, e.g. a hydrochloride salt) using methods known in the art, e.g. by diastereomeric salt crystallization or by chiral chromatography (step a).



Scheme 3

[0173] In some embodiments, intermediates **2** are intermediates of type **B**. Intermediates of type **B** in which A, m, n and R^2 are as described herein can be prepared by methods well known by a person skilled in the art and as exemplified by the general synthetic procedures outlined in Scheme 4.



Scheme 4

[0174] Ketones **7**, either commercially available or prepared by methods known in the art, can be subjected for example to a Wittig reaction with alkylidene triphenylphosphoranes of type **8a** in a suitable solvent such as, e.g. THF, Methyl-THF or DMSO to give intermediates **9** (step a). Phosphoranes **8a** can be formed by treating the corresponding phosphonium salts with a suitable base such as BuLi, NaH, or KOtBu in a suitable solvent such as THF, dioxane or Methyl-THF and may be isolated or used *in situ*. Phosphonium salts in turn are readily available from an aryl/heteroaryl/heterocyclic-substituted alkylhalide (with halide being Cl, Br and iodo) and triphenylphosphine in a suitable solvent such as toluene. Heating may be applied to accelerate the reaction or drive the reaction to completion (e.g. H. J. Cristau, F. Plénat in PATAI'S Chemistry of Functional Groups, Editor(s): Frank R. Hartley, 07th August 2006, Series Editor(s): Prof. Saul Patai).


[0175] Alternatively, intermediates **9** can be obtained using a Horner-Wadsworth-Emmons (HWE) reaction using ketones **7** and phosphonates **8b**, wherein R^a is alkyl, for example methyl or ethyl. Phosphonates **8b** are *in situ* α -metalated using a suitable base and solvent such as NaH, nBuLi or KOtBu in THF (step a). Phosphonates **8b** are readily prepared using for example the Arbuzov reaction by alkylation of an aryl/heteroaryl/heterocyclic halide (with halide being Cl, Br and iodo) with commercially available trialkyl phosphite (e.g. Chem. Rev. 1984, 84, 577).

[0176] Olefination reactions of both types are broadly described in literature (e.g. Current Org. Chem. 2015, 19(9), page 744; Chem. Rev. 1989, 89(4), 863; Org. React. 1977, 25, 73; Liebigs Ann./Recueil 1997, 1283; Acc. Chem. Res. 1983, 16, 411).

[0177] Reduction of the double bond in intermediates **9** using, e.g. hydrogen in the presence of a suitable catalyst such as palladium on charcoal in an appropriate solvent or solvent mixture such as EtOAc, MeOH or AcOH yields compounds **10** (step b).

[0178] Removal of the protective group from intermediates **10** applying methods known in the art (e.g., a Boc group using TFA in DCM or 4M HCl in dioxane at temperatures between 0°C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)₂ on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates **B** (step c).

[0179] In some embodiments, intermediates **2** are intermediates of type **C**. Intermediates of type **C** in which A, R^2 and p are as described herein, $r = 0, 1$ or 2 and $(m+n) = 2$ or 3 can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 5.




Scheme 5

[0180] Alkylation of optionally mono-protected piperazine or 1,4-diazepane derivatives **11a,b** (commercially available or synthesized in analogy to literature methods) with aryl/heteroaryl/heterocyclyl-substituted alkyl derivatives **12**, either commercially available or synthesized according to literature procedures and in which LG signifies a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. mesylate (methanesulfonate), OSO₂fluoroalkyl (e.g. triflate (trifluoromethanesulfonate) or OSO₂aryl (e.g. tosylate (p-toluenesulfonate) using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0°C and the boiling temperature of the solvent, gives intermediates **14a,b** ([step a](#)).

[0181] Alternatively, compounds **11a,b** can be subjected to a reductive amination reaction with aldehydes of type **13** using a suitable reducing agent and solvent such as NaBH₃CN in MeOH, AcOH or mixtures thereof to give intermediates **14a,b** ([step a](#)).

[0182] Removal of the protective group from intermediates **14b** applying methods known in the art (e.g., a Boc group using TFA in DCM or 4M HCl in dioxane at temperatures between 0°C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)₂ on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates **C** ([step c](#)).

[0183] In some embodiments, compounds of formula **I** are compounds of type **Ie**. Compounds **Ie** in which A, p, R¹ and R² are defined as herein and (m+n) = 2 or 3 can be prepared in analogy to literature procedures or the methods described under Scheme 6 below.



[Scheme 6](#)

[0184] Compounds **1** can be coupled with piperazine or 1,4-diazepane derivatives **11a** applying for example the conditions outlined under Scheme 1, step a, to give intermediates **15** ([step a](#)).


[0185] Intermediates **15** can be converted to compounds **IC** in analogy to the procedure described under Scheme 5, step a ([step b](#)).

[0186] Alternatively, compounds **1** can be coupled with mono-protected piperazine or 1,4-diazepane derivatives **11b** in which PG signifies a suitable protective group such as a Cbz or Boc protective group applying for example the conditions outlined under Scheme 1, step a, to give intermediates **16** ([step c](#)).

[0187] Removal of the protective group by published methods or as described under Scheme 5, step c, furnishes intermediates **15** ([step d](#)).

[0188] In some embodiments, intermediates **2** are intermediates of type **D**. Intermediates of type **D** in which A, m, n and R² are as described herein and R³ is selected from hydrogen, halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl and

halo-C₁₋₆-alkyl, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 7](#).



[Scheme 7](#)


[0189] Alcohols of type **17** can be subjected to a Mitsunobu reaction with intermediates **18** in which PG is a suitable protective group such as a Cbz, Boc or Bn, using an appropriate phosphine such as triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or DIAD in a suitable solvent such as THF to give intermediates **19** ([step a](#)). Mitsunobu reactions of that type are broadly described in literature (e.g. *Org. Chem. Front.* 2015, 2, 739; *Chem. Rev.* 2009, 109 (6), 2551).

[0190] Removal of the protective group from intermediates **19** applying literature methods and as described for example under [Scheme 3](#), step c, furnishes intermediates **D** ([step b](#)).

[0191] Alternatively, intermediates **19** may be prepared from alcohols **17** that can be alkylated with compounds **20** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0°C and the boiling temperature of the solvent ([step c](#)).

[0192] Furthermore, intermediates **19** may be synthesized via alkylation of alcohols of type **18** with compounds **21** under the conditions described under [step c](#) ([step d](#)).

[0193] In another embodiment, intermediates **2** are intermediates of type **E**. Intermediates of type **E** in which A, m, n, R² and R³ are as described herein, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 8](#). In case R³ is a hydroxy group a suitable protective group strategy known to those skilled in the art may be applied.



Scheme 8

[0194] The carboxylic acid functionality in derivatives **22** in which PG signifies a suitable protecting group such as, e.g. a Boc, Cbz or Bn protecting group, either commercially available or prepared by methods known in the art, can be converted into an acid chloride (LG = Cl) or Weinreb amide (LG = NMeOMe) by applying methods broadly described in literature to give intermediates **23** (step a).

[0195] Intermediates **23** can be reacted with compounds of type **24**, either commercially available or synthesized by methods known in the art and as described below to yield intermediates **25** (step b).


[0196] If compounds **24** are commercially not available they can be prepared in analogy to literature methods. For example, deprotonation of a reactive methyl group in optionally substituted heterocycles **27** using an appropriate base such nBuLi or LiHMDS in a suitable solvent, e.g. THF, hexane or mixtures thereof, at temperatures ranging from -78°C to room temperature, gives intermediates **24** in which MX = Li (step d).

[0197] Compounds **24** in which MX = MgHal with Hal being Cl, Br or I (Grignard reagents) may be prepared by reaction of the corresponding substituted benzyl halides **28** with magnesium in a suitable solvent such as THF, optionally in the presence of catalytic amounts of iodine at temperatures ranging from 0°C to the boiling point of the solvent (step d).

[0198] Compounds **25** can be further converted into compounds **26** by a deoxyfluorination reaction using a suitable fluorinating agent such as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminosulfur trifluoride) or aminodifluorosulfonium tetrafluoroborates (XtalFluor-E[®], XtalFluor-M[®] in the presence of, e.g. triethylamine trihydrofluoride and TEA or DBU) in a suitable solvent such as DCM or ACN (step d).

[0199] Removal of the protective group from intermediates **26** applying literature methods and as described for example under Scheme 3, step c, furnishes intermediates **E** (step e).

[0200] In a further embodiment, intermediates **2** are intermediates of type **F**. Intermediates **F** in which A, m, n, R² and R³ are as described herein, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 9. In case R³ is a hydroxy group a suitable protective group strategy known to those skilled in the art may be applied.



Scheme 9

[0201] The carboxylic acid functionality in intermediates **29**, either commercially available or prepared by methods known in the art, in which PG signifies a suitable protecting group such as, e.g. a Boc, Cbz or Bn

protecting group, can be converted for example into an acid chloride (LG = Cl) or Weinreb amide (LG = NMeOMe) by applying methods broadly described in literature to give intermediates **30** ([step a](#)).

[0202] Intermediates **30** can be reacted with compounds of type **31**, either commercially available or synthesized by methods known in the art and as described below to yield intermediates **32** ([step b](#)).


[0203] In case compounds **31** are commercially not available they can be prepared in analogy to literature methods. For example, deprotonation of optionally substituted aryl or heteroaryl rings **33** using an appropriate base such as *n*-BuLi, *sec*-BuLi, *tert*-BuLi, LiHMDS, NaH, KH in a suitable solvent, such as THF, *n*-hexane or mixtures thereof, at temperatures ranging from -78°C to room temperature, gives intermediates **31** in which, depending on the base used, MX = Li, Na or K ([step c](#)).

[0204] Compounds **31** in which MX = MgHal with Hal being Cl, Br or I (Grignard reagents) may be prepared by reaction of the corresponding optionally substituted aryl or heteroaryl halides **34** via direct insertion of magnesium (e.g. magnesium turnings optionally in the presence of catalytic amounts of iodine, powder in the presence of LiCl or Rieke magnesium, organic halides) or by halogen-magnesium exchange by treating **34** in which Hal is preferably bromine or iodine, with an alkylmagnesium halide such as *i*PrMgCl (optionally in the presence of LiCl) in suitable solvents such as diethyl ether or THF at temperatures ranging from 0°C to the boiling point of the solvent ([step d](#)).

[0205] Compounds **32** can be further converted into compounds **35** by a deoxyfluorination reaction using a suitable fluorinating agent such as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminosulfur trifluoride) or aminodifluorosulfonium tetrafluoroborates (XtalFluor-E[®], XtalFluor-M[®] in the presence of, e.g. triethylamine trihydrofluoride and TEA or DBU) in a suitable solvent such as DCM or ACN ([step e](#)).

[0206] Removal of the protective group from intermediates **35** applying literature methods and as described for example under Scheme 3, step c, furnishes intermediates **F** ([step f](#)).

[0207] In some embodiments, intermediates **2** are intermediates of type **G**. Intermediates of type **G** in which A, m, n, R² are as described herein and R³ is hydrogen, C₁₋₆-alkoxy, C₁₋₆-alkyl and halo-C₁₋₆-alkyl, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 10](#).




[Scheme 10](#)

[0208] Intermediates **38** may be prepared from alcohols **36** in which PG is a suitable protective group such as a Cbz, Boc or Bn, that can be alkylated with compounds **37** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. *p*-toluenesulfonate) using a suitable base, such as sodium hydride, potassium *tert*-butoxide, in an appropriate solvent (e.g. in DMF or THF) at temperatures between 0°C and the boiling temperature of the solvent ([step a](#)).

[0209] Removal of the protective group from intermediates **38** applying literature methods and as described for example under Scheme 4, step c, furnishes intermediates **G** ([step b](#)).

[0210] In some embodiments, intermediates **2** are intermediates of type **H**. Intermediates of type **H** in which A, m, n, R² and R³ are as described herein, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 11](#).




[Scheme 11](#)

[0211] Alcohols of type **17** can be subjected to a Mitsunobu reaction with intermediates **39** in which PG is a suitable protective group such as a Cbz, Boc or Bn, using an appropriate phosphine such as triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or DIAD in a suitable solvent such as THF to give intermediates **41** ([step a](#)). Mitsunobu reactions of that type are broadly described in literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109 (6), 2551).


[0212] Removal of the protective group from intermediates **41** applying literature methods and as described for example under Scheme 4, step c, furnishes intermediates **H** ([step b](#)).


[0213] Alternatively, intermediates **41** may be prepared from alcohols **17** that can be alkylated with compounds **40** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base such as Cs₂CO₃, NaH, in an appropriate solvent, such as DMF at temperatures between 0°C and the boiling temperature of the solvent ([step c](#)).

[0214] Reacting intermediates **H** with intermediates **1**, for example using the conditions described under scheme 1, step a, affords compounds of type **If**, wherein A, R¹, R², R³, m and n are as defined herein.



[0215] Alternatively, compounds of type **If** may be prepared according to [Scheme 12](#).






Scheme 12

[0216] Alcohols of type **17** can be subjected to a Mitsunobu reaction with intermediates **42**, using an appropriate phosphine such as triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or DIAD in a suitable solvent such as THF to give compounds **ID** ([step a](#)). Mitsunobu reactions of that type are broadly described in literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109 (6), 2551).

[0217] Alternatively, compounds **ID** may be directly prepared from alcohols **17** that can be alkylated with compounds **43** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base such as Cs₂CO₃, NaH, in an appropriate solvent, such as DMF at temperatures between 0°C and the boiling temperature of the solvent ([step b](#)).

[0218] In some embodiments, intermediates **2** are intermediates of type **J**. Intermediates of type **J** in which A, m, n, R² and R³ are as described herein, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 13](#).




Scheme 13


[0219] Intermediates **46** may be prepared from heterocycloalkyls or heteroaryls **45** that can be alkylated with compounds **44** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base such as Cs₂CO₃, K₂CO₃, NaH, in an appropriate solvent, such as DMF at temperatures between 0°C and the boiling temperature of the solvent ([step a](#)).


[0220] Removal of the protective group from intermediates **46** applying literature methods and as described for example under Scheme 4, step c, furnishes intermediates **J** ([step b](#)).

[0221] Reacting intermediates **J** with intermediates **1** affords compounds of type **Ig**, wherein A, R¹, R², R³, m and n are as defined herein.




[0222] Alternatively, compounds of type **Ig** may be directly prepared from from heterocycloalkyls or heteroaryls **45** that can be alkylated with compounds **47** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base such as Cs₂CO₃, K₂CO₃, NaH, in an appropriate solvent, such as DMF at temperatures between 0°C and the boiling temperature of the solvent ([Scheme 14](#)).





Scheme 14

[0223] In some embodiments, intermediates **2** are intermediates of type **K**. Intermediates of type **K** in which A, m, n, R² and R³ are as described herein, can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in [Scheme 15](#).




Scheme 15

[0224] Alcohols of type **48** can be subjected to a Mitsunobu reaction with intermediates **39** in which PG is a suitable protective group such as a Cbz, Boc or Bn, using an appropriate phosphine such as triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or DIAD in a suitable solvent such as THF to give intermediates **49** ([step a](#)). Mitsunobu reactions of that type are broadly described in literature (e.g. *Org. Chem. Front.* **2015**, 2, 739; *Chem. Rev.* **2009**, 109 (6), 2551).

[0225] Removal of the protective group from intermediates **49** applying literature methods and as described for example under Scheme 4, step c, furnishes intermediates **K** ([step b](#)).

[0226] Alternatively, intermediates **49** may be prepared from alcohols **48** that can be alkylated with compounds **40** in which LG is a suitable leaving group such as chlorine, bromine, iodine, OSO₂alkyl (e.g. methanesulfonate), OSO₂fluoroalkyl (e.g. trifluoromethanesulfonate) or OSO₂aryl (e.g. p-toluenesulfonate) using a suitable base such as Cs₂CO₃, NaH, in an appropriate solvent, such as DMF at temperatures between 0°C and the boiling temperature of the solvent ([step c](#)).

[0227] In some embodiments, intermediates **2** are intermediates of type **L**. Intermediates of type **L** in which A, m, n, R² and R³ are as described herein can be prepared by methods well known by a person skilled in the art and as exemplified by the general synthetic procedures outlined in [Scheme 16](#).



Scheme 16

[0228] Intermediates **51** can be prepared for example from aldehydes **50**, either commercially available or prepared by methods known in the art, using a Wittig reaction or Horner-Wadsworth-Emmons (HWE) reaction using alkylidene triphenylphosphoranes of type **8a** and phosphonates **8b**, respectively, as described under step a in Scheme 4 (step a).


[0229] Reduction of the double bond in intermediates **51** applying the conditions described under step b in Scheme 4 yields compounds **52** (step b).

[0230] Removal of the protective group from intermediates **52** applying methods known in the art and as outlined under step c in Scheme 4 furnishes intermediates **L** (step c).


[0231] Removal of the protective group from intermediates **51** applying methods known in the art and as outlined under step c in Scheme 4 furnishes intermediates **M** (step d).

[0232] In one aspect, the present invention provides a process of manufacturing the urea compounds of formula (I) described herein, comprising:

reacting a first amine of formula **1**, wherein R^1 is as described herein, preferably wherein R^1 is hydrogen,



with a second amine **2**, wherein A, L, m, n, X and R^2 are as described herein



in the presence of a base and a urea forming reagent,

to form said compound of formula (I).

[0233] In one embodiment, there is provided a process according to the invention, wherein said base is sodium bicarbonate.

[0234] In one embodiment, there is provided a process according to the invention, wherein said urea forming reagent is selected from bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole, preferably wherein said urea forming reagent is bis(trichloromethyl) carbonate.

[0235] In one aspect, the present invention provides a compound of formula (I) as described herein, when manufactured according to any one of the processes described herein.

MAGL Inhibitory Activity

[0236] Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of formula (I) as described herein for inhibiting MAGL in a mammal.

[0237] In a further aspect, the present invention provides compounds of formula (I) as described herein for use in a method of inhibiting MAGL in a mammal.

[0238] In a further aspect, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for inhibiting MAGL in a mammal.

[0239] In a further aspect, the present invention provides a method for inhibiting MAGL in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0240] Compounds were profiled for MAGL inhibitory activity by measuring the enzymatic activity of MAGL by following the hydrolysis of 4-nitrophenylacetate resulting in 4-nitrophenol, which absorbs at 405-412 nm (G.G. Muccioli, G. Labar, D.M. Lambert, Chem. Bio. Chem. 2008, 9, 2704-2710). This assay is hereinafter abbreviated "4-NPA assay".

[0241] The 4-NPA assay was carried out in 384 well assay plates (black with clear bottom, non-binding surface treated, Corning Ref. 3655) in a total volume of 40 μ L. Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 25 μ M to 1.7 nM. 1 μ L compound dilutions (100% DMSO) were added to 19 μ L MAGL (recombinant wild-type) in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100ml)). The plate was shaken for 1 min at 2000 rpm (Variomag Teleshake) and then incubated for 15 min at RT. To start the reaction, 20 μ L 4-Nitrophenylacetate (Sigma N-8130) in assay buffer with 6% EtOH was added. The final concentrations in the assay were 1 nM MAGL and 300 μ M 4-Nitrophenylacetate. After shaking (1 min, 2000 rpm) and 5 min incubation at RT, the absorbance at 405 nm was measured for a first time (Molecular Devices, SpectraMax Paradigm). A second measurement was then done after incubation for 80 min at RT. From the two measurements, the slope was calculated by subtracting the first from the second measurement.

[0242] Alternatively, compounds were profiled for MAGL inhibitory activity by determining the enzymatic activity by following the hydrolysis of the natural substrate 2-arachidonoylglycerol resulting in arachidonic acid, which can be followed by mass spectrometry. This assay is hereinafter abbreviated "2-AG assay".

[0243] The 2-AG assay was carried out in 384 well assay plates (PP, Greiner Cat# 784201) in a total volume of 20 μ L. Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 μ M to 0.8 pM. 0.25 μ L compound dilutions (100% DMSO) were added to 9 μ L MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100ml), 0.01% (v/v) Tween. After shaking, the plate was incubated for 15 min at RT. To start the reaction, 10 μ L 2-arachidonoylglycerol in assay buffer was added. The final concentrations in the assay was 50 pM MAGL and 8 μ M 2-arachidonoylglycerol. After shaking and 30 min incubation at RT, the reaction was quenched by the addition of 40 μ L of acetonitrile containing 4 μ M of d8-arachidonic acid. The amount of arachidonic acid was traced by an online SPE system (Agilent Rapidfire) coupled to a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE cartridge (G9205A) was used in an acetonitrile/water liquid setup. The mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1 $\rightarrow$ 259.1 for arachidonic acid and 311.1 $\rightarrow$ 267.0 for d8-arachidonic acid. The activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid].

Table 1

Ex.	IC ₅₀ MAGL [μ M] ^[a]
1	0.040
2	0.046
3	0.066
4	0.092
5	1.3

Ex.	IC ₅₀ MAGL [μM] ^[a]
6	5.7
7	0.011
8	0.013
9	0.035
10	0.039
11	0.042
12	0.077
13	0.087
14	0.191
15	0.190
16	0.208
17	0.268
18	0.892
19	1.5
20	1.8
21	0.909
22	2.1
23	0.856
24	0.004
25	0.452
26	0.684
27	0.007
28	0.018
29	0.005
30	0.273
31	0.049
32	0.020
33	0.004
34	0.438
35	0.019
36	0.119
37	1.3
38	0.160
39	0.116
40	0.012
42	1.2
43	0.529
44	0.038
45	0.850
46	0.005
47	0.005

Ex.	IC ₅₀ MAGL [μM] ^[a]
48	0.288
49	0.363
50	0.008
51	0.010
52	0.058
53	0.006
54	0.001
55	0.079
56	0.042
57	0.049
58	0.003
59	0.012
60	0.680
61	0.011
62	0.009
64	0.040
66	0.351
67	0.120
72	0.108
73	0.008
74	0.003
75	0.002
76	0.008
77	0.016
79	0.001
81	0.006
87	0.006 ^[b]
88	0.005 ^[b]
89	0.034 ^[b]
90	0.168 ^[b]
91	0.099 ^[b]
92	0.014 ^[b]
93	0.124
94	0.150
95	0.008
96	0.293
97	0.146
98	0.010
99	0.012

Ex.	IC ₅₀ MAGL [μM] ^[a]
100	0.082
101	0.011
102	0.022
103	0.005
104	0.451
105	0.285
108	0.001
109	0.223
110	2.179
111	0.020
112	0.012
113	0.005
114	0.005
115	0.003
116	0.004
117	0.010
118	0.132 ^[b]
119	0.014 ^[b]
120	0.007 ^[b]
121	0.151 ^[b]
122	0.008 ^[b]
123	0.082 ^[b]
124	1.035 ^[b]
139	0.002 ^[b]
140	0.059 ^[b]
141	0.040 ^[b]
142	0.075 ^[b]
201	0.239 ^[b]
202	0.054 ^[b]
203	0.871 ^[b]
204	0.100 ^[b]
205	0.086 ^[b]
206	0.023 ^[b]
207	0.050 ^[b]
208	0.003 ^[b]
209	0.074 ^[b]
210	0.080 ^[b]

Ex.	IC ₅₀ MAGL [μM] ^[a]
211	0.017 ^[b]
212	0.003 ^[b]
213	0.098 ^[b]
214	0.036 ^[b]
215	0.005 ^[b]
216	0.006 ^[b]
217	0.010 ^[b]
218	0.003 ^[b]
219	0.002 ^[b]
220	0.003 ^[b]
221	0.0007 ^[b]
222	0.143 ^[b]
223	0.075 ^[b]
224	0.003 ^[b]
225	0.007 ^[b]
226	0.045 ^[b]
227	0.067 ^[b]
228	0.126 ^[b]
229	0.0009 ^[b]
230	0.073 ^[b]
231	0.005 ^[b]
232	0.061 ^[b]
233	0.022 ^[b]
234	0.002 ^[b]
235	0.033 ^[b]
236	0.175 ^[b]
237	0.254 ^[b]
238	0.002 ^[b]
239	0.0004 ^[b]
240	0.016 ^[b]
241	0.015 ^[b]
242	0.012 ^[b]
243	0.010 ^[b]
244	0.030 ^[b]
245	1.7 ^[b]

Ex.	IC ₅₀ MAGL [μM] ^[a]
246	1.0 ^[b]
247	1.1 ^[b]
248	0.607 ^[b]
249	0.005 ^[b]
250	0.008 ^[b]
251	0.005 ^[b]
252	0.005 ^[b]
253	0.010 ^[b]
254	0.064 ^[b]
255	0.010 ^[b]
256	0.011 ^[b]
257	0.014 ^[b]
258	0.048 ^[b]
259	0.015 ^[b]
260	0.018 ^[b]
261	0.048 ^[b]
262	0.181 ^[b]
263	1.1 ^[b]
264	0.084 ^[b]
265	0.006 ^[b]
266	0.018 ^[b]
267	0.042 ^[b]
268	0.028 ^[b]
269	0.024 ^[b]
270	0.061 ^[b]
271	0.020 ^[b]
272	0.094 ^[b]
273	0.089 ^[b]
274	0.126 ^[b]
275	0.032 ^[b]
276	0.019 ^[b]
277	0.455 ^[b]
278	0.211 ^[b]
279	0.001 ^[b]
280	0.041 ^[b]

Ex.	IC ₅₀ MAGL [μ M] ^[a]
281	0.035 ^[b]
282	0.136 ^[b]
283	0.179 ^[b]
284	0.072 ^[b]
285	2.6 ^[b]
286	0.128 ^[b]
287	0.006 ^[b]
288	0.053 ^[b]
289	0.003 ^[b]
290	0.044 ^[b]
291	0.028 ^[b]
292	0.005 ^[b]
293	0.030 ^[b]
294	3.0 ^[b]
<i>[a]: if not indicated otherwise (see [b]), the activity was measured in 4-NPA assay; [b]: measured in 2-AG assay.</i>	

[0244] In one aspect, the present invention provides compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein, wherein said compounds of formula (I) and their pharmaceutically acceptable salts or esters have IC₅₀'s for MAGL inhibition below 25 μ M, preferably below 10 μ M, more preferably below 5 μ M as measured in the MAGL assay described herein.

[0245] In one embodiment, compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein have IC₅₀ (MAGL inhibition) values between 0.000001 μ M and 25 μ M, particular compounds have IC₅₀ values between 0.000005 μ M and 10 μ M, further particular compounds have IC₅₀ values between 0.00005 μ M and 5 μ M, as measured in the MAGL assay described herein.

[0246] In one embodiment, the present invention provides compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein, wherein said compounds of formula (I) and their pharmaceutically acceptable salts or esters have an IC₅₀ for MAGL below 25 μ M, preferably below 10 μ M, more preferably below 5 μ M as measured in an assay comprising the steps of:

1. a) providing a solution of a compound formula (I), or a pharmaceutically acceptable salt or ester thereof, in DMSO;
2. b) providing a solution of MAGL (recombinant wild-type) in assay buffer (50 mM tris(hydroxymethyl)aminomethane; 1 mM ethylenediaminetetraacetic acid);
3. c) adding 1 μ L of compound solution from step a) to 19 μ L of MAGL solution from step b);
4. d) shaking the mixture for 1 min at 2000 rpm;
5. e) incubating for 15 min at RT;
6. f) adding 20 μ L of a solution of 4-nitrophenylacetate in assay buffer (50 mM tris(hydroxymethyl)aminomethane; 1 mM ethylenediaminetetraacetic acid, 6% EtOH);
7. g) shaking the mixture for 1 min at 2000 rpm;
8. h) incubating for 5 min at RT;

9. i) measuring the absorbance of the mixture at 405 nm a first time;
10. j) incubating a further 80 min at RT;
11. k) measuring the absorbance of the mixture at 405 nm a second time;
12. l) subtracting the absorbance measured under i) from the absorbance measured under k) and calculating the slope of absorbance;

wherein:

1. i) the concentration of the compound of formula (I), or the pharmaceutically acceptable salt or ester thereof in the assay after step f) is in the range of 25 μ M to 1.7 nM;
2. ii) the concentration of MAGL in the assay after step f) is 1 nM;
3. iii) the concentration of 4-nitrophenylacetate in the assay after step f) is 300 μ M; and
4. iv) steps a) to l) are repeated for at least 3 times, each time with a different concentration of the compound of formula (I), or the pharmaceutically acceptable salt or ester thereof.

Using the Compounds of the Invention

[0247] In one aspect, the present invention provides compounds of formula (I) as described herein for use as therapeutically active substance.

[0248] In a further aspect, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0249] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal.

[0250] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of neurodegenerative diseases in a mammal.

[0251] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of cancer in a mammal.

[0252] In one aspect, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0253] In a preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal.

[0254] In a particularly preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prophylaxis of multiple sclerosis in a mammal.

[0255] In one aspect, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0256] In one embodiment, the present invention provides compounds of formula (I) as described herein for

use in the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal.

[0257] In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of cancer in a mammal.

[0258] In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neurodegenerative diseases in a mammal.

[0259] In one aspect, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0260] In a preferred embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal.

[0261] In a particularly preferred embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis in a mammal.

[0262] In one aspect, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

[0263] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal.

[0264] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of neurodegenerative diseases in a mammal.

[0265] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of cancer in a mammal.

[0266] In a further aspect, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

[0267] In a preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal.

[0268] In a particularly preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis in a mammal.

[0269] In one aspect, the present invention provides a method for the treatment or prophylaxis of

neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0270] In one embodiment, the present invention provides a method for the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0271] In one embodiment, the present invention provides a method for the treatment or prophylaxis of neurodegenerative diseases in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0272] In one aspect, the present invention provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression and/or pain in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0273] In a preferred embodiment, the present invention provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

[0274] In a particularly preferred embodiment, the present invention provides a method for the treatment or prophylaxis of multiple sclerosis in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.

Pharmaceutical Compositions and Administration

[0275] In one aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

[0276] The compounds of formula (I) and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).

[0277] The compounds of formula (I) and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.

[0278] Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semisolid substances and liquid polyols, etc.

[0279] Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.

[0280] Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.

[0281] Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semisolid or liquid polyols, etc.

[0282] Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

[0283] The dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given herein can be exceeded when this is shown to be indicated.

[0284] In accordance with the invention, the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of type 2 diabetes related microvascular complications (such as, but not limited to diabetic retinopathy, diabetic neuropathy and diabetic nephropathy), coronary artery disease, obesity and underlying inflammatory diseases, chronic inflammatory and autoimmune/inflammatory diseases.

Examples

[0285] For clarity, the following examples are provided for information purposes only:

41, 63, 65, 68, 69, 70, 71, 78, 80, 82, 83, 84, 85, 86, 106, 107, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 295.

[0286] The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples.

[0287] In case the preparative examples are obtained as a mixture of enantiomers, the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC) or crystallization.


[0288] All reaction examples and intermediates were prepared under an argon atmosphere if not specified otherwise.

Method A1

Example 11

rac-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0289]




[0290] To a solution of 4-nitrophenyl 4-(4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (100 mg, 245 μmol , BB2) in DMF (1.5 mL), rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (45.9 mg, 294 μmol , ChemBridge Corporation, BB1) and TEA (49.6 mg, 68.3 μL , 490 μmol) were added. The resultant reaction mixture was heated at 80 °C for 18 h. The reaction mixture was diluted with EtOAc and washed three times with H₂O and NaHCO₃. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, eluting with a gradient of MeOH/EtOAc 0-10%) to afford the title compound as an off-white oil (0.045 g; 43.2%). MS (ESI): m/z = 426.4 [M+H]⁺.

Method A2

Example 3

rac-(4aR,8aS)-6-[4-[(4-tert-Butylthiazol-2-yl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0291]




[0292] To an ice-cold suspension of bis(trichloromethyl) carbonate (45.3 mg, 153 μmol , CAS RN 32315-10-9) and NaHCO₃ (73.3 mg, 873 μmol) in DCM (2 mL) was added in one portion 4-tert-butyl-2-(4-piperidylmethyl)thiazole hydrochloride (60 mg, 218 μmol , Enamine Ltd) and the mixture was stirred at RT overnight. The suspension was filtered and the filtrate was evaporated. The residue was diluted in DCM (1 mL) and added dropwise to an ice-cold solution of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (50 mg, 218 μmol , ChemBridge Corporation, BB1) and DIPEA (152 μL , 870 μmol) in DCM (1 mL). The suspension was stirred at RT for 19 h to become a solution. The reaction mixture was poured on H₂O and DCM and the layers were separated. The aqueous layer was extracted three times with DCM. The organic layers were washed twice with water, dried over MgSO₄, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 4 g column using an MPLC system eluting with a gradient of DCM : MeOH (100 : 0 to 90 : 10) to provide the desired compound as a colorless foam (0.039 g; 42.5%). MS (ESI): m/z = 421.2 [M+H]⁺.

Method A3

Example 34

(+)- or (-)-4-[[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl] methyl] benzonitrile

[0293]




[0294] To an ice-cold solution of bis(trichloromethyl) carbonate (39.9 mg, 134 μ mol, CAS RN 32315-10-9) in DCM were added NaHCO_3 (64.5 mg, 768 μ mol) and (+)-cis-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (30 mg, 192 μ mol, BB1a) and the mixture was stirred at RT overnight. To the suspension was added 4-(piperidin-4-ylmethyl)benzonitrile (38.5 mg, 192 μ mol, CAS RN 333987-57-8) and DIPEA (99.3 mg, 134 μ L, 768 μ mol). The suspension was stirred at RT for 4.5 h. The reaction mixture was poured on H_2O and DCM and the layers were separated. The aqueous layer was extracted three times with DCM. The organic layers were washed twice with H_2O , dried over MgSO_4 , filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 4 g column using an MPLC system eluting with a gradient of DCM : MeOH (100 : 0 to 90 : 10) to furnish the desired compound as a colorless gum (0.023 g; 31.3%). MS (ESI): m/z = 383.2 $[\text{M}+\text{H}]^+$.

Method A4

Example 79

(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0295]




[0296] To a solution of 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (25 mg, 77.8 μ mol, BB7a) in NMP (1 mL) was added DIPEA (25.1 mg, 34 μ L, 195 μ mol) and 4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidine; hydrochloride salt (19.5 mg, 66.1 μ mol, BB12). The reaction vial was stirred at 140 $^\circ\text{C}$ for 45 min. The crude material was purified by reversed-phase HPLC to yield 23.2 mg of the desired product. MS (ESI): m/z = 440.2 $[\text{M}+\text{H}]^+$.

Method A5

Example 64

(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0297]




[0298] A microwave vial was heat gun-dried and charged with bis(trichloromethyl) carbonate (26.6 mg, 89.6 μ mol) and sodium bicarbonate (32.3 mg, 384 μ mol). The flask was placed under argon and DCM (1 mL) was added to give a suspension. The suspension was cooled by an ice-bath and 4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine; hydrochloride salt (36.1 mg, 121 μ mol, BB15) was added. The mixture was stirred at 0 °C for 15 min and at RT overnight. The reaction mixture was cooled down in an-ice bath and DCM (500 μ L) and DIPEA (49.7 mg, 67.1 μ L, 384 μ mol) followed by (4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (21.1 mg, 47.5 μ mol, BB1a) were added. The resulting off-white suspension was stirred at room temperature for 7 h. The reaction mixture was poured on water, DCM was added and the layers were separated. The aqueous layer was extracted twice with DCM. The combined organic layers were washed with brine, dried over MgSO_4 , filtered and evaporated to afford a yellow oil (58 mg). The crude product was purified by reverse-phase HPLC and lyophilized to provide the title compound as a white solid (21.1 mg, 37.1% yield). MS (ESI): m/z = 444.2 $[\text{M}+\text{H}]^+$.

Method A6

Example 39

(4aR,8aS)-6-[4-[(2-Fluoro-4-methoxyphenoxy)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0299]



[0300] To a solution of 2-fluoro-4-methoxyphenol (16.5 mg, 13 μ L, 116 μ mol), (4aR,8aS)-6-[4-(hydroxymethyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (34.5 mg, 116 μ mol, BB16) and triphenylphosphine (33.5 mg, 128 μ mol) in DCM (580 μ L) was added DIAD (25.8 mg,


24.8 μL , 128 μmol) dropwise and the reaction was stirred at room temperature for 22 h. The reaction mixture was diluted with DCM and washed with 1M aq. NaOH. The phases were separated and the aq. phase was extracted with DCM twice. The combined organic layers were dried over sodium sulfate, filtered and concentrated to dryness to give a red oil (99 mg). The crude product was purified by reverse-phase HPLC and lyophilized to afford the desired compound (20 mg, 40.9 % yield) as a white solid. MS (ESI): m/z = 422.3 $[\text{M}+\text{H}]^+$.

Method A7

Example 42 and 43


(4aS,8aR)-6-(4-(((6-(Trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b] [1,4]oxazin-3(4H)-one (Example 42) and (4aR,8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b] [1,4]oxazin-3(4H)-one (Example 43)

[0301]



Step a) *rac*-(4aR,8aS)-6-(4-(Chloromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0302]





To a solution of *rac*-(4aR,8aS)-6-(4-(hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (80 mg, 269 μmol , BB16) in dry DMF (2 mL) was added DIPEA (52.2 mg, 70.5 μL , 404 μmol), DMAP (1.64 mg, 13.5 μmol) and methanesulfonyl chloride (46.2 mg, 404 μmol) and the reaction mixture was stirred at room temperature for 2 h. Addition of 4,4-difluoropiperidine; hydrochloride salt (84.8 mg, 538 μmol), DIPEA (139 mg, 188 μL , 1.08 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction was then stirred at 70 $^{\circ}\text{C}$ for 14 h. The crude reaction was submitted for reversed-phase HPLC purification to yield the title compound as a side product (35 mg). MS (ESI): m/z = 315.1 $[\text{M}+\text{H}]^+$.

Step b) (4aS,8aR)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example 42) and (4aR,8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example 43)

[0303]






[0304] To a solution of rac-(4aR,8aS)-6-(4-(chloromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (70 mg, 222 μ mol) in dry DMF (1 mL) was added 6-(trifluoromethyl)pyridin-3-ol (54.2 mg, 332 μ mol) and Cs_2CO_3 (108 mg, 332 μ mol). The reaction mixture was stirred at 95 °C for 18 h. Insolubles were removed by filtration over Celite, the filtrate was concentrated down to dryness and the crude residue was purified and the enantiomers separated by chiral SFC to yield Example 42 (33.8mg) and Example 43 (32.5 mg). MS (ESI): m/z = 443.2 $[\text{M}+\text{H}]^+$ for both examples.

Method A8

Example 26

(4aS,8aR)-6-(4-((4-(Trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0305]




[0306] To a solution of rac-(4aR,8aS)-6-(4-(hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (75 mg, 252 μ mol, BB16) in dry DMF (2 mL) was added DIPEA (39.1 mg, 52.9 μ L, 303 μ mol), DMAP (3.08 mg, 25.2 μ mol) and methanesulfonyl chloride (30.3 mg, 265 μ mol) and the reaction mixture was stirred at room temperature for 2 h. 4-(Trifluoromethyl)-1H-pyrazole (68.6 mg, 504 μ mol) and K_2CO_3 (87.1 mg, 631 μ mol) were added and the reaction mixture was stirred at 90 °C for 18 h. Insolubles were removed by filtration over celite, the filtrate was concentrated to dryness in vacuo and the crude residue was directly purified by flash chromatography with an eluent mixture of DCM and MeOH (0% to 10%), to yield 90 mg of the desired product as a racemate. This was submitted for SFC chiral separation to yield Example 26 (25 mg) as a colorless oil and the enantiomer (31 mg) as a colorless oil. MS (ESI): m/z = 416.2 $[\text{M}+\text{H}]^+$.

Method A9

Example 37


(4aR,8aS)-6-(4-((4,4-Difluoropiperidin-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b]

[1,4]oxazin-3(4H)-one**[0307]**

[0308] To a solution of (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (40 mg, 256 μ mol, BB1a) in dry DMF (2 mL) cooled down to 0 °C was added DIPEA (39.7 mg, 53.7 μ L, 307 μ mol) and 4-nitrophenyl carbonochloridate (61.9 mg, 307 μ mol). The reaction mixture was stirred at 0 °C for 20 min. LCMS control showed formation of the intermediate carbamate. DIPEA (116 mg, 157 μ L, 896 μ mol) and 4,4-difluoro-1-(piperidin-4-ylmethyl)piperidine; dihydrochloride salt (89.5 mg, 307 μ mol, BB17) were added and the reaction mixture was then stirred at room temperature for 30 min, then stirred at 100 °C for 14 h. Volatiles were removed in vacuo and the crude residue was directly submitted for SFC purification to yield the desired compound (9.5 mg) as a light orange oil. MS (ESI): m/z = 401.3 $[M+H]^+$.

Method A10**Example 125**

(+)-(4aR,8aS)-6-[4-[2-(2-Chlorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0309]


[0310] In a sealed tube, 4-[2-(2-chlorophenyl)ethynyl]piperidine (BB 18, 0.02 g, 0.078 mmol) and 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB7a, 0.025 g, 0.078 mmol) were mixed in ACN (0.6 mL). Then, Huenig's base (0.041 mL, 0.234 mmol) was added, followed by DMAP (0.005 g, 0.039 mmol) and the reaction mixture was heated to 90 °C overnight. The mixture was evaporated to dryness and the crude residue purified by reverse phase HPLC to give the title compound (0.013 g, 41%) as a colorless solid. MS (ESI): m/z = 402.2 $[M+H]^+$.

Method B1

Example 1

(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0311]




[0312] The enantiomers of example 3 were separated by preparative chiral HPLC (Chiralcel OD column) using an isocratic mixture of EtOH (containing 0.05% of NH_4OAc) : n-heptane (20 : 80). The fractions were evaporated to provide the desired compound as a colorless solid (0.012 g; 34.3%). MS (ESI): m/z = 421.2 $[\text{M}+\text{H}]^+$.

Method B2

Example 12

(+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0313]




[0314] The enantiomers of example 13 were separated using preparative chiral HPLC (Chiralpak AD column) using an isocratic mixture of EtOH (containing 0.05% of NH_4OAc): n-heptane (40 : 60). The fractions were evaporated to yield the desired compound as a light brown oil (0.013 g; 28.4%). MS (ESI): m/z = 428.2 $[\text{M}+\text{H}]^+$.

Method B3

Examples 103, 104 and 105

(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (Isomer A+B, Isomer C, Isomer D)

[0315]




[0316] The stereoisomers of example 117 were separated by preparative chiral HPLC (Reprosil Chiral NR column) using an isocratic mixture of EtOH (containing 0.05% of NH_4OAc): n-heptane (40 : 60) to provide examples 103 and 104 as single isomers and example 105 as mixture of two stereoisomers. The fractions were evaporated to provide the desired compounds as colorless solids.

Method C

Example 21

rac-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one







[0317]















[0318] A mixture of rac-cis-6-(piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (35 mg, 130 μmol , BB3), 4-(trifluoromethyl)benzaldehyde (22.7 mg, 17.4 μL , 130 μmol) and sodium triacetoxyborohydride (27.6 mg, 130 μmol) in DCM (1 mL) was stirred at RT for 15 h. The reaction mixture was concentrated and the residue was purified by preparative HPLC to give the desired compound as a white solid (8 mg, 14.4%). MS (ESI): $m/z = 427.4$ $[\text{M}+\text{H}]^+$.







[0319] If not indicated otherwise the following examples were synthesized from rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (ChemBridge Corporation) and the suitable building blocks in analogy to the reaction methods described herein.







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
2	(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 4	405.3 $[\text{M}+\text{H}]^+$	B1







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
4	rac-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Supplier of building block: BCH Research (UK) and BB1	405.4 [M+H] ⁺	A2
				
5	(-)-(4aS,8aR)-6-(4-((4-(tert-Butyl)thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 3	421.2 [M+H] ⁺	B1
				
6	(-)-(4aS,8aR)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 4	405.3 [M+H] ⁺	B1
				
7	rac-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Supplier of building block: UkrOrgSyntez Ltd. and BB1	426.2 [M+H] ⁺	A2
				
8	(+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 11	426.4 [M+H] ⁺	B1
				
9	rac-(4aR,8aS)-6-(4-((4-Chlorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-[(4-Chlorophenoxy)methyl]piperidine (CAS RN 63608-33-3) and BB1	408.3 [M+H] ⁺	A2
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
10	rac-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	4-(4-Chloro-benzyl)-piperidine hydrochloride (CAS RN 36938-76-8) and BB1	392.2 [M+H] ⁺	A2
13	rac-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	4-(4-Trifluoromethylphenoxy)piperidine hydrochloride (CAS RN 28033-37-6) and BB1	428.2 [M+H] ⁺	A2
14	(+)-(4aS,8aS)-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	Example 17	426.3 [M+H] ⁺	B1
15	rac-(4aR,8aS)-6-[4-(Phenoxymethyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB4 and BB1	374.4 [M+H] ⁺	A1
16	rac-(4aR,8aS)-6-(4-((5,6-Dihydro-4H-cyclopenta[d]thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	FCH Group and BB1	405.2 [M+H] ⁺	A2
17	rac-(4aS,8aS)-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	4-(4-Trifluoromethyl benzyl) piperidine HCl (CAS RN 192990-03-7) and BB6	426.3 [M+H] ⁺	A2






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
18	rac-(4aR,8aS)-6-(4-((3-Phenyl-1,2,4-oxadiazol-5-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	3-Phenyl-5-(piperidin-4-ylmethyl)-1,2,4-oxadiazole (CAS RN 1239730-22-3) and BB1	426.3 [M+H] ⁺	A2
				
19	(-)-(4aR,8aR)-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 17	426.4 [M+H] ⁺	B1
				
20	(-)-(4aS,8aR)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 11	426.4 [M+H] ⁺	B1
				
22	rac-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	1-(4-Chlorobenzyl)-piperazine (CAS RN 23145-88-2) and BB1	393.2 [M+H] ⁺	A2
				
23	(-)-(4aS,8aR)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 7	426.2 [M+H] ⁺	B1
				
24	(+)-(4aF,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 7	426.2 [M+H] ⁺	B1






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
25	rac-(4aR,8aS)-6-[4-[[5-(Trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB5 and BB1	427.2 [M+H] ⁺	A2
				
27	rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Supplier of building block: HDH Pharma, Inc. and BB1	432.2 [M+H] ⁺	A2
				
28	(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Supplier of building block: ZereneX Molecular Limited and BB1a	398.1 [M+H] ⁺	A2
				
29	(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 27	432.2 [M+H] ⁺	B1
				
30	(+)- or (-)-(4aS,8aR)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 27	432.2 [M+H] ⁺	B1
				

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
31	(+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-[4-(Trifluoromethoxy)benzyl]piperidine (CAS RN 681482-50-8) and BB1a	442.2 [M+H] ⁺	A2
				
32	(+)- or (-)-(4aR,8aS)-6-(4-((2,4-Difluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-((2,4-Difluorophenoxy)methyl)piperidine HCl CAS RN 614731-39-4 and BB1a	410.2 [M+H] ⁺	A5
				
33	(+)- or (-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Building block prepared as described in WO2013/179024 and BB1a	410.2 [M+H] ⁺	A2
				
35	(+)- or (-)-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-(4-Chloro-benzyl)-piperidine hydrochloride (CAS RN 36938-76-8) and BB1a	392.2 [M+H] ⁺	A2
				
36	(+)- or (-)-(4aR,8aS)-6-[3-[[4-(Trifluoromethyl)phenyl]methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	3-[[4-(Trifluoromethyl)phenyl]methyl]azetidine (CAS RN 937614-88-5) and BB1a	398.3 [M+H] ⁺	A1
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
38	(+)- or (-)-(4aR,8aS)-6-(4-(((5-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB8 and BB1a	405.3 [M+H] ⁺	A2
				
40	(+)- or (-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB9 and BB1a	462.1 [M+H] ⁺	A2
				
41	(4aR,8aS)-6-[3-[[[2,2,2-Trifluoro-1-[4-(trifluoromethyl)phenyl] ethyl]amino]methyl]azetidine-1-carbonyl]hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB19 and BB1a	495.18 [M+H] ⁺	A3
				
44	(+)- or (-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-(3-(Trifluoromethyl)phenoxy)piperidine (CAS RN 337912-66-0) and BB1a	428.2 [M+H] ⁺	A3
				
45	(4aS,8aR)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	2-Chloro-4-(trifluoromethoxy)phenol (CAS: 35852-58-5) and BB1b	492.2 [M+H] ⁺	A6
				
46	(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	2-Chloro-4-(trifluoromethoxy)phenol (CAS RN: 35852-58-5) and BB1a	492.2 [M+H] ⁺	A6
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
47	(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB20 and BB1a	432.2 [M+H] ⁺	A5
				
48	(4aS,8aR)-6-[4-[(2-Chloro-4-fluorophenoxy)methyl]-4-methylpiperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB12 and BB7b	440.2 [M+H] ⁺	A4 (1:1 ACN: iPrOH)
				
49	(4aS,8aR)-6-(4-((2,4-Difluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-[(2,4-Difluorophenoxy)methyl]piperidine hydrochloride (CAS RN: 614731-39-4) and BB7b	410.2 [M+H] ⁺	A4
				
50	(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	4-Chloro-2-fluorophenyl 4-piperidinylmethyl ether; hydrochloride salt (CAS: 946680-87-1) and BB7A	426.2 [M+H] ⁺	A4 (microw ave heating)
				
51	(4aR, 8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB21 and BB7a	460.2 [M+H] ⁺	A4
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
52	(4aR, 8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB22 and BB7a	460.2 [M+H] ⁺	A4
				
53	(+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB91 and BB1a	495.3 [M+H] ⁺	A3
				
54	(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB23 and BB1a	476.3 [M+H] ⁺	A5
				
55	5-Fluoro-2-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile	BB24 and BB1a	417.2 [M+H] ⁺	A5
				
56	(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	1-[[2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)phenyl]methyl]piperazine (synthesized according to WO2015/179559) and BB1a	496.26 [M+H] ⁺	A3
				
57	(4aR,8aS)-6-(3-((2-Chloro-4-fluorophenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b]	BB25 and BB1a	398.2 [M+H] ⁺	A5






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	[1,4]oxazin-3(4H)-one			
				
58	(+)- or (-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB10 and BB1a	494.3 [M+H] ⁺	A3
				
59	(4aR,8aS)-3-Chloro-4-((1-(3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile	BB26 and BB1a	433.2 [M+H] ⁺	A5
				
60	(4aR,8aS)-6-(4-((4-(Trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB27 and BB1a	416.3 [M+H] ⁺	A9
				
61	(4aR, 8aS)-6-(4-((4-Fluoro-2-methylphenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB28 and BB1a	406.3 [M+H] ⁺	A5
				
62	(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB29 and BB1a	448.2 [M+H] ⁺	A5
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
63	N-Benzyl-N-(2-hydroxyethyl)-1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidine-4-carboxamide	BB30 and BB1a	445.24 [M+H] ⁺	A3
65	N-Benzyl-1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidine-4-carboxamide	BB31 and BB1a	401.22 [M+H] ⁺	A3
66	(4aR, 8aS)-6-(4-((4-(tert-Butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB32 and BB1a	404.3 [M+H] ⁺	A9 (purified by RP-HPLC)
67	(2R,4aR,8aS)-2-Methyl-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	4-(4-Trifluoromethyl benzyl)piperidine HCl (CAS RN 192990-03-7) and BB33	440.3 [M+H] ⁺	A3
68	(4aR,8aS)-6-(3-(((2,2,2-Trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB34 and BB1a	495.18 [M+H] ⁺	A3

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
69	(4aR,8aS)-6-(3-(((1-(2,4-Dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB35 and BB1a	495.11 [M+H] ⁺	A3 followed by RP- HPLC
				
70	(4aR,8aS)-6-(3-(((1-(2-Chlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB35 and BB1a	461.16 [M+H] ⁺	A3 followed by RP- HPLC
				
71	(4aR,8aS)-6-(3-(((2,2,2-Trifluoro-1-phenylethyl)amino)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB35 and BB1a	427.2 [M+H] ⁺	A3 followed by RP- HPLC
				
72	(+)- or (-)-(4aR,8aS)-6-(4-(Benzo[d]oxazol-2-ylmethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB11 and BB7a	399.2 [M+H] ⁺	A1
				
73	(+)- or (-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB13 and BB7a	504.1 [M+H] ⁺	A1
				

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
74	(4aR,8aS)-6-cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB36 and BB1a	440.1 [M+H] ⁺	A3
				
75	(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB37	448.2 [M+H] ⁺	A4 (solvent ACN instead of NMP)
				
76	(4aR,8aS)-6-(3-((4-(Trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB38	414.2 [M+H] ⁺	A4 (solvent ACN instead of NMP)
				
77	(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB39	448.2 [M+H] ⁺	A4 (solvent ACN instead of NMP)
				
78	2-chloro-4-fluoro-N-(1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)benzamide	BB7a and BB40	411.2 [M+H] ⁺	A4 (solvent ACN not NMP)
				
80	(4aR,8aS)-6-(3-((Methyl(2,2,2-trifluoro-1-(4-	BB41 and BB1a	509.2	A3







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidene-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one		[M+H] ⁺	
				
81	(+)- or (-)-(4aR,8aS)-6-(4-(2-(1H-Pyrazol-4-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB14 and BB7a	492.2 [M+H] ⁺	A1
				
82	N-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]-N-methyl-1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxamide	BB42 and BB1a	509.2 [M+H] ⁺	A3
				
83	N-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]-2-[2-chloro-3-(trifluoromethyl)phenyl]-N-methylacetamide	BB43 and BB1a	517.18 [M+H] ⁺	A3
				
84	N-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]-2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methylacetamide	BB44 and BB1a	517.18 [M+H] ⁺	A3
				
85	N-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]-N-methyl-4-(trifluoromethyl)benzamide	N-methyl-N-(piperidin-4-yl)-4-(trifluoromethyl)benzamide	469.20 [M+H] ⁺	A3






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	(trifluoromethyl)benzamide	hydrochloride (CAS RN 1580795-67-0) and BB1a		
				
86	N-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]-N-methyl-2-[3-(trifluoromethyl)phenyl]acetamide	BB94 and BB1a	483.22 [M+H] ⁺	A3
				
87	(4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB88 and BB1a	414.3 [M+H] ⁺	A5
				
88	(4aR,8aS)-6-[3-[[3-Methoxy-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB45 and BB1a	444.3 [M+H] ⁺	A4 (ACN as solvent)
				
89	(4aR,8aS)-6-[4-[[5-Methyl-6-(trifluoromethyl)pyridin-3-yl]oxymethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB46 and BB1a	457.2 [M+H] ⁺	A3
				
90	(4aR,8aS)-6-[3-[(3-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	3-[(3-Chlorophenoxy)methyl]pyrrolidine (CAS RN 914299-54-0) and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
91	(4aR,8aS)-6-[3-[(2-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB47 and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)
				
92	(4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB48 and BB1a	444.2 [M+H] ⁺	A4 (ACN as solvent)
				
93	(4aR,8aS)-6-[3-[(2-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB49 and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)
				
94	(4aR,8aS)-6-[3-[(3-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB50 and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)
				
95	(4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB51 and BB1a	466.23 [M+H] ⁺	A4 (ACN as solvent)
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
96	(4aR,8aS)-6-[3-[(4-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB52 and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)
97	(4aR,8aS)-6-[3-[(4-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB53 and BB1a	394.15 [M+H] ⁺	A4 (ACN as solvent)
98	(4aR,8aS)-6-[4-[[2-Methyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB54 and BB1a	440.4 [M+H] ⁺	A3
99	(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB55 and BB1a	460.16 [M+H] ⁺	A3
100	(4aR,8aS)-6-[3-[[4-(Trifluoromethyl)phenyl]methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	3-(4-Trifluoromethylbenzyl)pyrrolidine hydrochloride salt (CAS RN: 957988-84-4) and BB1a	412.19 [M+H] ⁺	A3
101	(4aR,8aS)-6-[3-[[3-Fluoro-5-(Trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB56 and BB1a	432.2 [M+H] ⁺	A4 (ACN as solvent)






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
102	(4aR,8aS)-6-[3-[[2-Fluoro-6-(trifluoromethyl)phenyl]methoxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB1a and BB57	446.3 [M+H] ⁺	A4 (ACN as solvent)
103	(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (Isomer D)	Example 117	428.19 [M+H] ⁺	B3
104	(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (Isomer C)	Example 117	428.19 [M+H] ⁺	B3
105	(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (Isomers A and D)	Example 117	428.19 [M+H] ⁺	B3
106	(4aR,8aS)-6-[3-[[[2,2,2-Trifluoro-1-(4-fluorophenyl)ethyl] amino] methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB58 and BB1a	445.19 [M+H] ⁺	A3

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
107	(4aR,8aS)-6-[4-[2,2,2-Trifluoro-1-[[3-(trifluoromethyl)phenyl]methylamino]ethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB59 and BB1a	523.22 [M+H] ⁺	A3
108	(4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB60 and BB1a	448.2 [M+H] ⁺	A4 (1:1 iPrOH: ACN as solvent)
109	(4aR,8aS)-6-[3-[(2-Chloro-4-fluorophenoxy)methyl]-3-fluoroazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB61 and BB1a	416.2 [M+H] ⁺	A4 (1:1 iPrOH: ACN as solvent)
110	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB62 and BB1a	500.2 [M+H] ⁺	A4 (ACN as solvent)
111	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-methylazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB63 and BB1a	446.2 [M+H] ⁺	A4 (ACN as solvent)







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
112	(4aR,8aS)-6-[3-[[2,4-Difluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB64 and BB1a	450.2 [M+H] ⁺	A4 (ACN as solvent)
				
113	(4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB65 and BB1a	432.2 [M+H] ⁺	A4 (ACN as solvent)
				
114	(4aR,8aS)-6-[3-[[3-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB66 and BB1a	432.2 [M+H] ⁺	A4 (ACN as solvent)
				
115	(4aR,8aS)-6-[3-[[2-Methoxy-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB67 and BB1a	444.3 [M+H] ⁺	A4 (ACN as solvent)
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
116	(4aR,8aS)-6-[3-[[4-Chloro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB68 and BB1a	448.2 [M+H] ⁺	A4 (1:1 iPrOH: ACN as solvent)
117	(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB69 and BB1a	428.18 [M+H] ⁺	A3
118	(4aR,8aS)-6-[3-[4-(Trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB70 and BB1a	400.2 [M+H] ⁺	A4 (ACN as solvent)
119	(4aR,8aS)-6-[4-[4-Chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB71 and BB1a	462.2 [M+H] ⁺	A4 (ACN as solvent)
120	(4aR,8aS)-6-[4-(4-Chloro-3-cyclopropylphenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB72 and BB1a	434.1 [M+H] ⁺	A4 (ACN as solvent)






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
121	(4aR,8aS)-6-[4-(4-Chloro-3-morpholin-4-ylphenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB73 and BB1a	479.2 [M+H] ⁺	A4 (ACN as solvent)
				
122	(4aR,8aS)-6-[4-[2-Methyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB74 and BB1a	442.1 [M+H] ⁺ Hans	A4 (ACN as solvent)
				
123	2-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]oxy-5-(trifluoromethyl)benzonitrile	BB75 and BB1a	453.0 [M+H] ⁺ Hans	A4 (ACN as solvent)
				
124	(4aR,8aS)-6-[4-(Oxazolo[5,4-c]pyridin-2-ylmethyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB76 and BB1a	400.2 [M+H] ⁺	A4 (ACN as solvent)
				
126	(+)-(4aR,8aS)-6-[4-[2-(4-Chloropyridin-3-yl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB77	403.3 [M+H] ⁺	A10
				
127	(+)-(4aR,8aS)-6-[4-[2-(3-Chloropyridin-2-yl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-	BB78	403.2 [M+H] ⁺	A10






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	hexahydropyrido[4,3-b][1,4]oxazin-3-one			
				
128	(+)-(4aR,8aS)-6-[4-[2-(2-Chloro-4-fluorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB79	420.3 [M+H] ⁺	A10
				
129	(+)-(4aR,8aS)-6-[4-[2-(3-Chlorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB80	402.3 [M+H] ⁺	A10
				
130	(+)-(4aR,8aS)-6-[4-[2-(4-Chlorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB81	402.3 [M+H] ⁺	A10
				
131	(+)-(4aR,8aS)-6-[4-[2-(2,4-Dichlorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB82	436.3 [M+H] ⁺	A10
				
132	(+)-(4aR,8aS)-6-[4-[2-(2-Chlorophenyl)ethynyl]-4-hydroxypiperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB83	418.4 [M+H] ⁺	A10






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
133	(+)-(4aR,8aS)-6-[3-[2-(2-Chlorophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB84	374.2 [M+H] ⁺	A10
134	(+)-(4aR,8aS)-6-[3-((2,4-Dichlorophenyl)ethynyl)azetidine-1-carbonyl]hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB85	408.3 [M+H] ⁺	A10
135	(+)-(4aF, 8aS)-6-[3-[2-(2-Chloro-4-fluorophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB86	392.2 [M+H] ⁺	A10
136	rac-(4aR,8aS)-6-[4-[N-methyl-4-(trifluoromethyl)anilino]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB92	413.2 [M+H] ⁺	A1 (ACN as solvent DIPEA as base)
137	rac-(4aR,8aS)-6-[3-[N-methyl-4-(trifluoromethyl)anilino]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB93	441.2 [M+H] ⁺	A1 (ACN as solvent DIPEA as base)






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
139	(4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB95	430.4 [M+H] ⁺	A1 (ACN as solvent DIPEA as base)
				
140	(4aR,8aS)-6-[4-[(2-Chloro-4-fluorophenoxy)methyl]azepane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one [Epimer A]	BB96	440.18 [M+H] ⁺	A3 followed by chiral SFC
				
141	(4aR,8aS)-6-[4-[(2-Chloro-4-fluorophenoxy)methyl]azepane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one [Epimer B]	BB96	440.18 [M+H] ⁺	A3 followed by chiral SFC
				
142	(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]azepane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB97	440.2 [M+H] ⁺	A3
				
143	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl]sulfanylazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB98 and BB1a	450.1 [M+H] ⁺	A3
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
144	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl] sulfonylazetidide-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB99 and BB1a	482.2 [M+H] ⁺	A3
				
145	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl] sulfinylazetidide-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (mixture of sulfoxide isomers)	BB100 and BB1a	466.2 [M+H] ⁺	A3
				
146	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl] sulfinylazetidide-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 145	466.2 [M+H] ⁺	SFC, Chiralpak AD, 40% MeOH
	 (sulfoxide isomer A)			
147	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl]sulfinylazetidide-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (sulfoxide isomer B)	Example 145	466.2 [M+H] ⁺	SFC, Chiralpak AD, 40% MeOH
				
148	(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenyl] sulfanylmethyl] a zetidide-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB101 and BB1a	464.1 [M+H] ⁺	A3
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
152	(4aR,8aS)-6-[3-[[2-Chloro-4-(trifluoromethyl)phenyl]sulfonylmethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB 104 and BB1a	496.1 [M+H] ⁺	A3
				
153	(4aR,8aS)-6-[3-[[2-Chloro-4-(trifluoromethyl)phenyl]sulfinylmethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (mixture of sulfoxide isomers)	BB 105 and BB1a	480.1 [M+H] ⁺	A3
				
154	(4aR,8aS)-6-[3-[[2-Chloro-4-(trifluoromethyl)phenyl] sulfinylmethyl] azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (sulfoxide isomer A)	Example 153	480.1 [M+H] ⁺	A3, then HPLC Reprosil Chiral NR, 60% heptane, 40% EtOH + NH ₄ Ac
				
155	(4aR,8aS)-6-[3-[[2-Chloro-4-(trifluoromethyl)phenyl]sulfinylmethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (sulfoxide isomer B)	Example 153	480.1 [M+H] ⁺	A3, then HPLC Reprosil Chiral NR, 60% heptane, 40% EtOH + NH ₄ Ac
				
156	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methylsulfany]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4] oxazin-3-one	BB 106 and BB1a	448.1 [M+H] ⁺	A3
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
157	(+)-(4aR,8aS)-6-(3-((2,6-Dichlorophenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB 107	408.2 [M+H] ⁺	A10
				
158	(4aR,8aS)-6-[3-[2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB108	426.3 [M+H] ⁺	A10
				
159	(4aR,8aS)-6-(3-((2,6-Difluorophenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB109	376.3 [M+H] ⁺	A10
				
160	(4aR,8aS)-6-(3-((3-Chloro-4-(trifluoromethyl)phenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB110	442.3 [M+H] ⁺	A10
				
161	(4aR,8aS)-6-(3-((2-Chloro-6-fluorophenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB111	392.3 [M+H] ⁺	A10
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
162	(4aR,8aS)-6-(3-((2-Chloro-4-cyclopropylphenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB112	414.4 [M+H] ⁺	A10
				
163	(4aR,8aS)-6-(3-((2-Methoxyphenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB113	370.4 [M+H] ⁺	A10
				
164	(4aR,8aS)-6-[3-[2-[4-Chloro-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB114	442.3 [M+H] ⁺	A10
				
165	(4aR,8aS)-6-[3-[2-(3-Chlorophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB115	374.3 [M+H] ⁺	A10
				
166	(4aR,8aS)-6-[3-[2-[4-(Trifluoromethoxy)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB116	424.3 [M+H] ⁺	A10
				
167	(4aR,8aS)-6-[3-[2-[4-(Trifluoromethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-	BB117	408.4 [M+H] ⁺	A10







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	hexahydropyrido[4,3-b][1,4]oxazin-3-one			
				
168	(4aR,8aS)-6-[3-[2-(3-Fluoro-2-methylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB118	372.2 [M+H] ⁺	A10
				
169	(4aR,8aS)-6-[3-[2-(2,6-Dimethylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB119	368.4 [M+H] ⁺	A10
				
170	(4aR,8aS)-6-[3-[2-[2-(Trifluoromethoxy)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB120	424.3 [M+H] ⁺	A10
				
171	(4aR,8aS)-6-[3-[2-(2-Bromophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB121	420.3 [M+H] ⁺	A10
				
172	(4aR,8aS)-6-(3-((2-Chloro-3-fluorophenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB122	392.3 [M+H] ⁺	A10







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
173	(4aR,8aS)-6-(3-(o-Tolyethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB123	354.3 [M+H] ⁺	A10
				
174	(4aR,8aS)-6-[3-[2-(4-Chloro-2-fluorophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB124	392.3 [M+H] ⁺	A10
				
175	(4aR,8aS)-6-[3-[2-[2-(Difluoromethoxy)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB125	406.3 [M+H] ⁺	A10
				
176	2-[2-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-Hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]ethynyl]-3-chlorobenzonitrile	BB126	399.3 [M+H] ⁺	A10
				
177	(4aR,8aS)-6-[3-[2-[4-(Difluoromethoxy)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB127	406.3 [M+H] ⁺	A10
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
178	1-[4-[2-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]ethynyl]phenyl]cyclopropane-1-carbonitrile	BB128	405.4 [M+H] ⁺	A10
				
179	(4aR,8aS)-6-[3-[2-(4-Cyclopropylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB129	380.4 [M+H] ⁺	A10
				
180	(4aR,8aS)-6-[3-[2-[4-(1-Hydroxycyclopropyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB130	396.4 [M+H] ⁺	A10
				
181	(4aR,8aS)-6-[3-[2-(3-Methoxyphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB131	370.3 [M+H] ⁺	A10
				
182	(4aR,8aS)-6-[3-[2-[2-(Difluoromethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB132	390.3 [M+H] ⁺	A10
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
183	(4aR,8aS)-6-[3-[2-(3-Methoxy-2-methylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB133	384.3 [M+H] ⁺	A10
				
184	(4aR,8aS)-6-[3-[2-(2-Chloro-6-methylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB134	388.3 [M+H] ⁺	A10
				
185	(4aR,8aS)-6-[3-[2-(2-Chloro-5-fluorophenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB135	392.2 [M+H] ⁺	A10
				
186	(4aR,8aS)-6-[3-[2-(4-Methylsulfonylphenyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB136	418.3 [M+H] ⁺	A10
				
187	(4aR,8aS)-6-[3-[2-(5-Chlorothiophen-2-yl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB137	380.2 [M+H] ⁺	A10
				
188	(4aR,8aS)-6-[3-[2-(5-Chlorothiophen-3-	BB138	380.2	A10







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	yl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one		[M+H] ⁺	
				
189	(4aR,8aS)-6-[3-[2-[2-Chloro-6-fluoro-4-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB139	460.3 [M+H] ⁺	A10
				
190	(4aR,8aS)-6-[3-[2-(2-Chlorophenyl)ethynyl]-3-hydroxyazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB140	390.3 [M+H] ⁺	A10
				
191	(4aR,8aS)-6-[3-[2-[2-(Methoxymethyl)phenyl]ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB141	384.3 [M+H] ⁺	A10
				
192	(4aR,8aS)-6-(4-((2-(Trifluoromethyl)phenyl)ethynyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB143	436.4 [M+H] ⁺	A10
				
193	(4aR,8aS)-6-(4-((2-Methoxyphenyl)ethynyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b]	BB144	398.4 [M+H] ⁺	A10






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	[1,4]oxazin-3(4H)-one			
				
194	(4aR,8aS)-6-(4-(o-Tolyethynyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB145	382.4 [M+H] ⁺	A10
				
195	(4aR,8aS)-6-(4-((2,6-Dimethylphenyl)ethynyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB146	396.4 [M+H] ⁺	A10
				
196	(4aR,8aS)-6-(4-((2,4-Dichlorophenyl)ethynyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB147	450.3 [M+H] ⁺	A10
				
197	(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenyl)ethynyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB148	434.4 [M+H] ⁺	A10
				
198	(4aR,8aS)-6-[3-[2-(1-Hydroxycyclopentyl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB149	330.3 [M-H ₂ O+H] ⁺	A10
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
199	(4aR,8aS)-6-[3-[2-(Cyclopenten-1-yl)ethynyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB149 (Elimination product isolated during synthesis of example 198)	330.3 [M+H] ⁺	A10
				
200	(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenyl)ethynyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB142	442.3 [M+H] ⁺	A10
				
201	(4aR,8aS)-6-[4-[3-Pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB98	494.2 [M+H] ⁺	A4
				
202	(4aR,8aS)-6-[4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB99	524.2 [M+H] ⁺	A4
				
203	(4aR,8aS)-6-[4-[3-(1,2,4-Triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB100	495.2 [M+H] ⁺	A4
				






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
204	(4aR,8aS)-6-[3-[4-Chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB101	434.1 [M+H] ⁺	A4
				
205	(4aR,8aS)-6-[4-(4-Chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB102	460.2 [M+H] ⁺	A4
				
206	(4aR,8aS)-6-(4-(3-Morpholino-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB103	513.3 [M+H] ⁺	A4
				
207	(4aR,8aS)-6-[4-[4-Chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB104	461.2 [M+H] ⁺	A4
				
208	(4aR,8aS)-6-[4-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB105	468.2 [M+H] ⁺	A4
				
209	(4aR,8aS)-6-[4-[3-Pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-	BB7a and BB106	494.3 [M+H] ⁺	A4






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	hexahydropyrido[4,3-b][1,4]oxazin-3-one			
				
210	(4aR, 8aS)-6-[4-(4-Chlorophenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and 4-(4-Chlorophenoxy)piperidine hydrochloride (CAS RN 63843-53-8)	394.1 [M+H] ⁺	A4
				
211	(4aR, 8aS)-6-[4-[[2,6-Difluoro-4-(trifluoromethyl)phenyl]methyl]piperidin e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB107	462.2 [M+H] ⁺	A4
				
212	(4aR, 8aS)-6-[4-[4-Chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB108	522.2 [M+H] ⁺	A4
				
213	(4aR, 8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB109	434.1 [M+H] ⁺	A4
				
	(4aR, 8aS)-6-[3-[[2-Fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidin e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB110	432.1 [M+H] ⁺	A4
214				





Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
215	 (4aR,8aS)-6-[3-[2-(2-Fluoro-4-methylphenyl)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB111	376.0 [M+H] ⁺	A4
				
216	(4aR,8aS)-6-[3-[2-[4-Methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB112	442.3 [M+H] ⁺	A4
				
217	(4aR,8aS)-6-[3-[4-Methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB113	428.3 [M+H] ⁺	A4
				
218	(4aR,8aS)-6-[3-[2-[2-Methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB114	442.1 [M+H] ⁺	A4
				
219	(4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB115	426.1 [M+H] ⁺	A4
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
220	(4aR,8aS)-6-[3-[2-[2-Acetyl-4-(trifluoromethyl)phenyl] ethyl] azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB116	454.3 [M+H] ⁺	A4
				
221	(4aR, 8aS)-6-[3-[2-[2-Bromo-4-(trifluoromethyl)phenyl] ethyl] azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB117	491.0 [M+H] ⁺	A4
				
224	(4aR, 8aS)-6-[3-[(3,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB170 and BB1a	414.1 [M+H] ⁺	A3
				
225	(4aR,8aS)-6-[3-[(2,5-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB171 and BB1a	414.1 [M+H] ⁺	A3
				
226	(4aR,8aS)-6-[3-[[3-(Trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB173 and BB1a	429.4 [M+H] ⁺	A3
				
227	(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-	BB173 and BB1a	442.2 [M+H] ⁺	A3 Chiral HPLC (Reprosil)

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction A, mixture of 2 isomers)			Chiral NR, 60% n- heptane, 40% EtOH + NH ₄ Ac
				
228	(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction B, one isomer)	BB173 and BB1a	442.2 [M+H] ⁺	A3 Chiral HPLC (Reprosil Chiral NR, 60% n- heptane, 40% EtOH + NH ₄ Ac
				
229	(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction C, one isomer)	BB173 and BB1a	442.2 [M+H] ⁺	A3 Chiral HPLC (Reprosil Chiral NR, 60% n- heptane, 40% EtOH + NH ₄ Ac
				
230	(4aR,8aS)-6-[3-[[5-(Trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB174 and BB1a	415.2 [M+H] ⁺	A3
				
231	(4aR,8aS)-6-[rel-(3R,4R)-3-Methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridyl]oxymethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (piperidine subst. cis, isomer A)	BB175 and BB1a	471.2 [M+H] ⁺	A3 SFC: OD-H column, 20% EtOH
				
232	(4aR,8aS)-6-[rel-(3S,4S)-3-Methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridyl]oxymethyl]piperidine-1-	BB175 and BB1a	471.2 [M+H] ⁺	A3 SFC: OD-H column,







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (piperidine subst. cis, isomer B)			20% EtOH
				
233	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methylazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (mixture of 4 stereoisomers)	BB176 and BB1a	464.2 [M+H] ⁺	A3
				
234	(4aR,8aS)-6-[3-[[4,5-bis(Trifluoromethyl)pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB177 and BB1a	483.2 [M+H] ⁺	A3
				
235	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB178 and BB1a	464.1 [M+H] ⁺	A3 HPLC: YMC-Triart C18, 25-45-60-100% ACN in water
				
236	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methylazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction A, mixture of 2 stereoisomers)	Example 233	464.4 [M+H] ⁺	Reprosil Chiral NR, 70% Heptan, 30% EtOH + NH ₄ Ac
				
237	(4aR,8aS)-6-[3-[[2-Fluoro-4-	Example 233	464.3	Reprosil







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction B, one stereoisomer)		[M+H] ⁺	Chiral NR, 70% Heptan, 30% EtOH + NH ₄ Ac
				
238	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction C, one stereoisomer)	Example 233	464.4 [M+H] ⁺	Reprosil Chiral NR, 70% n-heptane, 30% EtOH + NH ₄ Ac
				
239	(4aR, 8aS)-6-[3-[(4-Chloro-2-phenoxyphenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB179 and BB1a	472.2 [M+H] ⁺	A3
				
240	(4aR,8aS)-6-[3-[[2-Fluoro-4-(pentafluoro-lambda6-sulfanyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB180 and BB1a	490.1 [M+H] ⁺	A3
				
241	(4aR,8aS)-6-[3-[[1-(2,4-Dichlorophenyl)cyclopropyl] methoxy] azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB181 and BB1a	454.3 [M+H] ⁺	A3
				







Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
242	(4aR,8aS)-6-[3-[[6-(4-Fluorophenoxy)-4-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB182 and BB1a	525.3 [M+H] ⁺	A3
				
243	(4aR,8aS)-6-[3-[[6-(4-Fluorophenoxy)-5-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB183 and BB1a	525.3 [M+H] ⁺	A3
				
244	(4aR,8aS)-6-[3-[[4-(4-Fluorophenyl)thiazol-2-yl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB184 and BB1a	447.2 [M+H] ⁺	A3
				
245	(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB185 and BB1a	514.2 [M+H] ⁺	A3
				
246	(4aR, 8aS)-6-[rac-(2R,3 S)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methylpyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (mixture of two stereoisomers)	BB186 and BB1a	508.1 [M+H] ⁺	A3






Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
247	(4aR, 8aS)-6-[rel-(2R,3 S)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methylpyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction A, one stereoisomer)	Example 246	508.0 [M+H] ⁺	HPLC: Reprosil Chiral NR, 60% n- heptane, 40% EtOH + NH ₄ Ac
				
248	(4aR, 8aS)-6-[rel-(2S,3R)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methylpyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (fraction B, one stereoisomer)	Example 246	508.0 [M+H] ⁺	HPLC: Reprosil Chiral NR, 60% n- heptane, 40% EtOH + NH ₄ Ac
				
249	(+)-(4aR,8aS)-6-[3-[[2,4-bis(Trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB187	482.1 [M+H] ⁺	A10
				
250	(+)-(4aR,8aS)-6-(3-((2-Methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB188	428.3 [M+H] ⁺	A10
				
251	(+)-(4aR,8aS)-6-(3-((4-Methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and	444.2 [M+H] ⁺	A10
		BB189		



Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
252	(4aR,8aS)-6-[2-Methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl] methoxy] azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB190	458.2 [M+H] ⁺	A10
253	(4aR,8aS)-6-[2-Methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidin e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB191	442.3 [M+H] ⁺	A10
254	(+)-(4aR,8aS)-6-[4-[2-Fluoro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB192	446.3 [M+H] ⁺	A10
255	(+)-(4aR,8aS)-6-[4-[3-Chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB193	462.3 [M+H] ⁺	A10
256	(+)-(4aR,8aS)-6-[3-(4-Chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB194	406.4 [M+H] ⁺	A10
257	(+)-(4aR,8aS)-6-[4-[2-Chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB195	462.3 [M+H] ⁺	A10

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
258	(+)-(4aR, 8aS)-6-[3-(3-Bromo-2-chlorophenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB196	446.0 [M+H] ⁺	A10
				
259	(+)-(4aR, 8aS)-6-[3-(2-Chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB197	406.4 [M+H] ⁺	A10
				
260	(+)-(4aR, 8aS)-6-[3-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB199	440.1 [M+H] ⁺	A10
				
261	(+)-(4aR, 8aS)-6-[3-[3-Chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB200	434.1 [M+H] ⁺	A10
				
262	(+)-5-[[1-[(4aR, 8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]oxy]-2-(trifluoromethyl)benzonitrile	BB7a and BB202	453.4 [M+H] ⁺	A10
				
264	(+)-(4aR, 8aS)-6-[3-(3-Bromo-4-chlorophenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-	BB7a and BB205	444.2 [M+H] ⁺	A10

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	hexahydropyrido[4,3-b][1,4]oxazin-3-one			
				
279	(4aR,8aS)-6-[3-[2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB206	430.2 [M+H] ⁺	A4 ACN as solvent followed by prep-HPLC
				
280	(4aR,8aS)-6-[3-[4-Fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB207	432.2 [M+H] ⁺	A4 ACN as solvent followed by prep-HPLC
				
281	(4aR,8aS)-6-[3-[2,2-Difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB208	448.3 [M+H] ⁺	A4 ACN as solvent followed by prep-HPLC
				
282	(4aR,8aS)-6-[3-[3-(Trifluoromethoxy)phenyl]methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and 3-(3-(Trifluoromethoxy)benzyl)azetidine hydrochloride (CAS RN 1354963-49-7)	414.3 [M+H] ⁺	A4 ACN as solvent followed by prep-HPLC
				
283	(4aR,8aS)-6-[3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB7a and BB209	432.2 [M+H] ⁺	A4 ACN as solvent followed by MPLC (n-heptane)
				

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				EtOAc/EtOH 3/1 (70 : 30 to 10 : 90)
284	(4aR,8aS)-6-[3-[2-Chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	BB7a and BB210	448.2 [M+H] ⁺	A4 ACN as solvent followed by MPLC (n-heptane : EtOAc/EtOH 3/1 (70 : 30 to 10 : 90))
285	(4aR,8aS)-6-[(3R or 3S)-3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	Example 283	432.2 [M+H] ⁺	B3
286	(4aR,8aS)-6-[(3S or 3R)-3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 	Example 283	432.2 [M+H] ⁺	B3
287		BB1a and BB211	374.2 [M+H] ⁺	A3
288	(4aR,8aS)-6-(3-((3-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one 	BB7a and BB212	448.3 [M+H] ⁺	A4
289	(4aR,8aS)-6-(3-((E)-2-Fluoro-6-	BB1a and BB213	428.2	A3


Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
	(trifluoromethyl)styryl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one		[M+H] ⁺	
				
290	(4aR,8aS)-6-(3-((2,3-Dimethylbenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB214	374.2 [M+H] ⁺	A4 (ACN as solvent)
				
291	(4aR,8aS)-6-(3-((2,4-Dimethylbenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB215	374.2 [M+H] ⁺	A4 (ACN as solvent)
				
292	(4aF,8aS)-6-(3-((2-Methyl-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	BB7a and BB216	428.2 [M+H] ⁺	A4 (ACN as solvent)
				
293	(4aR,8aS)-6-(3-(4-Hydroxy-2-(Trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 216	427.2 [M+H] ⁺	G
				
294	(4aR,8aS)-6-[3-[[4-Methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB217	428.2 [M+H] ⁺	A3

Ex.	Systematic Name / Structure	Building block(s)	MS, m/z	Method
				
295	(4aR,8aS)-6-(3-((2-Fluoro-6-(trifluoromethyl)benzyl)thio)azetidine-1-carbonyl)hexahydro-2H-pyrido [4,3-b] [1,4]oxazin-3(4H)-one	BB1a and BB218	448.1 [M+H] ⁺	A3
				

Example 222

(4aR,8aS)-6-[3-[[6-Fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0320]

**Step a) *tert*-Butyl 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxylate**

[0321] To a solution of *tert*-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS Nr. 142253-56-3) (2.60 g, 13.9 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (CAS Nr. 39890-98-7) (3.00 g, 13.9 mmol) in THF (60 mL) was added NaH (60%, 1.11 g, 27.8 mmol) and the mixture was stirred 3 h at 25 °C. The solution was poured into sat. aq. NH₄Cl (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were concentrated under vacuum to give crude *tert*-butyl 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxylate (3.00 g, 59%) as colorless oil, which was used directly in the next step. LC-MS (ESI): m/z = 367.1 [M+H]⁺.

Step b) 2-(Azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine

[0322] A solution of trifluoroacetic acid (6.3 mL, 81.8 mmol, 10 eq) and *tert*-butyl 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxylate (3.00 g, 8.18 mmol) in DCM (30 mL) was stirred at 25 °C for 4 h. The solution was concentrated under vacuum to give a residue, which was purified by Prep-

HPLC (HCl condition) to give 2-(azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (1.00 g, 46%) as white solid. LC-MS (ESI): $m/z = 267.0$ $[M+H]^+$.

Step c) (4aR,8aS)-6-[3-[[6-Chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0323] A solution of 2-(azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (150 mg, 0.560 mmol), *N,N*-diisopropylethylamine (0.29 mL, 1.69 mmol) and 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2*H*-pyrido[4,3-*b*][1,4]oxazine-6(5*H*)-carboxylate (BB7a) (199 mg, 0.620 mmol) in ACN (5 mL) was stirred at 25 °C for 16 h. The solution was concentrated under vacuum to give a residue, which was purified by prep-HPLC (TFA conditions) to give (4aR,8aS)-6-[3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-*b*][1,4]oxazin-3-one (100 mg, 40%) as colorless oil. LC-MS (ESI): $m/z = 449.2$ $[M+H]^+$.


Step d) (4aR,8aS)-6-[3-[[6-Fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-*b*][1,4]oxazin-3-one

[0324] A solution of (4aR,8aS)-6-[3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-*b*][1,4]oxazin-3-one (75 mg, 0.17 mmol) and cesium fluoride (101 mg, 0.670 mmol) in DMSO (3 mL) was stirred at 80 °C for 16 h. The solution was filtered and purified by prep-HPLC (TFA conditions) to give (4aR,8aS)-6-[3-[[6-fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-*b*][1,4]oxazin-3-one (22 mg, 28%) as white solid. LC-MS (ESI): $m/z = 433.0$ $[M+H]^+$.

Example 223

(4aR,8aS)-6-[3-[[6-Fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-*b*][1,4]oxazin-3-one

[0325]



Step a) *tert*-Butyl 3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxylate

[0326] To a solution of *tert*-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS Nr. 142253-56-3) (1.56 g, 8.33 mmol) in THF (50 mL) was added NaH (60%, 741 mg, 18.5 mmol) followed by 2,6-dichloro-3-(trifluoromethyl)pyridine (CAS Nr. 55304-75-1) (2.00 g, 9.26 mmol). The resulting mixture was stirred at 25 °C for 3 h. The solution was poured into sat.aq. NH_4Cl (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were concentrated under vacuum to give a residue, which was purified by flash column chromatography (petroleum ether:EtOAc = 5:1) to give *tert*-butyl 3-[[6-chloro-5-(trifluoromethyl)-2-

pyridyl]oxymethyl]azetidine-1-carboxylate (1.10 g, 32%) as colorless oil. LC-MS (ESI): $m/z = 311.0$ $[M-56+H]^+$.

Step b) 6-(Azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine

[0327] A solution of trifluoroacetic acid (0.37 mL, 4.8 mmol) and *tert*-butyl 3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxylate (1.1 g, 3.0 mmol) in DCM (30 mL) was stirred at 25 °C for 4 h. The solution was concentrated under vacuum to give a residue which was purified by Prep-HPLC (HCl condition) to give 6-(azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (600 mg, 75%) as white solid. LC-MS (ESI): $m/z = 267.0$ $[M+H]^+$.

Step c) (4aR,8aS)-6-[3-[[6-Chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0328] To a solution of 6-(azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (100 mg, 0.380 mmol) and 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB7a) (120 mg, 0.380 mmol) in ACN (5 mL) was added N,N-diisopropylethylamine (0.13 mL, 0.75 mmol) with stirring at 25 °C. The solution was stirred at 25 °C for 16 h. The solution was concentrated under vacuum to give a residue, which was purified by Prep-HPLC (TFA conditions) to give (4aR,8aS)-6-[3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (76 mg, 45%) as white solid. LC-MS (ESI): $m/z = 449.1$ $[M+H]^+$.

Step d) (4aR,8aS)-6-[3-[[6-Fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0329] A solution of (4aR,8aS)-6-[3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (70 mg, 0.16 mmol) and cesium fluoride (95 mg, 0.62 mmol) in DMSO (3 mL) was stirred at 60 °C for 24 h. The solution was filtered and then purified by Prep-HPLC (TFA conditions) to give (4aR,8aS)-6-[3-[[6-fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (38 mg, 49%) as white solid. LC-MS (ESI): $m/z = 433.3$ $[M+H]^+$.

Synthesis of building blocks

BB1a & BB1b

(+)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one and (-)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one

[0330] The enantiomers of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (BB1, 500 mg, 2.18 mmol, ChemBridge Corporation) were separated by preparative chiral HPLC (ReprosilChiral NR column) using an isocratic mixture of EtOH (containing 0.05% of NH_4OAc) : n-heptane (30 : 70).

[0331] First eluting enantiomer: (+)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (BB1a). Yellow solid (0.150 g; 44.0%). MS (ESI): $m/z = 157.1$ $[M+H]^+$.

[0332] Second eluting enantiomer: (-)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one. (BB1b). Yellow solid (0.152 g; 44.6%). MS (ESI): $m/z = 157.1$ $[M+H]^+$.

BB2

(4-Nitrophenyl) 4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate

[0333] To a solution of 4-(4-(trifluoromethyl)benzyl)piperidine (100 mg, 411 μ mol, CAS RN 192990-03-7) in DCM (1 mL), TEA (83.2 mg, 115 μ L, 822 μ mol) was added. On cooling to 0 °C, 4-nitrophenyl carbonochloridate (91.1 mg, 452 μ mol, CAS RN 7693-46-1) was added, the reaction mixture was allowed to warm to RT and stirred for 18 hours. The reaction mixture was diluted with DCM and subsequently washed with H₂O and sat. aqueous NaHCO₃ solution. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (silica 10 g, eluting with EtOAc/Heptane 0-50 %), to afford title compound as a light yellow solid. (0.165 g; 98.3%). MS (ESI): $m/z = 409.3$ $[M+H]^+$.

BB3

rac-(4aR,8aS)-6-(Piperazine-1-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0334] To a mixture of rac-tert-butyl 4-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperazine-1-carboxylate (100 mg, 271 μ mol) in DCM (3 mL) was added TFA (155 mg, 105 μ L, 1.36 mmol) and the mixture was stirred at RT for 15 h under an argon atmosphere. The reaction mixture was washed with a saturated aqueous NaHCO₃ solution. The H₂O layer was concentrated in vacuo to give a white solid which was triturated with DCM for 30 min. before it was filtered. The filtrate was concentrated to give a light yellow gum (70 mg, 96.1%).

[0335] MS (ESI): $m/z = 269.3$ $[M+H]^+$.

Step a) rac-tert-Butyl 4-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperazine-1-carboxylate

[0336] To a mixture of triphosgene (1.29 g, 4.36 mmol) and Na₂CO₃ (1.98 g, 18.7 mmol) in THF (3 mL) at 0 °C were added dropwise a solution of tert-butyl piperazine-1-carboxylate (1.16 g, 6.23 mmol, CAS RN 57260-71-6) in THF (90 mL). The reaction mixture was stirred for 10 min. at 0 °C, then allowed to warm up to RT and stirring was continued at RT for 5 h. The suspension was filtered off and the filtrate was concentrated in vacuo. The residue was dissolved in THF (40 mL) and added dropwise to a stirred suspension of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one hydrochloride (1200 mg, 6.23 mmol, Chembridge Corporation) and DIPEA (4.83 g, 6.53 mL, 37.4 mmol) in THF (40 mL) at 0 °C. After 30 min. at 0 °C, the reaction mixture was allowed to warm up to RT, and stirred at RT for 15 h. The mixture was filtered and the filtrate

concentrated in vacuo. The residue was diluted with DCM and washed with water, aq. NaHCO₃ solution and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated to give a white solid (1.13g, 58.6%). MS (ESI): m/z = 313.3 [M+H]⁺.

BB4**(4-Nitrophenyl) 4-(phenoxyethyl)piperidine-1-carboxylate**

[0337] The compound was prepared in analogy to BB2 using 4-(phenoxyethyl)piperidine (CAS N63614-86-8) to afford title compound as a white solid which was used in the next step without further purification.

BB5**2-(4-Piperidylmethyl)-5-(trifluoromethyl)pyridine; hydrochloride salt**

[0338] tert-Butyl 4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylate (320 mg, 0.930 mmol) was dissolved in 4 M HCl in EtOAc (10.0 mL, 40 mmol) and the solution stirred at 20 °C for 2 h. The mixture was concentrated to yield the desired compound as light yellow solid (0.259, 94.8%). MS (ESI): m/z = 245.0 [M-HCl+H]⁺.

Step a) tert-Butyl 4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylate

[0339] 2-Bromo-5-(trifluoromethyl)pyridine (500.0 mg, 2.21 mmol, CAS RN 1000773-62-5) was degassed before 9-BBN solution 0.5 M in THF (4.87 mL, 2.43 mmol, CAS RN 280-64-8) was added. The resulting solution was refluxed for 1 h. After cooling to RT, the solution was added to a solution of tert-butyl 4-methylenepiperidine-1-carboxylate (480.1 mg, 2.43 mmol, CAS RN 159635-49-1), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) chloride (161.89 mg, 0.220 mmol, CAS RN 72287-26-4) and K₂CO₃ (611.56 mg, 4.42 mmol) in DMF (5 mL) and water (0.5 mL). The resulting mixture was heated at 80 °C for 4 h. The mixture was cooled to RT and poured into water, the pH was adjusted to 11 with 10% aqueous NaOH and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and evaporated to give a crude oil, which was purified by column chromatography (silica adsorbent; gradient of PE : EtOAc 10 : 1 then 5 : 1) to yield the desired compound as a light yellow oil (320 mg, 0.930 mmol, 42%). MS (ESI): m/z = 289.0 [M-C₄H₈+H]⁺.

BB6**rac-(4aS,8aS)-Hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one**

[0340] rac-Benzyl (4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (125 mg, 431 μmol) was dissolved in MeOH (5 mL). The reaction solution was degassed in vacuo and backfilled with argon. Pd-C (20 mg, 188 μmol) was added under an argon atmosphere. Argon was evacuated from the reaction

mixture and backfilled with hydrogen. The reaction mixture was stirred at RT for 15 h under a hydrogen atmosphere. The reaction mixture was filtered through a syringe filter and concentrated in vacuo to afford the desired product as a white solid (62 mg, 92.2%). MS (ESI): m/z = 157.098 $[M+H]^+$.

Step a) *rac-Benzyl (3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylate*

[0341] To a stirred suspension of *rac-Benzyl (3S,4S)-3-amino-4-hydroxypiperidine-1-carboxylate* (317 mg, 1.27 mmol, synthesized according to patent US 2011/59118 A1) and sodium acetate (208 mg, 2.53 mmol, CAS RN 127-09-3) in a mixture of acetone (4 mL)/H₂O (0.5 mL) was added dropwise a solution of chloroacetyl chloride (150 mg, 107 μ L, 1.33 mmol, CAS RN 79-04-9) in acetone (3 mL) between 0-5°C. After the addition the reaction mixture was stirred at RT for 1h and subsequently evaporated to dryness giving a yellow gum. The crude product was purified by silica gel chromatography to afford the desired product as a yellow solid (385 mg, 93%). MS (ESI): m/z = 325.2 $[M-H]^-$.

[0342] Step b) *rac-Benzyl (4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate* To a stirred solution of *rac-Benzyl (3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylate* (385 mg, 1.18 mmol) in dry THF (4 mL) was added NaH (67.9 mg, 1.7 mmol) at 0°C. The mixture was allowed to reach RT and then stirred for 90 min under an argon atmosphere. H₂O (5 mL) was added and stirring was continued for 10 min at RT. THF was removed in vacuo from the reaction mixture. The residue was treated with DCM and the organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and then concentrated in vacuo. The residue was purified by flash chromatography (12 g reversed phase column, gradient 0-100% ACN (0.1% FA) in water (0.1% FA) to afford the desired product as a white solid (133 mg, 38.9%). MS (ESI): m/z = 291.3 $[M+H]^+$.

BB7a and BB7b

4-Nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB7a) and 4-nitrophenyl (4aS,8aR)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB7b)

[0343] To a suspension of *rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one*; dihydrochloride salt (4.5 g, 19.6 mmol, BB1) in dry DCM (125 mL) at 0 °C was added DIPEA (6.35 g, 8.58 mL, 49.1 mmol) followed by 4-nitrophenyl carbonochloridate (4.35 g, 21.6 mmol). The reaction mixture was stirred at 0 °C for 10 min and at RT for 2 h. The crude reaction was diluted with DCM and transferred into a separating funnel for extraction with sat. aq. Na₂CO₃ solution. The organic phase was collected and the aqueous phase was back-extracted with DCM. The combined organic phases were dried over Na₂SO₄ and evaporated down to dryness to yield 6.62 g of a crude racemic product (BB7) as a yellow solid. The crude material was directly submitted for a chiral SFC separation to yield enantiomer BB7b (2.72 g, second eluting enantiomer) as a yellow solid and enantiomer BB7a (3.25 g, first eluting enantiomer) as a light beige solid but contaminated with BB7b. A further SFC chiral separation was carried out to yield 2.71 g of BB7a. MS (ESI): m/z = 322.2 $[M+H]^+$ for both enantiomers.

BB8

5-tert-Butyl-2-(4-piperidylmethyl)oxazole; hydrochloride salt

[0344] A solution of tert-butyl 4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylate (167 mg, 518 μ mol) in HCl 2M in diethyl ether (2.59 mL, 5.18 mmol) was stirred at RT for 5 h before another 1.29 mL (2.59 mmol) of HCl 2M in diethyl ether was added. The white suspension was stirred at RT overnight. The mixture was cooled down in an ice-bath, then filtered and washed with diethyl ether to get the desired compound as a colorless solid (0.126 g, 94.0%). MS (ESI): m/z = 223.2 $[M+H]^+$.

Step a) (5-tert-Butyloxazol-2-yl)methyl-triphenyl-phosphonium bromide

[0345] To a solution of 2-(bromomethyl)-5-(tert-butyl)oxazole (600 mg, 2.75 mmol, CAS RN 1334492-54-4) in diethyl ether (5 mL) was added triphenylphosphine (722 mg, 2.75 mmol, CAS RN 603-35-0) and the mixture was stirred at RT for 64 h. The suspension was cooled down in an ice-bath and then filtered. The filter cake was washed a small volume of cold diethyl ether to give the desired compound as a light yellow solid (0.864 g, 65.4%). MS (ESI): m/z = 400.2 $[M-Br+H]^+$.

Step b) tert-Butyl 4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylate

[0346] To an ice-cold suspension of (5-tert-butyloxazol-2-yl)methyl-triphenyl-phosphonium bromide (355 mg, 739 μ mol) in THF (7 mL) was added potassium tert-butyrate 1M solution in THF (738 μ L, 738 μ mol) and the reaction stirred at this temperature for 15 min. Then, tert-butyl 4-oxopiperidine-1-carboxylate (162 mg, 813 μ mol, CAS RN 79099-07-3) was added to the turbid, orange solution and stirring was continued at 0 °C for another 15 min., then at RT for 42 h. The reaction mixture was poured on half-saturated aqueous NH_4Cl solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over $MgSO_4$, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 12 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) to provide the desired compound as a colorless solid (0.180 mg; 76.0%). MS (ESI): m/z = 321.3 $[M+H]^+$.

Step c) tert-Butyl 4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylate

[0347] To a solution of tert-butyl 4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylate (180 mg, 562 μ mol) in MeOH (1 mL) and EtOAc (1 mL) was added Pd/C 10% (17.9 mg, 16.9 μ mol) and the suspension was stirred under a hydrogen atmosphere at 1.3 bar for 2 h. The suspension was filtered over a microfilter and the filtrate was evaporated to get the desired compound as a colorless oil (0.167 g; 92.2%). MS (ESI): m/z = 323.3 $[M+H]^+$.

BB12

4-[(2-Chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine; hydrochloride salt

[0348] To a solution of tert-butyl 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine-1-carboxylate (186 mg, 0.520 mmol) in EtOAc (1.5 mL) was added HCl in EtOAc (4 M, 1.5 mL) at 0 °C. The solution was stirred at 15 °C for 3 h. The solution was concentrated under vacuum, then dried by lyophilization to give desired product

as a white solid (64.0 mg, 0.220 mmol, 40.3% yield). MS (ESI): $m/z = 258 [M+H]^+$.

Step a) *tert*-Butyl 4-methyl-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate

[0349] To a solution of *tert*-butyl 4-(hydroxymethyl)-4-methyl-piperidine-1-carboxylate (500 mg, 2.14 mmol, CAS RN: 614730-97-1) in DCM (5 mL) was added NEts (0.45 mL, 3.22 mmol) and methanesulfonyl chloride (0.23 mL, 3.0 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The mixture was washed twice with water (3 mL each) at 0 °C, and dried over Na₂SO₄. The organic layer was concentrated in vacuum to yield the desired compound as colorless oil (766 mg, 2.46 mmol, 98.5%) which was used in the next step without further purification. MS (ESI): $m/z = 256 [M-56+H]^+$.

Step b) *tert*-Butyl 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine-1-carboxylate

[0350] To a solution of *tert*-butyl 4-methyl-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (450 mg, 1.46 mmol) in DMF (5 mL) was added Cs₂CO₃ (620 mg, 1.9 mmol) and 2-chloro-4-fluorophenol (0.14 mL, 1.46 mmol) at 15 °C. The mixture was heated to 90 °C and stirred for 16 h. The reaction solution was diluted by EtOAc (10 mL), washed twice with brine (10 mL each), and dried over Na₂SO₄. The organic layer was concentrated under vacuum to give the crude product (0.7 g) as light yellow oil. The crude product was purified by prep-HPLC and dried by lyophilization to give the desired compound as colorless solid (186 mg, 0.520 mmol, 35.5% yield). MS (ESI): $m/z = 302 [M-56+H]^+$.

BB15

4-[(2-Chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine; hydrochloride salt

[0351] To a solution of *tert*-butyl 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine-1-carboxylate (220 mg, 0.610 mmol) in EtOAc (2 mL) was added HCl/EtOAc (0.4 mL, 3.6 mmol) at 0 °C. The solution was stirred at 15 °C for 2.5 h. The solution was concentrated in vacuo, then dried by lyophilization to give desired product as a white solid (136.7 mg, 75.4%).

Step a) *tert*-Butyl 4-fluoro-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate

[0352] To a solution of *tert*-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (500 mg, 2.14 mmol) in DCM (5 mL) was added NEts (0.45 mL, 3.22 mmol) and methanesulfonyl chloride (0.23 mL, 3 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The mixture was washed twice with H₂O (3 mL each) at 0 °C, and dried over Na₂SO₄. The organic layer was concentrated to provide the compound as a colorless oil (766 mg, 98.5%) which was used in next step without further purification. MS (ESI): $m/z = 256 [M-56+H]^+$.

Step b) *tert*-Butyl 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine-1-carboxylate

[0353] To a solution of *tert*-butyl 4-fluoro-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (383 mg, 1.23 mmol) in DMF (4 mL) was added Cs₂CO₃ (601 mg, 1.85 mmol), 2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol)

and 2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol) at 15 °C. The mixture was heated to 85 °C and stirred for 16 h. The mixture was extracted three times with EtOAc (5 mL each) at 15 °C, the combined organic layers washed three times with brine (5 mL each), dried over Na₂SO₄, filtered and evaporated. The crude product was purified by preparative HPLC and dried by lyophilization to give the desired compound as light yellow oil (275 mg, 0.760 mmol, 61.5%). MS (ESI): m/z = 306 [M-56+H]⁺.

BB16

rac-(4aR,8aS)-6-(4-(Hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0354] To a suspension of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; dihydrochloride salt (450 mg, 1.96 mmol, BB1) in dry DMF (9 mL) cooled down to 0 °C under an inert atmosphere was added DIPEA (787 mg, 1.06 mL, 6.09 mmol) and 4-nitrophenyl carbonochloridate (475 mg, 2.36 mmol). The reaction mixture was stirred at 0 °C for 30 min. Piperidin-4-ylmethanol (271 mg, 2.36 mmol, CAS RN 6457-49-4) and DIPEA (381 mg, 515 µL, 2.95 mmol) were added, and the reaction mixture was stirred at 100 °C for 14 h. Volatiles were removed in vacuo and the crude residue was purified by flash chromatography with a 24 g SiO₂ column using an eluent mixture of DCM and MeOH (5% to 25%). The crude product was submitted for SFC purification to yield the desired compound as a light yellow oil (338 mg). MS (ESI): m/z = 298.3 [M+H]⁺.

BB17

4,4-Difluoro-1-(piperidin-4-ylmethyl)piperidine; dihydrochloride salt

[0355] To a solution of tert-butyl 4-((4,4-difluoropiperidin-1-yl)methyl)piperidine-1-carboxylate (453 mg, 1.07 mmol) in dioxane (2.5 mL) was added HCl (4.0M solution in dioxane) (2.67 mL, 10.7 mmol) and the reaction mixture was stirred at room temperature for 14 h. Volatiles were removed in vacuo to yield the desired compound as a white solid (286 mg) which was used in the next step without further purification. MS (ESI): m/z = 219.3 [M+H]⁺.

Step a) tert-Butyl 4-((4,4-difluoropiperidin-1-yl)methyl)piperidine-1-carboxylate

[0356] To a solution of a tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN: 158407-04-6) in dry DMF (4 mL) was added 4,4-difluoropiperidine; dihydrochloride salt (425 mg, 2.7 mmol) and Cs₂CO₃ (1.17 g, 3.59 mmol). The reaction mixture was then stirred at 80 °C under microwave radiation for 60 min. Insolubles were removed by filtration, the filtrate was then concentrated in vacuo, and the obtained crude residue was suspended in DCM and filtered through a pad of Celite to give a crude yellow oil, which was purified by flash chromatography on a SiO₂ column, using an eluent mixture of n-heptane and EtOAc (10% to 60%) to yield the desired product as a colorless oil (453 mg). The compound was carried forwards to the next step without further purification. MS (ESI): m/z = 319.3 [M+H]⁺.

BB19

N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan-1-amine; bis(trifluoroacetate) salt

[0357] To a solution of tert-butyl 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate (1 g, 2.42 mmol) in DCM (10 mL) was added TFA (5.53 g, 3.74 mL, 48.5 mmol). The resulting reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated *in vacuo* to yield the desired compound as colorless oil (1.29 g). MS (ESI): $m/z = 313.5$ $[M+H]^+$.

Step a) tert-Butyl 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate

[0358] To a dry flask with septum was added under nitrogen tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (0.852 g, 4.57 mmol), triethylamine (1.39 g, 1.91 mL, 13.7 mmol), 2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan-1-one (1.11 g, 780 μ L, 4.57 mmol), and dry DCM (28 mL). Titanium tetrachloride 1 M in DCM (2.29 mL, 2.29 mmol) was added via a syringe to the ice-cooled flask (exothermic). The reaction was stirred overnight at RT, then carefully quenched with a solution of NaCNBH₃ (862 mg, 13.7 mmol) in MeOH (8.79 g, 11.1 mL, 274 mmol) and stirred overnight. The reaction was basified with sat. NaHCO₃ solution. The obtained insoluble material was filtered off over celite. Extraction of the filtrate with DCM, the organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane to yield tert-butyl 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate which was used in the next step without further purification.

BB26

3-Chloro-4-(4-piperidylmethoxy)benzonitrile; hydrochloride salt

[0359] To a solution of tert-butyl 4-[(2-chloro-4-cyano-phenoxy)methyl]piperidine-1-carboxylate (300 mg, 0.860 mmol) in EtOAc (3 mL) was added HCl in EtOAc (4M, 2.0 mL) at 0 °C. The solution was stirred at 15 °C for 3 h. The solution was concentrated *in vacuo*, then dried by lyophilization to give desired product as a white solid (238 mg, 0.830 mmol, 96% yield). MS (ESI): $m/z = 251$ $[M+H]^+$.

Step a) tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate

[0360] To a solution of N-Boc-4-piperidinemethanol (10.0 g, 46.5 mmol, 1 eq) in DCM (200 mL) was added NEt₃ (7.04 g, 69.7 mmol), then methanesulfonyl chloride (3.95 mL, 51.1 mmol) was added at 0 °C and the mixture was stirred at 0 °C for 1 h. The mixture was poured into ice-water, the aqueous phase was extracted twice with DCM (50 mL each). The combined organic layers were washed with brine (50 mL), and concentrated under vacuum. The residue was directly used without any purification. MS (ESI): $m/z = 238.1$ $[M+H]^+$.

Step b) tert-Butyl 4-[(2-chloro-4-cyano-phenoxy)methyl]piperidine-1-carboxylate

[0361] To a solution of tert-butyl 4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (700 mg, 2.39 mmol) in DMF (7 mL) was added Cs₂CO₃ (855 mg, 2.62 mmol) and 3-chloro-4-hydroxybenzonitrile (0.25 mL, 2.39 mmol) at 15 °C. The mixture was heated to 85 °C and stirred for 16 h. The reaction mixture was diluted with EtOAc (8 mL) at 15 °C, washed three times with brine (8 mL each), the combined organic layers were dried over Na₂SO₄ and evaporated. The colorless residue (0.75 g) was purified by prep-HPLC and dried by lyophilization to give the desired product as a white solid (531 mg, 1.51 mmol, 53.4 %). MS (ESI): m/z = 295 [M-56+H]⁺.

BB27

4-((4-(Trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine; hydrochloride salt

[0362] To a solution of tert-butyl 4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate (430 mg, 1.29 mmol) in dioxane (3 mL) was added HCl (4 M solution in dioxane; 3.22 mL, 12.9 mmol) and the reaction mixture was stirred at RT for 14 h. Volatiles were removed in vacuo to give the crude product (362 mg) which was used in the next step without further purification. MS (ESI): m/z = 234.2 [M+H]⁺.

Step a) tert-Butyl 4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate

[0363] To a solution of a tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN: 158407-04-6) in dry DMF (4 mL) was added 4-(trifluoromethyl)-1H-imidazole (293 mg, 2.16 mmol) and Cs₂CO₃ (1.17 g, 3.59 mmol). The reaction mixture was then stirred at 80 °C for 14 h. Insolubles were removed by filtration, and the filtrate was concentrated in vacuo. The crude residue was suspended in DCM and filtered through a pad of Celite to give a yellow oil, which was purified by flash chromatography with a SiO₂ column, using an eluent mixture of n-heptane and EtOAc (10% to 90%). This yielded the first fraction (301 mg) of the desired product as a colorless oil, and a second fraction (261 mg) of a mixture of the desired product with impurities. The second fraction was submitted for SFC purification, and the purified product was combined with the first fraction to yield 430 mg of the desired product as a colorless oil. MS (ESI): m/z = 334.2 [M+H]⁺.

BB29

3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine

[0364] Trifluoroacetic acid (2 g, 1.35 mL, 17.5 mmol) was added to a solution of tert-butyl 3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carboxylate (320 mg, 875 µmol) in DCM (4.37 mL) and the solution was stirred at RT for 2 h. The solvent was removed under reduced pressure and the resulting pale oil (470 mg) was diluted with EtOAc and washed with aq. Na₂CO₃ solution. The aqueous phase was extracted three times with EtOAc, and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford the compound as a yellow oil (259 mg, 877 µmol). MS (ESI): m/z = 266.1 [M+H]⁺.

Step a) tert-Butyl 3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carboxylate

[0365] To a solution of 2-chloro-4-(trifluoromethyl)phenol (525 mg, 357 μ L, 2.67 mmol), tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (500 mg, 2.67 mmol, CAS RN: 142253-56-3) and triphenylphosphine (770 mg, 2.94 mmol) in DCM (13.4 mL) was added DIAD (594 mg, 571 μ L, 2.94 mmol) dropwise and the reaction was stirred at RT for 17 h. The reaction mixture was quenched by addition of sat. aq. NaHCO_3 solution (20 mL). The phases were separated and the aq. phase was extracted with DCM twice. The combined organic layers were dried over Na_2SO_4 and concentrated to dryness. The residue was dissolved in EtOH (7 mL) and a homogeneous solution of zinc chloride (218 mg, 1.6 mmol) in EtOH (2 mL, 0.5 M) was added. The mixture was stirred for 30 min during which a white solid precipitated. The white solid was filtered off and washed with EtOH. The filtrate was concentrated to give a yellow oil with a white precipitate. The crude was immobilized on Isolute and purified by column chromatography (40 g, 0 to 30 % EtOAc in heptanes) to afford the title compound as a white solid (764.6 mg, 1.99 mmol, 74.4%). MS (ESI): m/z = 310. $1[\text{M}-56+\text{H}]^+$.

BB30

N-benzyl-N-(2-hydroxyethyl)piperidine-4-carboxamide hydrochloride

[0366] To a solution of tert-butyl 4-(benzyl(2-hydroxyethyl)carbamoyl)piperidine-1-carboxylate (0.080 g, 221 μ mol) in DCM (1 mL) was added HCl 2 M in diethyl ether (1.1 mL, 2.21 mmol). The resultant reaction mixture was stirred at RT for 1 h and then concentrated under vacuum at 22 °C to yield the desired compound as a colorless oil (63 mg) (BB30). MS (ESI): m/z = 263.18 $[\text{M}+\text{H}]^+$.

Step a) tert-Butyl 4-(benzyl(2-hydroxyethyl)carbamoyl)piperidine-1-carboxylate

[0367] In a 10 mL glastube, to 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436 μ mol) in DMF (2 mL) was added 2-(benzylamino)ethan-1-ol (72.5 mg, 480 μ mol), DIPEA (169 mg, 229 μ L, 1.31 mmol) and HATU (182 mg, 480 μ mol), stirred at RT for 1 h and extracted with H_2O /DCM. The crude material was purified by flash chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane) to yield the compound as a light yellow oil (156 mg).

BB31

N-benzylpiperidine-4-carboxamide hydrochloride

[0368] tert-Butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate (0.138 g, 433 μ mol) was dissolved in DCM (1 mL) and HCl 2M in diethyl ether (2.17 mL, 4.33 mmol) was added. The reaction mixture was stirred for 2 h. The residue was concentrated *in vacuo* to yield the compound (108 mg) as a colorless oil. MS (ESI): m/z = 219.15 $[\text{M}+\text{H}]^+$.

Step a) tert-Butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate

[0369] In a 10 mL glastube, to 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436 μ mol) in DMF (2 mL) was added phenylmethanamine (51.4 mg, 52.4 μ L, 480 μ mol), DIPEA (169 mg, 229 μ L, 1.31 mmol) and

HATU (182 mg, 480 μ mol), stirred at RT for 2 h and extracted with H₂O/DCM. The crude material was purified by flash chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane) to yield the compound as a colorless oil (0.138 g).

BB32

4-((4-(tert-Butyl)-1H-pyrazol-1-yl)methyl)piperidine; hydrochloride salt

[0370] To a solution of tert-butyl 4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate (100 mg, 311 μ mol) in dioxane (1 mL) was added HCl (4.0M solution in dioxane; 1.17 mL, 4.67 mmol) and the reaction mixture was stirred at RT for 14 h. Volatiles were removed in vacuo to give 84 mg of a crude product which was used in the next step without further purification. MS (ESI): m/z = 222.3 [M+H]⁺.

Step a) *tert-Butyl 4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate*

[0371] To a solution of a tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN 158407-04-6) in dry DMF (4 mL) was added 4-(tert-butyl)-1H-pyrazole (268 mg, 2.16 mmol) and NaH (86.3 mg, 2.16 mmol). The reaction mixture was stirred at 80 °C for 14 h. The reaction was quenched by addition of few drops of sat. aq. NH₄Cl solution, and transferred into a separating funnel for partitioning between DCM and sat. aq. NaHCO₃ solution. The organic phase was collected and the aqueous phase was back-extracted with DCM. The combined organic phases were dried over Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography with a SiO₂ column, eluting with a mixture of n-heptane and EtOAc (5% to 60%) to yield the desired compound as a colorless oil (102 mg). MS (ESI): m/z = 322.3 [M+H]⁺.

BB33

(2R,4aR,8aS)-2-methyl-4a,5,6,7,8,8a-hexahydro-4H-pyrido [4,3-b] [1,4] oxazin-3-one

[0372] To a solution of 6-benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Isomer A, 1.10 g, 4.26 mmol) in EtOAc (16 mL) and MeOH (16 mL) was added under argon Pd-C (227 mg, 213 μ mol) and the suspension was stirred under a hydrogen atmosphere (balloon) at 1 bar for 24 h. The suspension was filtered over a microglass filter and washed with 20 mL EtOAc under inert gas. The filtrate was evaporated to give BB33 as a colorless solid (715 mg). MS (ESI): m/z = 170.8 [M+H]⁺. Note: Only the single enantiomer formed during the reduction.

Step a) *2-Methyl-4H-pyrido[4,3-b][1,4]oxazin-3-one*

[0373] To a solution of 3-aminopyridin-4-ol (2.5 g, 22.7 mmol) in DMF (100 mL) was added dropwise 2-chloropropanoyl chloride (3.03 g, 2.31 mL, 23.8 mmol) and the mixture was stirred at RT for 30 min. After addition of K₂CO₃ (7.84 g, 56.8 mmol), the suspension was heated to 100 °C (oil bath) for 20 h. The DMF was removed in vacuo, then 100 mL EtOAc were added and stirred at RT for 10 min, and it was washed with 50 mL H₂O, extracted 3 times with EtOAc. The organic phases were combined, dried with MgSO₄ and concentrated

under vacuo to yield 3.72 g of 2-methyl-4H-pyrido[4,3-b][1,4]oxazin-3-one which was used in the next step without further purification.

Step b) 6-Benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-6-ium bromide

[0374] A suspension of 2-methyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (3.72 g, 22.7 mmol) in DCM (32 mL) and MeOH (8 mL) was treated with (bromomethyl)benzene (4.65 g, 3.23 mL, 27.2 mmol) and the mixture was stirred at RT for 60 h. A suspension formed, which was cooled down to 0°C, 20 mL n-hexane were added and then the precipitate was filtered. The residue was washed with 15 mL of cold DCM/n-hexane to yield the compound as an off-white solid (5.2 g). MS (ESI): $m/z = 255$ $[M+H]^+$.

Step c) 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0375] To a suspension of 6-benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-6-ium bromide (5.2 g, 15.5 mmol) in EtOH (38 mL) was added in portions NaBH₄ (763 mg, 20.2 mmol) (exothermic, 22°C to 30°C, yellow suspension). After the exothermic reaction faded out the mixture was stirred at room temperature for 3 h, then at 60 °C for 1h and at 22 °C for 1h. The reaction mixture was evaporated, partitioned between H₂O and EtOAc and the layers were separated. The aqueous layer was extracted once with EtOAc. The organic layers were washed twice with H₂O, dried over MgSO₄, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 120 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (50 to 100 in 30 min.) to provide the compound as a light yellow solid (2.48 g) which could be used in the following step without further purification.

Step d) 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0376] The enantiomers were separated by preparative chiral HPLC (Chiralcel OD column) using an isocratic mixture of EtOH (containing 0.05% of NH₄OAc) : n-heptane (10 : 90). The fractions were evaporated to provide the desired compounds as light yellow solids (Isomer A 1. 17 g, Isomer B 1.10 g).

BB34

N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethan-1-amine

[0377] In a 100 mL two-necked flask, benzyl 3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate (0.913 g, 2.05 mmol) was dissolved in a mixture of THF (5 mL) and MeOH (5 mL). Pd/C 10% (109 mg, 102 µmol) was added under argon. The flask was purged and backfilled with H₂ gas (3 times). The reaction mixture was then stirred at 25°C for 4 h. The suspension was filtered over decalite, concentrated and the resulting title compound (611 mg, colorless oil) used directly for the next step. MS (ESI): $m/z = 313.4$ $[M+H]^+$.

Step a) Benzyl 3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate

[0378] To a dry flask with septum was added benzyl 3-(aminomethyl)azetidine-1-carboxylate (0.5 g, 2.27 mmol), NEt₃ (689 mg, 949 μ L, 6.81 mmol), 2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethan-1-one (554 mg, 391 μ L, 2.27 mmol), and dry DCM (15 mL). Titanium tetrachloride 1M in DCM (1.13 mL, 1.13 mmol) was added via a syringe and the flask was cooled in an ice bath (exothermic). The reaction was stirred at RT overnight, carefully quenched with a solution of NaCNBH₃ (428 mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136 mmol) and acetic acid (0.1 mL) and stirred at RT overnight. The reaction was basified with sat. aq. NaHCO₃ solution and the insoluble material obtained was filtered away over celite. The filtrate was extracted with DCM. The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane) to yield the desired compound as a colorless oil (913 mg). MS (ESI): m/z = 447.2 [M+H]⁺.

BB35

N-(azetidin-3-ylmethyl)-1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-amine

[0379] In a 100 mL two-necked flask, benzyl 3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carboxylate (0.660 g, 1.48 mmol) was dissolved in EtOAc (20 mL) to give a colorless solution. Pd/C 10% (78.5 mg, 73.8 μ mol) was added under argon. The flask was purged and backfilled with H₂ gas (3 times). The reaction mixture was stirred at 25 °C for 4 h. LC-MS showed a mixture of the title product N-(azetidin-3-ylmethyl)-1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-amine together with the dehalogenated side-products N-(azetidin-3-ylmethyl)-1-(2-chlorophenyl)-2,2,2-trifluoroethan-1-amine and N-(azetidin-3-ylmethyl)-1-phenyl-2,2,2-trifluoroethan-1-amine. The reaction mixture was filtered over decalite, concentrated *in vacuo* and used directly for the next step.

Step a) Benzyl 3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylidene]amino]methyl]azetidine-1-carboxylate

[0380] To a dry flask with septum was added under nitrogen benzyl 3-(aminomethyl)azetidine-1-carboxylate (0.500 g, 2.27 mmol, CAS RN 1016731-24-0), NEt₃ (689 mg, 949 μ L, 6.81 mmol), 1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-one (556 mg, 2.27 mmol), and dry DCM (16.4 mL). Titanium tetrachloride (1 M solution in DCM; 1.13 mL, 1.13 mmol) was added via a syringe to the ice-cooled flask (exothermic). The reaction was stirred at RT overnight, carefully quenched with a solution of NaCNBH₃ (428 mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136 mmol) and stirred for 6 h. LCMS indicated the reaction stopped at the imine.

[0381] The reaction was basified with sat. NaHCO₃. The obtained insoluble material was filtered over celite and the filtrate was extracted with DCM. The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane) to give the desired compound as a colorless oil (1g).

Step b) Benzyl 3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carboxylate

[0382] In a 25 mL two-necked flask, benzyl 3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylidene]amino]methyl]azetidine-1-carboxylate (1 g, 2.25 mmol) was dissolved in THF (10 mL) and MeOH (1 mL) to give a colorless solution. Acetic acid (135 mg, 129 μ L, 2.25 mmol) and NaCNBH₃ (423 mg, 6.74 mmol) were added. The reaction mixture was stirred at 25°C for 6 h. The reaction was basified with sat. NaHCO₃. The

obtained insoluble material was filtered over celite and the filtrate was extracted with DCM. The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in heptane) to afford the title compound as a colorless oil (660 mg) which used in the next step without further purification.

BB36**cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine; hydrochloride salt**

[0383] tert-Butyl cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate (115 mg, 321 µmol) was dissolved in DCM (2 mL) and 2M HCl in ether (161 µL, 321 µmol) was added. The reaction was stirred at RT for 6 h, then the solvent was removed *in vacuo*. The crude product (94 mg, colorless foam) was used in the next step without purification. MS (ESI): *m/z* = 258.2 [M+H]⁺.

Step a) tert-Butyl cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate

[0384] Mitsunobu reaction: In a 50mL four-necked sulphonation flask under argon, tert-butyl cis-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate (840 mg, 3.66 mmol) was dissolved in THF (15 mL), 2-chloro-4-fluorophenol (590 mg, 439 µL, 4.03 mmol) and triphenylphosphine (1.06 g, 4.03 mmol) were added. The clear solution was stirred 5 min at RT, then cooled to 0-2°C and DEAD (702 mg, 638 µL, 4.03 mmol) was added over 10 min. The reaction mixture was stirred at 2-4 °C for 1 h, then stirred over night at RT. 50 mL diethylether were added, the mixture was washed with 2x 25 mL water, 3x 20 mL 1 N NaOH, 1x 20 mL brine, the organic phase was dried with Mg₂SO₄, after removing the solvent *in vacuo* 2.7 g yellow oil were obtained. To remove the triphenylphosphin oxide, the residue was stirred in n-Heptane/diethylether for 30 min, the solids was filtered away, the filtrate was concentrated *in vacuo*, to obtain 1.8 g crude product that was purified by flash chromatography (silica gel, 50 g, 0% to 30% EtOAc in heptane, 40 min): tert-butyl cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate, 1.21 g white solid.

BB39**3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine; trifluoroacetate salt**

[0385] To a solution of tert-butyl 3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carboxylate (415 mg, 1.14 mmol) in DCM (5 mL) was added TFA (1.3 g, 875 µL, 11.4 mmol) and the reaction mixture was stirred at RT for 3 h. Volatiles were removed *in vacuo* to yield 455 mg of a light yellow oil that was used in the next step without further purification. MS (ESI): *m/z* = 266.1 [M+H]⁺.

Step a) tert-Butyl 3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carboxylate

[0386] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (200 mg, 1.15 mmol) in dry THF (5 mL) was added potassium tert-butoxide (1.65 M solution in THF, 735 µL, 1.21 mmol) and the reaction mixture was stirred at RT for 15 min followed by addition of 1-(bromomethyl)-2-fluoro-4-(trifluoromethoxy)benzene (315 mg, 1.15 mmol). The reaction mixture was then stirred at room temperature for 14 h. The crude reaction was

diluted with EtOAc and extracted with aq. 1 M NaHCO₃ solution, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO₄ and evaporated down to dryness to yield 418 mg of the crude product which was used in the next step without further purification. MS (ESI): $m/z = 310.1$ [M-56+H]⁺.

BB40**N-(azetidin-3-yl)-2-chloro-4-fluoro-benzamide; trifluoroacetate salt**

[0387] To a solution of tert-butyl 3-[(2-chloro-4-fluoro-benzoyl)amino]azetidine-1-carboxylate (346 mg, 1.05 mmol) in DCM (3.5 mL) was added TFA (0.7 mL) at 0 °C. The solution was stirred at 0 °C for 2 h. The reaction was concentrated in vacuum to give the crude product (600 mg) as light yellow oil. The crude product was purified by prep-HPLC (0.1% TFA in H₂O and MeCN) and dried by lyophilization to give desired compound as colorless solid (223 mg, 0.650 mmol, 59.2% yield). MS (ESI): $m/z = 229$ [M+H]⁺.

Step a) tert-Butyl 3-[(2-chloro-4-fluoro-benzoyl)amino]azetidine-1-carboxylate

[0388] To a solution of 2-chloro-4-fluorobenzoic acid (500 mg, 2.86 mmol), 1-Boc-3-(amino)azetidine (493 mg, 2.86 mmol) and DMAP (35.0 mg, 0.290 mmol) in THF (10 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (714 mg, 3.72 mmol) at 0 °C. The mixture was heated to 30 °C and stirred for 16 h. The reaction was diluted with EtOAc (5 mL), washed three times with brine (10 mL each) and dried over Na₂SO₄. The organic layer was concentrated in vacuum to give the crude product (0.72 g) as yellow oil. The crude product was purified by prep-HPLC and dried by lyophilization to give desired compound as a colorless solid (546 mg, 1.66 mmol, 57.9 % yield). MS (ESI): $m/z = 273$ [M-56+H]⁺.

BB41**N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-N-methyl-1-[4-(trifluoromethyl)phenyl]ethanamine; trifluoroacetate salt**

[0389] To a solution of tert-butyl 3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate (0.256 g, 600 µmol) in DCM (5 mL) was added TFA (1.37 g, 925 µL, 12 mmol). The resulting reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated *in vacuo* to provide the desired compound as a colorless oil (268 mg). MS (ESI): $m/z = 327.4$ [M+H]⁺.

Step a) tert-Butyl 3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azetidine-1-carboxylate

[0390] To a dry flask with septum and 3 Å molecular sieves was added under nitrogen tert-butyl 3-((methylamino)methyl)azetidine-1-carboxylate (0.300 g, 293 µL, 1.5 mmol), TEA (455 mg, 626 µL, 4.49 mmol), 2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan-1-one (363 mg, 255 µL, 1.5 mmol), and dry DCM (9.86 mL).

Titanium tetrachloride 1 M in DCM (749 μ L, 749 μ mol) was added via a syringe to the ice-cooled flask (exothermic). The reaction was stirred at RT overnight, carefully quenched with a solution of NaCNBH₃ (282 mg, 4.49 mmol) in MeOH (3.64 mL, 89.9 mmol) and stirred at RT for 2 h. The reaction was basified with sat. NaHCO₃ solution. The obtained insoluble material was filtered over celite and the filtrate was extracted with DCM. The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane) and was used directly for the next step.

BB42**N-methyl-N-(piperidin-4-yl)-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamide hydrochloride**

[0391] To a solution of tert-butyl 4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piperidine-1-carboxylate (0.301 g, 706 μ mol) in DCM (2 mL) was added HCl 2M in diethyl ether (3.53 mL, 7.06 mmol). The resulting reaction mixture was stirred at RT overnight and then concentrated under vacuum at 22°C to give 256 mg of BB42 as off white solid, MS (ESI): m/z = 327.2 [M+H]⁺

Step a) tert-butyl 4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piperidine-1-carboxylate

[0392] In a 20 mL glastube, to 1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (177 mg, 770 μ mol) in DMF (5 mL) was added HATU (293 mg, 770 μ mol) and DIPEA (271 mg, 367 μ L, 2.1 mmol). The reaction mixture was stirred for 15 min and then tert-butyl 4-(methylamino)piperidine-1-carboxylate (0.15 g, 700 μ mol) was added. The reaction mixture was stirred at RT for 2 hours. The reaction mixture was extracted with Water/DCM. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in heptane) to yield the desired compound as a light yellow oil (301mg). MS (ESI): m/z = 371.2 [M-56+H]⁺

BB43**2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamide; hydrochloride salt**

[0393] To a solution of tert-butyl 4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1-carboxylate (0.301 g, 692 μ mol) in DCM (2 mL) was added HCl (3.46 mL, 6.92 mmol). The resulting reaction mixture was stirred at RT for 2 days and then concentrated under vacuum at 22 °C to yield 252 mg of BB43 as off white solid. MS (ESI): m/z = 335.1 [M+H]⁺.

Step a) tert-butyl 4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1-carboxylate

[0394] In a 20mL glass tube, to 2-(2-chloro-3-(trifluoromethyl)phenyl)acetic acid (184 mg, 770 μ mol) in DMF (5 mL) was added HATU (293 mg, 770 μ mol), DIPEA (271 mg, 367 μ L, 2.1 mmol). The reaction mixture was stirred for 15 min and then tert-butyl 4-(methylamino)piperidine-1-carboxylate (0.150 g, 700 μ mol) was added. The reaction mixture was stirred at RT for 2 hours, and then extracted with Water/DCM. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in heptane) to yield tert-butyl 4-(2-(2-

chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1-carboxylate as light yellow oil, 301mg, MS (ESI): $m/z = 379.1$ $[M-56+H]^+$

BB44**2-(2-Chloro-5-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamide; hydrochloride salt**

[0395] Synthesized from 2-(2-chloro-5-(trifluoromethyl)phenyl)acetic and tert-butyl 4-(methylamino)piperidine-1-carboxylate. See synthesis of BB43 for details. MS (ESI): $m/z = 335.1$ $[M+H]^+$.

BB46**3-Methyl-5-(piperidin-4-ylmethoxy)-2-(trifluoromethyl)pyridine; dihydrochloride salt**

[0396] In a 25 mL tube tert-butyl 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate (87 mg, 232 μ mol) was dissolved in DCM (2 mL) and then HCl in ether 2M (697 μ L, 1.39 mmol) was added, the reaction mixture was stirred 12 h at RT. The mixture was concentrated in vacuum, yielding 80 mg of BB46 as a white solid. MS (ESI): $m/z = 275.2$ $[M+H]^+$.

Step a) tert-Butyl 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate

[0397] In a 5 mL tube, tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (80.7 mg, 375 μ mol) was dissolved in DMF (1.5mL), then NaH in Oil 60% (18 mg, 450 μ mol) was added at room temperature, the mixture was stirred for 20 min, then 5-bromo-3-methyl-2-(trifluoromethyl)pyridine (90 mg, 60 μ L, 375 μ mol) was added, and it was stirred for 2 hr at RT, yielding a brown solution. 10 mL sat. NH_4Cl were added, it was extracted with water/ethyl acetate, dried over $MgSO_4$, the solvent was removed at 40 °C/150 mbar. The crude product was purified by flash chromatography (silica gel, 20 g, 0 to 40% EtOAc in n-heptane, in 35 min) to yield 87 mg of tert-butyl 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate. MS (ESI): $m/z = 319.2$ $[M-56+H]^+$

BB58**N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-1-(4-fluorophenyl)ethan-1-amine**

[0398] In a 100 mL two-necked flask, benzyl 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carboxylate (707 mg, 1.64 mmol) was combined with THF (5 mL) and MeOH (5 mL) to give a colorless solution. Pd/C 10% (87.3 mg, 82.1 μ mol) was added under argon. The flask was purged and backfilled with H_2 (3 times). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was filtered over decalite, concentrated and used directly for the next step. Colorless oil (472 mg). MS (ESI): $m/z = 263.2$ $[M+H]^+$ (the ortho-chlorine was lost during the hydrogenation).

Step a:) Benzyl 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carboxylate

[0399] To a dry flask under a stream of nitrogen was added benzyl 3-(aminomethyl)azetidine-1-carboxylate (0.5 g, 2.27 mmol), triethylamine (689 mg, 949 μ L, 6.81 mmol), 1-(2-chloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone (519 mg, 2.27 mmol), and dry DCM (15 mL). Titanium tetrachloride 1M in DCM (1.13 mL, 1.13 mmol) was added via a syringe to the ice-cooled flask (exothermic). The reaction was stirred overnight at RT, carefully quenched with a methanolic solution of sodium cyanoborohydride (428 mg, 6.81 mmol) in methanol (4.36 g, 5.51 mL, 136 mmol) + Acetic Acid (0.1 mL) and stirred overnight at RT. The reaction was basified with sat. NaHCO_3 . The insoluble material obtained was filtered away over celite, the filtrate was extracted with DCM, the organic layers were combined, washed with brine, dried over Na_2SO_4 and concentrated. Purification: The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in heptane) to yield 707 mg of Benzyl 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-carboxylate as a colorless oil. MS (ESI): $m/z = 431.2$ $[\text{M}+\text{H}]^+$.

BB59

2,2,2-Trifluoro-1-(piperidin-4-yl)-N-(3-(trifluoromethyl)benzyl)ethan-1-amine; hydrochloride salt

[0400] To a solution of tert-butyl 4-(2,2,2-trifluoro-1-((3-(trifluoromethyl)benzyl)amino)ethyl)piperidine-1-carboxylate (0.140 g, 318 μ mol) in DCM (2 mL) was added HCl 2M in diethyl ether (1.59 mL, 3.18 mmol). The resulting reaction mixture was stirred at RT overnight and then concentrated under vacuum at 22 °C to yield 119 mg of the title compound as off-white solid. MS (ESI): $m/z = 340.8$ $[\text{M}+\text{H}]^+$.

Step a) tert-Butyl 4-(2,2,2-trifluoro-1-((3-(trifluoromethyl)benzyl)amino)ethyl)piperidine-1-carboxylate

[0401] A solution of tert-butyl 4-(1-amino-2,2,2-trifluoroethyl)piperidine-1-carboxylate (0.150 g, 531 μ mol) and 3-(trifluoromethyl)benzaldehyde (92.5 mg, 71.1 μ L, 531 μ mol) in 1,2-DCE (1 mL) was stirred for 1 hour at RT. Sodium triacetoxyborohydride (225 mg, 1.06 mmol) was then added at 0°C, and the reaction mixture was stirred at RT overnight. The reaction mixture was poured onto sat. NaHCO_3 and extracted with DCM. The organic layers were combined, washed with brine, dried over Na_2SO_4 and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in heptane) to yield 145 mg of the desired compound as a colorless oil. MS (ESI): $m/z = 383.1$ $[\text{M}-56+\text{H}]^+$

BB69

2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt

[0402] To a solution of tert-butyl 2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate (0.36 g, 1.04 mmol) in DCM (4 mL) was added trifluoroacetic acid (1.19 g, 10.4 mmol). The resulting reaction mixture was stirred at RT for 1 hour. The reaction mixture was concentrated on high vacuum to yield BB69 as a light yellow oil, 399 mg, mixture of all four stereoisomers. MS (ESI): $m/z = 246.1$ $[\text{M}+\text{H}]^+$.

Step a) *tert*-Butyl 2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate

[0403] In a 25 mL two-necked flask, *tert*-butyl-3-hydroxy-2-methylazetidine-1-carboxylate (215 mg, 1.15 mmol) was dissolved in DMF (5 mL) to give a colorless solution. At 0°C, sodium hydride (60 % dispersion in mineral oil) (41.8 mg, 1.05 mmol) was added. The reaction mixture was stirred at 0 °C for 15 min. Then 1-(bromomethyl)-4-(trifluoromethyl)benzene (0.250 g, 1.05 mmol) was added at 0°C. The reaction mixture was stirred at RT overnight. The reaction mixture was poured onto 20 mL sat. NH₄Cl and extracted with EtOAc (2 × 50 mL). The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 70% EtOAc in heptane) to yield 360 mg of *tert*-butyl 2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate as a colorless oil. MS (ESI): *m/z* = 290.1 [M-56+H]⁺

BB87**3-Fluoro-5-(trifluoromethyl)benzyl 4-methylbenzenesulfonate**

[0404] To a solution of (3-fluoro-5-(trifluoromethyl)phenyl)methanol (100 mg, 72.5 µL, 515 µmol, Eq: 1) in DCM (2.58 mL) was added *p*-toluenesulfonic anhydride (185 mg, 567 µmol), DIPEA (79.9 mg, 108 µL, 618 µmol) and DMAP (6.29 mg, 51.5 µmol). The reaction mixture was stirred for 4 h at 0 °C and for 2 days at room temperature. The reaction mixture was taken up in EtOAc and washed with water and brine. The organic layers were dried over MgSO₄ and concentrated *in vacuo* to give a yellow oil (178 mg) which was used without further purification.

[0405] In analogy to BB39, and if not specified otherwise, the intermediates shown in the following table were prepared from commercially available benzyl bromides or the prepared tosylate intermediates and the corresponding *tert*-butyl 3-hydroxyazetidine-1-carboxylate building blocks.

BB No.	Systematic Name	Starting material	MS, <i>m/z</i>
BB37	3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	1-(Bromomethyl)-2-chloro-4-(trifluoromethyl)benzene	266.1 [M+H] ⁺
BB38	3-((4-(Trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	1-(Bromomethyl)-4-(trifluoromethyl)benzene	232.1 [M+H] ⁺
BB45	3-((3-Methoxy-4-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	4-(Bromomethyl)-2-methoxy-1-(trifluoromethyl)benzene	262.2 [M+H] ⁺
BB56	3-((3-Fluoro-5-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	3-Fluoro-5-(trifluoromethyl)benzyl 4-methylbenzenesulfonate (BB87)	250.1 [M+H] ⁺
BB60	3-((3-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	4-(Bromomethyl)-2-chloro-1-(trifluoromethyl)benzene	266.1 [M+H] ⁺
BB62	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-3-(trifluoromethyl)azetidine; trifluoroacetate salt	1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and <i>Tert</i> -butyl 3-hydroxy-3-(trifluoromethyl)azetidine-1-carboxylate (CAS: 398489-42-4)	318.3 [M+H] ⁺

BB No.	Systematic Name	Starting material	MS, m/z
BB63	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-3-methylazetidine; trifluoroacetate salt	1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and Tert-butyl 3-hydroxy-3-methylazetidine-1-carboxylate (CAS: 1104083-23-9)	264.1 [M+H] ⁺
BB64	3-((2,4-Difluoro-5-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	1-(Bromomethyl)-2,4-difluoro-5-(trifluoromethyl)benzene	268.1 [M+H] ⁺
BB65	3-((2-Fluoro-5-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	2-(Bromomethyl)-1-fluoro-4-(trifluoromethyl)benzene	250.1 [M+H] ⁺
BB66	3-((2-Fluoro-5-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	4-(Bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene	250.1 [M+H] ⁺
BB67	3-((2-Methoxy-4-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	1-(Bromomethyl)-2-methoxy-4-(trifluoromethyl)benzene	262.2 [M+H] ⁺
BB68	3-((4-Chloro-2-(trifluoromethyl)benzyl)oxy)azetidine; trifluoroacetate salt	1-(Bromomethyl)-4-chloro-2-(trifluoromethyl)benzene	266.2 [M+H] ⁺
BB88	3-[(2,4-dichlorophenyl)methoxy]azetidine	1-(Bromomethyl)-2,4-dichlorobenzene	232.1 [M+H] ⁺
BB170	3-((3,4-Dichlorobenzyl)oxy)azetidine; 2,2,2-trifluoroacetate	4-(Bromomethyl)-1,2-dichlorobenzene	232.1 [M+H] ⁺
BB171	3-((2,5-Dichlorobenzyl)oxy)azetidine; 2,2,2-trifluoroacetate	2-(Bromomethyl)-1,4-dichlorobenzene	232.1 [M+H] ⁺
BB172	3-((3-(Trifluoromethoxy)benzyl)oxy)azetidine; 2,2,2-trifluoroacetate	3-(Bromomethyl)-trifluoromethoxybenzene	248.1 [M+H] ⁺
BB173	2-Methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine; 2,2,2-trifluoroacetate	tert-Butyl 3-hydroxy-2-methylazetidine-1-carboxylate and 4-(bromomethyl)-1-methyl-2-(trifluoromethyl)benzene	266.2 [M+H] ⁺
BB178	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)methyl)azetidine; 2,2,2-trifluoroacetate	tert-Butyl 3-(hydroxymethyl)azetidine-1-carboxylate and 1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene	264.2 [M+H] ⁺
BB180	[4-(Azetidin-3-yloxymethyl)-3-fluoro-phenyl]-pentafluoro- $\square$ 6-sulfane; 2,2,2-trifluoroacetate	(4-(Bromomethyl)-3-fluorophenyl)pentafluoro- $\square$ 6-sulfane	308.2 [M+H] ⁺
BB185	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-3-(trifluoromethyl)pyrrolidine; 2,2,2-trifluoroacetate	tert-Butyl 3-hydroxy-3-(trifluoromethyl)pyrrolidine-1-carboxylate and 1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene	332.2 [M+H] ⁺
BB187	3-[[2,4-bis(Trifluoromethyl)phenyl]methoxy]azetidine	1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene	336.2 [M+H] ⁺
BB 188	3-[[2-Methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine	1-(Bromomethyl)-2-methyl-3-(trifluoromethyl)benzene	246.1 [M+H] ⁺
	3-[[2-Methyl-4-	1-(Bromomethyl)-2-methyl-4-	262.1

BB No.	Systematic Name	Starting material	MS, m/z
BB 189	(trifluoromethoxy)phenyl] methoxy] a zetidine	(trifluoromethoxy)benzene	[M+H] ⁺
BB 190	2-Methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]a zetidine	1-(Bromomethyl)-2-methyl-4-(trifluoromethoxy)benzene and tert-butyl 3-hydroxy-2-methylazetidine-1-carboxylate	276.2 [M+H] ⁺
BB 191	2-Methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine	1-(Bromomethyl)-2-methyl-3-(trifluoromethyl)benzene and tert-Butyl 3-hydroxy-2-methylazetidine-1-carboxylate	260.2 [M+H] ⁺
BB207	3-[[4-Fluoro-2-(trifluoromethyl)phenyl] methoxy] azetidine; 4-methylbenzenesulfonate	1-(Chloromethyl)-4-fluoro-2-(trifluoromethyl)benzene (CAS RN 248262-29-5)	250.2 [M+H] ⁺
BB212	3-[[3-Fluoro-4-(trifluoromethoxy)phenyl] methoxy] a zetidine; 2,2,2-trifluoroacetate	4-(Bromomethyl)-2-fluoro-1-(trifluoromethoxy)benzene	Used without purification
BB217	3-((4-Methyl-3-(trifluoromethyl)benzyl)oxy)azetidine; 2,2,2-trifluoroacetate	4-(Bromomethyl)-1-methyl-2-(trifluoromethyl)benzene. tBuOK as base	246.2 [M+H] ⁺

[0406] In analogy to BB29, intermediates BB20, BB25 and BB61 of the following table were prepared from the commercially available phenols. Where trifluoroacetate salts are indicated, the crude product resulting from concentration of the reaction mixture was used directly without further neutralization or purification.

BB No.	Systematic Name	Starting material	MS, m/z
BB20	3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine; trifluoroacetate salt	2-Fluoro-4-(trifluoromethyl)phenol (CAS RN: 77227-78-2)	250.1 [M+H] ⁺
BB25	3-[(2-Chloro-4-fluorophenoxy)methyl] azetidine	2-Chloro-4-fluorophenol (CAS RN: 1996-41-4)	216.1 [M+H] ⁺ (purified by RP-HPLC)
BB61	3-((2-Chloro-4-fluorophenoxy)methyl)-3-fluoroazetidine; trifluoroacetate salt	2-Chloro-4-fluorophenol (CAS RN: 1996-41-4) and tert-Butyl 3-fluoro-3-(hydroxymethyl)azetidine-1-carboxylate (CAS: 1126650-66-5)	234.1 [M+H] ⁺

[0407] In analogy to BB26, intermediates BB21 - BB24 and BB28 of the following table were prepared from the commercially available phenols.

BB No.	Systematic Name	Starting material	MS, m/z
BB21	4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)pi peridine; hydrochloride salt	4-Fluoro-2-(trifluoromethyl)phenol (CAS: 130047-19-7)	278.1 [M+H] ⁺
BB22	4-[[2-Fluoro-4-(trifluoromethyl)phenoxy]methyl]pi peridine; hydrochloride salt	2-Fluoro-4-(trifluoromethyl)phenol (CAS: 77227-78-2)	278.0 [M+H] ⁺
	4-((2-Chloro-4-	2-Chloro-4-(trifluoromethyl)phenol (CAS:	294.1

BB No.	Systematic Name	Starting material	MS, m/z
BB23	(trifluoromethyl)phenoxy)methyl]piperidine; hydrochloride salt	35852-58-5)	[M+H] ⁺
BB24	5-Fluoro-2-(piperidin-4-ylmethoxy)benzonitrile; hydrochloride salt	5-Fluoro-2-hydroxybenzonitrile (CAS: 91407-41-9)	235.1 [M+H] ⁺
BB28	4-[(4-Fluoro-2-methylphenoxy)methyl]piperidine; hydrochloride salt	4-Fluoro-2-methylphenol (CAS: 452-72-2)	224.0 [M+H] ⁺
BB170	3-((3,4-Dichlorobenzyl)oxy)azetidine 2,2,2-trifluoroacetate	4-(Bromomethyl)-1,2-dichlorobenzene	232.1 [M+H] ⁺
BB171	3-((2,5-Dichlorobenzyl)oxy)azetidine 2,2,2-trifluoroacetate	2-(Bromomethyl)-1,4-dichlorobenzene	232.1 [M+H] ⁺
BB172	3-((3-(Trifluoromethoxy)benzyl)oxy)azetidine 2,2,2-trifluoroacetate	3-(Bromomethyl)-trifluoromethoxybenzene	248.1 [M+H] ⁺
BB173	2-Methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine 2,2,2-trifluoroacetate	tert-Butyl 3-hydroxy-2-methylazetidine-1-carboxylate and 4-(Bromomethyl)-1-methyl-2-(trifluoromethyl)benzene	266.2 [M+H] ⁺
BB178	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)methylazetidine 2,2,2-trifluoroacetate	tert-Butyl 3-(hydroxymethyl)azetidine-1-carboxylate and 1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene	264.2 [M+H] ⁺
BB180	[4-(Azetidin-3-ylloxymethyl)-3-fluoro-phenyl]-pentafluoro- α -6-sulfane 2,2,2-trifluoroacetic acid	(4-Bromomethyl)-3-fluorophenyl)pentafluoro- α -6-sulfane	308.2 [M+H] ⁺
BB185	3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-3-(trifluoromethyl)pyrrolidine 2,2,2-trifluoroacetate	tert-Butyl 3-hydroxy-3-(trifluoromethyl)pyrrolidine-1-carboxylate and 1-(Bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene	332.2 [M+H] ⁺
BB187	3-[[2,4-bis(Trifluoromethyl)phenyl]methoxy]azetidine	1-(Bromomethyl)-2,4-bis(trifluoromethyl)benzene	336.2 [M+H] ⁺
BB188	3-[[2-Methyl-3-(trifluoromethyl)phenyl] methoxy]azetidine	1-(Bromomethyl)-2-methyl-3-(trifluoromethyl)benzene	246.1 [M+H] ⁺
BB189	3-[[2-Methyl-4-(trifluoromethoxy)phenyl] methoxy]azetidine	1-(Bromomethyl)-2-methyl-4-(trifluoromethoxy)benzene	262.1 [M+H] ⁺
BB190	2-Methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azetidine	1-(Bromomethyl)-2-methyl-4-(trifluoromethoxy)benzene and tert-butyl 3-hydroxy-2-methylazetidine-1-carboxylate	276.2 [M+H] ⁺
BB191	2-Methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl] methoxy]azetidine	1-(Bromomethyl)-2-methyl-3-(trifluoromethyl)benzene and tert-Butyl 3-hydroxy-2-methylazetidine-1-carboxylate	260.2 [M+H] ⁺
BB207	3-[[4-Fluoro-2-(trifluoromethyl)phenyl] methoxy]azetidine; 4-methylbenzenesulfonate	1-(Chloromethyl)-4-fluoro-2-(trifluoromethyl)benzene (CAS RN 248262-29-5)	250.2 [M+H] ⁺
	3-[[3-Fluoro-4-	4-(Bromomethyl)-2-fluoro-1-	Used

BB No.	Systematic Name	Starting material	MS, m/z
BB212	(trifluoromethoxy)phenyl]methoxy]azetidine; 2,2,2-trifluoroacetate	(trifluoromethoxy)benzene	without purification
BB217	3-((4-Methyl-3-(trifluoromethyl)benzyl)oxy)azetidine; 2,2,2-trifluoroacetate	4-(Bromomethyl)-1-methyl-2-(trifluoromethyl)benzene. tBuOK as base	246.2 [M+H] ⁺
BB218	3-((2-Fluoro-6-(trifluoromethyl)benzyl)thio)azetidine 2,2,2-trifluoroacetate	tert-Butyl 3-mercaptoazetidine-1-carboxylate and 2-(Bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene	266.2 [M+H] ⁺

Method D1

BB9

4-[2-Chloro-4-(trifluoromethyl)phenoxy]piperidine; trifluoroacetate salt

[0408] A mixture of tert-butyl 4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (750.0 mg, 1.97 mmol) in DCM (20 mL) and TFA (0.76 mL) was stirred at 20 °C for 12 h. The mixture was concentrated. The residue was dissolved in H₂O (20 mL) and washed twice with PE : EA = 10 : 1 (20 mL each). The aqueous layer was lyophilized to give the desired product as light yellow solid (716 mg, 1.82 mmol, 87.8%). MS (ESI): m/z = 280.1 [M+H]⁺.

Step a) tert-Butyl 4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0409] A mixture of 2-chloro-4-(trifluoromethyl)phenol (500 mg, 2.54 mmol), 1-Boc-4-hydroxypiperidine (768 mg, 3.82 mmol) and triphenylphosphine (1334 mg, 5.09 mmol) in THF (10 mL) was stirred at 0 °C until completely dissolved. DIAD (1542 mg, 7.63 mmol) was slowly added dropwise at 0 °C. The mixture was stirred at 20 °C for 3 h and then concentrated under vacuum. The residue was purified by prep-HPLC to give the desired compound as light yellow solid (760 mg, 2 mmol, 78.7% yield). MS (ESI): m/z = 324.0 [M-56+H]⁺.

BB57

3-(((2-Fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine; trifluoroacetate salt

[0410] To a solution of tert-butyl 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylate (158 mg, 435 μmol) in DCM (1.74 mL) was added TFA (793 mg, 536 μL, 6.96 mmol) and the reaction was stirred at room temperature for 3 h. The reaction mixture was concentrated to give 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine; trifluoroacetate salt (202 mg, 434 μmol, 99.7 % yield) as a colorless oil. The crude was used without further purification. MS (ESI): m/z = 264.1 [M+H]⁺.

Step a) Tert-butyl 3-(((2-fluoro-4-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylate

[0411] To a solution of tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (100 mg, 534 μ mol) in dry THF (2.67 mL) was added potassium tert-butoxide 1.65 M solution in THF (340 μ L, 561 μ mol) and the turbid reaction mixture was stirred at RT for 15 min followed by addition of 1-(bromomethyl)-2-fluoro-6-(trifluoromethyl)benzene (137 mg, 534 μ mol). The reaction mixture was then stirred at room temperature for 3 h. The crude reaction was diluted with ethyl acetate and extracted with sat. aq. NaHCO₃ solution, the organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness to yield a clear oil. The crude was immobilized on Isolute and purified by column chromatography eluting with 0 to 30 % EtOAc in heptanes to afford tert-butyl 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylate (158 mg, 413 μ mol, 77.3 % yield) as a colorless oil. MS (ESI): m/z = 308.1 [M-56+H]⁺

Method D2

BB10

4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine; formic acid salt

[0412] A mixture of tert-butyl 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate (440 mg, 0.610 mmol) and 5.0 mL of 4 M HCl in EtOAc in EtOAc (10 mL) was stirred at 20 °C for 12 h. The mixture was concentrated under vacuum. The residue was redissolved in H₂O (5 mL), washed twice with PE : EA (3 : 1; 10 mL each) and the layers were separated. The aqueous layer was purified by prep-HPLC to give the desired compound as light yellow solid (124 mg, 0.350 mmol, 65.3% yield). MS (ESI): m/z = 312.2 [M+H]⁺.

Step a) tert-Butyl 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate

[0413] A solution of tert-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (500 mg, 1.19 mmol), cyclopentyl bromide (266 mg, 1.78 mmol), Ir(dF(CF₃)ppy)₂(dtbbpy)PF₆ (13.4 mg, 0.010 mmol, CAS RN 870987-63-6), NiCl₂.glyme (0.77 mg, 0.060 mmol), dtbbpy (19.2 mg, 0.070 mmol, CAS RN 72914-19-3), TTMSS (296 mg, 1.19 mmol, CAS RN 1873-77-4) and Na₂CO₃ (252 mg, 2.38 mmol) in DMF (20 mL) was degassed by bubbling argon stream for 20 min. The reaction mixture was irradiated with Blue LED (4×1) at 25 °C for 16 h. The mixture was diluted with H₂O and then extracted three times with EtOAc (100 mL each). The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by prep-HPLC to give the compound as a colorless oil (460 mg, 1.12 mmol, 53.8%). MS (ESI): m/z = 354.1 [M-56+H]⁺.

Step b) tert-Butyl 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate

[0414] To a mixture of tert-butyl 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (460 mg, 0.640 mmol) in EtOAc (10 mL) was added wet Pd/C (40 mg), and then the mixture was stirred at 20 °C for 12 h under H₂ (1520 mmHg). The mixture was filtered and the filtrate was concentrated to give the compound as colorless oil (460 mg, 1.12 mmol, 99.5%). MS (ESI): m/z = 356.1 [M+H-56]⁺.

BB11

2-(4-Piperidylmethyl)-1,3-benzoxazole; formic acid salt

[0415] A solution of 2-aminophenol (1.0 g, 9.16 mmol) and 1-Boc-4-piperidylacetic acid (2.68 g, 11 mmol) in polyphosphoric acid (2.2 g) was stirred at 180 °C for 2 h. The mixture was diluted with a mixture of 12M aqueous NH₄OH solution and ice to reach pH > 7, and then extracted three times with EtOAc (10 mL each). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated, and the residue was purified by prep-HPLC to give the desired compound as a brown oil (251 mg, 0.960 mmol, 9.7%). MS (ESI): m/z = 217.2 [M+H]⁺.

Method D3

BB13

4-[4-Chloro-3-(4-chlorophenyl)phenoxy]piperidine; hydrochloride salt

[0416] A solution of tert-butyl 4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylate (1000 mg, 2.37 mmol) in a 4 M solution of HCl in dioxane (50 mL) was stirred at 20 °C for 12 h. The mixture was concentrated to give the title compound as a white solid (845 mg, 2.35 mmol, 96.2%). MS (ESI): m/z = 322.0 [M+H]⁺.

Step a) *tert-Butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate*

[0417] A mixture of 3-bromo-4-chlorophenol (1000 mg, 4.82 mmol), 1-Boc-4-hydroxypiperidine (1164 mg, 5.78 mmol) and triphenylphosphine (2529 mg, 9.64 mmol) was stirred in THF (10 mL) until completely dissolved. Then DIAD (1948 mg, 9.64 mmol) was slowly added drop wise at 0 °C. The mixture was stirred at 20 °C for 12 h, concentrated and the residue was purified by reversed flash chromatography to give the compound as yellow oil (1300 mg, 3.33 mmol, 69.0%). MS (ESI): m/z = 336.0 [M-56+H]⁺.

Step b) *tert-Butyl 4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylate*

[0418] To a solution of tert-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (1150 mg, 2.94 mmol) and 4-chlorophenylboronic acid (506 mg, 3.24 mmol), Na₂CO₃ (1248 mg, 11.8 mmol) in 1,4-dioxane (20 mL) and H₂O (5 mL) was added tetrakis(triphenylphosphine)palladium(0) (340 mg, 0.290 mmol, CAS RN 14221-01-3), and the mixture was stirred at 110 °C under N₂ atmosphere for 12 h. The mixture was filtered, the filtrate was concentrated, and the residue was purified by silica gel column chromatography, eluting with a 5 - 20% EtOAc - PE gradient to give the desired compound as light yellow oil (1100 mg, 2.6 mmol, 88.5%). MS (ESI): m/z = 366.1 [M-56+H]⁺.

BB14

4-[[2-(1H-Pyrazol-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine; trifluoroacetate salt

[0419] To a mixture of *tert*-butyl 4-[[2-(1-*tert*-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate (150.0 mg, 0.290 mmol) in DCM (5 mL) was added TFA (1.0 mL). The mixture was stirred at 20 °C for 15 h. The mixture was concentrated under vacuum and then lyophilized to give the title compound as light yellow gum (149 mg, 0.280 mmol, 85.1% yield). MS (ESI): $m/z = 310.0$ $[M+H]^+$.

Step a) *tert*-Butyl 4-[[2-(1-*tert*-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate

[0420] A mixture of *tert*-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (600 mg, 1.43 mmol), *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyrazole-1-carboxylate (846 mg, 2.86 mmol) and K_2CO_3 (592 mg, 4.28 mmol) in DMF (10 mL) and H_2O (0.5 mL) was stirred at 80 °C for 12 h. The mixture was poured into H_2O (30 mL) and extracted twice with EtOAc (50 mL each). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 and filtered. The filtrate was concentrated in vacuum to give the compound as light yellow oil (520 mg, 1.02 mmol, 71.8% yield). MS (ESI): $m/z = 308.1$ $[M+H]^+$.

Step b) *tert*-Butyl 4-[[2-(1-*tert*-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate

[0421] A mixture of *tert*-butyl 4-[[2-(1-*tert*-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (180 mg, 0.350 mmol) and wet Pd/C (18 mg) in EtOAc (10 mL) was stirred at 30 °C for 24 h under H_2 atmosphere (~1520 mm Hg). The mixture was filtered and concentrated under vacuum to give the compound as brown oil (150 mg, 0.290 mmol, 83%). MS (ESI): $m/z = 354.1$ $[M-56-100+H]^+$.

BB18

4- [2-(2-Chlorophenyl)ethynyl] piperidine

[0422] To a suspension of *tert*-butyl 4-((2-chlorophenyl)ethynyl)piperidine-1-carboxylate (0.05 g, 0.156 mmol) in MeOH (3 mL) was added 4 M HCl in dioxane (0.391 mL, 1.56 mmol) and the reaction mixture was stirred at room temperature for 2 h. The mixture was evaporated to dryness and the residue triturated in diisopropyl ether, filtered off and further dried under high vacuum to give the title compound as a white solid as the hydrochloride salt (0.02 g, 50%). MS (ESI): $m/z = 220.1$ $[M+H]^+$.

Step a) *tert*-Butyl 4-[2-(2-chlorophenyl)ethynyl]piperidine-1-carboxylate

[0423] In a sealed tube, a mixture of *tert*-butyl 4-ethynylpiperidine-1-carboxylate (0.1 g, 0.478 mmol, CAS RN 287192-97-6), 1-bromo-2-chlorobenzene (0.084 mL, 0.717 mmol), copper (I) iodide (0.002 g, 0.009 mmol), TEA (0.666 mL, 4.78 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.027 g, 0.038) in THF (2.8 mL)

was degassed for 5 min under Argon. The reaction mixture was then heated to 70 °C and stirred for 4 h. The mixture was filtered off over a pad of Dicalite, washed with EtOAc and the mother liquors were evaporated to dryness. The residue was purified by silica gel flash chromatography, eluting with a gradient of 0-50% EtOAc/n-heptane to give the title compound as a white solid (0.05 g, 33%). MS (ESI): m/z = 264.1 [M-56+H]⁺.

BB48a

tert-Butyl 4-[[2-fluoro-4-(trifluoromethyl)phenyl] methyl] piperidine-1-carboxylate

[0424] A degassed solution of tert-butyl 4-methylenepiperidine-1-carboxylate (4465 mg, 22.6 mmol, CAS RN 159635-49-1) in 9-BBN (45.3 mL, 22.6 mmol) was refluxed for 1 h. After cooling to room temperature, the solution was added into a solution of 4-bromo-3-fluorobenzotrifluoride (5.0 g, 20.6 mmol, CAS RN 40161-54-4), Pd(dppf)Cl₂ (1514 mg, 2.06 mmol) and K₂CO₃ (5687 mg, 41.1 mmol) in DMF (50 mL) and water (5 mL). The resulting mixture was heated at 80 °C for 5 h. After the mixture was cooled to room temperature and poured into water, the pH was adjusted to 11 with 10% aqueous NaOH solution, and the mixture was extracted with EtOAc. The combined organic extracts were dried with brine and Na₂SO₄, filtered, and evaporated to give a residue, which was further purified by column chromatography (silica gel, PE : EtOAc = 10 : 1 to 5 : 1) to give the compound as light yellow solid (240 mg, 3.2%). MS (ESI): m/z = 306 [M+H-56]⁺.

BB51a

[0425] A mixture of tert-butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (1000 mg, 2.62 mmol) and PtO₂ (100 mg, 0.440 mmol) in EtOAc (20 mL) was stirred at 20 °C for 12 h under H₂ atmosphere (1520 mmHg). The mixture was filtered and the filtrate concentrated to furnish the compound as light yellow solid (940 mg, 93.5%). MS (ESI): m/z = 328.2 [M+H]⁺.

Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene

[0426] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene (5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45 mmol) and NBS (4.07 g, 23.01 mmol) in CCl₄ (50.0 mL, 23.0 mmol) was stirred at 70 °C for 5 h. The mixture was poured into water (20 mL) and extracted twice with DCM (20 mL each). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated in vacuum to give the desired compound as light yellow oil which was used in the next step without further purification (7.1 g, 97%).

Step b) 2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene

[0427] A mixture of 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3 mmol) and triethyl phosphite (30 mL) was stirred at 155 °C for 5 h. The mixture was concentrated in vacuum to remove triethyl phosphite, the residue was diluted with water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by column chromatography (PE : EtOAc = 100 : 1 to 10:1) to give the compound as light yellow oil which was used without further purification in the next step (8 g, 95.5%).

Step c) *tert*-Butyl 4-(2-bromo-4-(trifluoromethyl)benzylidene)piperidine-1-carboxylate

[0428] To a mixture of 2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene (6.9 g, 18.4 mmol) in THF (100 mL) was added sodium hydride (2.21 g, 55.2 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h, then 1-Boc-4-piperidone (7.33 g, 36.79 mmol, CAS RN 79099-07-3) was added and the mixture was stirred at 20 °C for 12 h. The mixture was poured into water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by column chromatography (PE : EA = 100 : 1 to 50 : 1) to yield the desired compound as off-white solid (4 g, 51.7%). MS (ESI): m/z = 365.9 [M-56+H]⁺.

Step d) *tert*-butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate

[0429] A mixture of *tert*-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS RN 411235-57-9) and potassium carbonate (1973 mg, 14.3 mmol) in DMF (10 mL) and water (0.5 mL) was stirred at 80 °C under nitrogen atmosphere for 12 h. The mixture was poured into water (50 mL), extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and concentrated in vacuum. The residue was purified by prep-HPLC to give the compound as light yellow oil (1020 mg, 56.2% yield). MS (ESI): m/z = 326.0 [M-56+H]⁺.

BB53a***tert*-Butyl 3-[(4-chlorophenyl)methoxy]pyrrolidine-1-carboxylate**

[0430] A solution of N-Boc-3-hydroxypyrrolidine (1.0 g, 5.34 mmol) and 4-chlorobenzyl bromide (1.32 g, 6.41 mmol) in ACN (10 mL) was added potassium carbonate (1.48 g, 10.68 mmol). The mixture was stirred at 80 °C for 15 h. Then the mixture was concentrated and diluted with water and extracted three times with EtOAc (10 mL each). The combined organic layers were concentrated to give the desired compound as colorless oil (326 mg, 19.6% yield) MS (ESI): m/z = 256.0 [M-56+H]⁺.

Method D4**BB70****3-[4-(Trifluoromethyl)phenoxy] azetidine**

[0431] To a solution of *tert*-butyl 3-[4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate (500 mg, 1.58 mmol, BB70a) in DCM (3 mL) was added TFA (1.0 mL, 0.950 mmol) at 25 °C, the reaction was stirred at this temperature for 12 h. The mixture was concentrated and the residue was purified via prep-HPLC to provide the compound as colorless solid (150 mg, 0.690 mmol, 43.8%). MS (ESI): m/z = 218.1 [M+H]⁺.

BB72a**tert-Butyl 4-(4-chloro-3-cyclopropyl-phenoxy)piperidine-1-carboxylate**

[0432] To a solution of tert-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500 mg, 1.28 mmol, BB90), potassium carbonate (354 mg, 2.56 mmol) and cyclopropylboronic acid (121 mg, 1.41 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II) (187.28 mg, 0.260 mmol). The mixture was stirred at 100 °C under nitrogen atmosphere for 12 h. The reaction mixture was filtered and the filtrate was diluted with EtOAc (30 mL), washed with water and then brine, the organic phase was dried over Na₂SO₄, concentrated. The residue was purified by silica gel column (eluting with a gradient of 5% - 10% EtOAc-PE) to give the compound as light yellow oil (220 mg, 48.9%). MS (ESI): m/z = 296.1 [M-56+H]⁺.

BB73a**tert-Butyl 4-(4-chloro-3-morpholino-phenoxy) piperidine-1-carboxylate**

[0433] To a solution of tert-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500 mg, 1.28 mmol, BB90), cesium carbonate (834 mg, 2.56 mmol), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene (159 mg, 0.260 mmol) and morpholine (112 mg, 1.28 mmol) in DMF (10 mL) was added tris(dibenzylideneacetone)dipalladium(0) (187 mg, 0.260 mmol) and the mixture was stirred at 110 °C under nitrogen atmosphere for 12 h. The reaction mixture was filtered, the filtrate was diluted with EtOAc (30 mL), washed with water and then brine, the organic phase was dried over Na₂SO₄, and concentrated. The residue was purified by silica gel column (eluting with a gradient of 5% - 10% EtOAc-PE) to give the desired compound (360 mg, 70.9% yield) as light yellow oil. MS (ESI): m/z = 397.1 [M +H]⁺.

BB74a**tert-Butyl 4-[2-methyl-4-(trifluoromethyl)phenoxy] piperidine-1-carboxylate**

[0434] To a solution of tert-butyl 4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (2.0 g, 4.71 mmol, BB74b) in THF (40 mL) was added lithium methide (11.8 mL, 18.9 mmol) dropwise at -70 °C. The mixture was stirred at -70 °C for 1 h and then stirred at 20 °C for 12 h. The mixture was poured into ice water (100 mL) and extracted three times with EtOAc (50 mL each). The combined organic layer was washed with brine (100 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to yield the compound as light yellow solid (780 mg, 46%). MS (ESI): m/z = 260.1 [M-100+H]⁺.

BB75a**tert-Butyl 4-[2-cyano-4-(trifluoromethyl)phenoxy] piperidine-1-carboxylate**

[0435] To a solution of zinc cyanide (2214 mg, 18.9 mmol) and tert-butyl 4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (1600 mg, 3.77 mmol, BB74b) in DMA (30 mL) was added dppf (627 mg, 1.13 mmol), N,N-diisopropylethylamine (1.97 mL, 11.3 mmol), Zinc dust (245 mg, 3.77 mmol) and Pd₂(dba)₃ (1036 mg, 1.13 mmol) at 20 °C, then the mixture was stirred at 140 °C under nitrogen atmosphere for 4 h. The mixture was filtered. The filtrate was poured into water (100 mL) and extracted three times with EtOAc (50 mL each). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated over vacuum to give the title compound as light brown solid (2.3 g, crude). MS (ESI): m/z = 315.0 [M-56+H]⁺.

BB76a

tert-Butyl 4-(oxazolo [5,4-c] pyridin-2-ylmethyl)piperidine-1-carboxylate

[0436] To a solution of hexachloroethane (2.47 g, 10.4 mmol) in toluene (20 mL) was added triphenylphosphine (3.28 g, 12.5 mmol) and NEt₃ (4.65 mL, 33.4 mmol). The mixture was stirred at 80 °C for 5 min, then tert-butyl 4-[2-[(3-hydroxy-4-pyridyl)amino]-2-oxoethyl]piperidine-1-carboxylate (1.4 g, 4.17 mmol) was added and stirred at 80 °C for 12 h. The mixture was concentrated to remove toluene, then diluted with water (100 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude was purified by silica gel chromatography (PE : EtOAc = 10 : 1 to 1 : 0) to give the compound as a yellow oil (814 mg, 21% yield). MS (ESI): m/z = 318.1 [M+H]⁺.

Step a) tert-Butyl 4-[2-[(3-hydroxy-4-pyridyl)amino]-2-oxo-ethyl]piperidine-1-carboxylate

[0437] A solution of 4-aminopyridin-3-ol (3.0 g, 27.3 mmol) and 1-Boc-4-piperidylacetic acid (7.95 g, 32.7 mmol) in DMF (30 mL) was added HOBt (6.26 g, 40.9 mmol), EDCI (6.34 g, 40.87 mmol) and NEt₃ (11.39 mL, 81.74 mmol). The mixture was stirred at 20 °C for 15 h. Then the mixture was concentrated, the residue taken up in water (100 mL), and then extracted three times with EtOAc (20 mL each). The organic phase was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by reversed phase chromatography and lyophilized to give two batches of the desired compound. Batch 1 as colorless solid (1.2 g, 85% purity, 11.1%), and batch 2 as colorless solid (520 mg, 76.7% purity, 4.4% yield). MS (ESI): m/z = 336.1 [M+H]⁺ for both batches.

BB77

4-Chloro-3-(2-piperidin-4-ylethynyl)pyridine

[0438] Intermediate BB77 was prepared in analogy to BB18, but using 3-bromo-4-chloro-pyridine in step a), to give the title compound as an orange solid. MS (ESI): m/z = 221.1 [M+H]⁺.

BB78

3-Chloro-2-(2-piperidin-4-ylethynyl)pyridine

[0439] Intermediate BB78 was prepared in analogy to BB18, but using 2-bromo-3-chloro-pyridine in step a), to give the title compound as a yellow solid. MS (ESI): $m/z = 221.1$ $[M+H]^+$.

BB79

4- [2-(2-Chloro-4-fluorophenyl)ethynyl] piperidine

[0440] Intermediate BB79 was prepared in analogy to BB18, but using 1-bromo-2-chloro-4-fluorobenzene in step a), to give the title compound as a white solid. MS (ESI): $m/z = 238.1$ $[M+H]^+$.

BB80

4- [2-(3-Chlorophenyl)ethynyl] piperidine

[0441] Intermediate BB80 was prepared in analogy to BB18, but using 1-bromo-3-chlorobenzene in step a), to give the title compound as a colorless amorphous solid. MS (ESI): $m/z = 220.2$ $[M+H]^+$.

BB81

4- [2-(4-Chlorophenyl)ethynyl] piperidine

[0442] Intermediate BB81 was prepared in analogy to BB18, but using 1-bromo-4-chlorobenzene in step a), to give the title compound as a yellow amorphous solid. MS (ESI): $m/z = 220.2$ $[M+H]^+$.

BB82

4-[2-(2-Chloro-4-chlorophenyl)ethynyl]piperidine

[0443] Intermediate BB82 was prepared in analogy to BB18, but using 1-bromo-2,4-dichloro-benzene in step a), to give the title compound as a light yellow amorphous solid. MS (ESI): $m/z = 254.1$ $[M+H]^+$.

BB83

4- [2-(2-Chlorophenyl)ethynyl] piperidin-4-ol

[0444] Intermediate BB83 was prepared in analogy to BB18, but using *tert*-butyl 4-ethynyl-4-hydroxypiperidine-1-carboxylate (CAS RN 275387-83-2) in step a), to give the title compound as a yellow amorphous solid. MS (ESI): $m/z = 218$. $1[M-H_2O+H]^+$.

BB84

3- [2-(2-Chlorophenyl)ethynyl] azetidine

[0445] To a solution *tert*-butyl 3-[2-(2-chlorophenyl)ethynyl]azetidine-1-carboxylate (0.035 g, 0.120 mmol) in DCM (0.6 mL) was added TFA (0.92.4 mL, 1.2 mmol) and the reaction mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM, poured into a saturated aq. $NaHCO_3$ solution and extracted with DCM. The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered, evaporated and further dried on the high vacuum to give the crude title compound (0.02 g, 87%) as a light yellow oil. MS (ESI): $m/z = 192.0$ $[M+H]^+$.

Step a) *tert*-Butyl 3-[2-(2-chlorophenyl)ethynyl]azetidine-1-carboxylate

[0446] The compound was prepared in analogy to intermediate BB18, but using *tert*-butyl 3-ethynylazetidine-1-carboxylate (CAS RN 287193-01-5) in step a), to give the title compound as a white solid. MS (ESI): $m/z = 236.1$ $[M-56+H]^+$.

BB85

3- [2-(2,4-Dichlorophenyl)ethynyl] azetidine

[0447] Intermediate BB85 was prepared in analogy to intermediate BB84, but using 1-bromo-2,4-dichlorobenzene in step a), to give the title compound as a light yellow oil. MS (ESI): $m/z = 226.1$ $[M+H]^+$.

BB86

3- [2-(2-Chloro-4-fluoro-phenyl)ethynyl] azetidine

[0448] Intermediate BB86 was prepared in analogy to intermediate BB84, but using 1-bromo-2-chloro-4-fluorobenzene in step a), to give the title compound as a yellow oil. MS (ESI): $m/z = 210.1$ $[M+H]^+$.

[0449] In analogy to BB9a the following building blocks were prepared from the respective building blocks

BB No.	Systematic Name	Starting materials	MS, m/z
BB54a	tert-Butyl 4-[[2-methyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate	tert-Butyl 4-methylenepiperidine-1-carboxylate	302.1 [M+H-56] ⁺
		4-Bromo-3-methyl benzotrifluoride	
BB55a	tert-Butyl 4-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate	tert-Butyl 4-methylenepiperidine-1-carboxylate	322.0 [M+H-56] ⁺
		4-Bromo-3-chlorobenzotrifluoride	

[0450] In analogy to BB15a the following building blocks were prepared from the respective building blocks.

BB No.	Systematic Name	Starting materials	MS, m/z
BB49a	tert-Butyl 3-[(2-chlorophenyl)methoxy]pyrrolidine-1-carboxylate	2-Chlorobenzyl bromide N-Boc-3-hydroxypyrrolidine	256.0 [M-56+H] ⁺
BB50a	tert-Butyl 3-[(3-chlorophenyl)methoxy]pyrrolidine-1-carboxylate	3-Chlorobenzyl bromide	256.0 [M-56+H] ⁺
		N-BOC-3-hydroxypyrrolidine	

[0451] In analogy to BB9 step a, the following building blocks were prepared from the respective starting materials.

BB No.	Systematic Name	Starting materials	MS, m/z
BB47a	tert-Butyl 3-[(2-chlorophenoxy)methyl]pyrrolidine-1-carboxylate	2-Chlorophenol	256.0 [M-56+H] ⁺
		tert-Butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate	
BB52a	tert-Butyl 3-[(4-chlorophenoxy)methyl]pyrrolidine-1-carboxylate	4-Chlorophenol	256.0 [M-56+H] ⁺
		tert-Butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate	
BB70a	tert-Butyl 3-[4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate	4-(Trifluoromethyl)phenol	Used without further purification
		tert-Butyl 3-hydroxyazetidine-1-carboxylate	
BB71a	tert-Butyl 4-[4-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carboxylate	1-Boc-4-hydroxypiperidine	324.0 [M-56+H] ⁺
		4-Chloro-3-(trifluoromethyl)phenol	
BB74b	tert-Butyl 4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate	2-Bromo-4-(trifluoromethyl)phenol	369.9 [M-56+H] ⁺
		1-BOC-4-hydroxypiperidine	
BB89a	tert-Butyl 3-[(3-chlorophenoxy)methyl]pyrrolidine-1-carboxylate	3-Chlorophenol	256.0 [M-56+H] ⁺
		tert-Butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate	

BB No.	Systematic Name	Starting materials	MS, m/z
BB90	tert-Butyl 4-(3-bromo-4-chloro-phenoxy) piperidine-1-carboxylate	3-Bromo-4-chlorophenol	336.0 [M-56+H] ⁺
		1-BOC-4-hydroxypiperidine	

Method D5**BB51****4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine formic acid salt**

[0452] To a mixture of tert-butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate (940 mg, 2.45 mmol, BB51a) in DCM (10 mL) was added TFA (2.0 mL, 2.45 mmol). The mixture was stirred at 20 °C for 12 h. The mixture was concentrated under vacuum. The residue was purified twice by prep-HPLC to furnish the desired compound as light yellow gum (111 mg, 12.4%). MS (ESI): m/z = 284.2 [M+H]⁺.

Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene

[0453] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene (5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45 mmol) and NBS (4.07 g, 23.0 mmol) in CCl₄ (50.0 mL, 23.0 mmol) was stirred at 70 °C for 5 h. The mixture was poured into water (20 mL) and extracted twice with DCM (20 mL each). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated in vacuum to give the compound as light yellow oil (7.1 g, 97%) which was used in the next step without further purification.

Step b) 2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene

[0454] A mixture of 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3 mmol) and triethyl phosphite (30.0 mL) was stirred at 155 °C for 5 h. The mixture was concentrated in vacuum to remove triethyl phosphite. The residue was diluted with water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (PE : EA = 100 : 1 to 10 : 1) to give the title compound as light yellow oil (8 g, 21.3 mmol, 95.5%) which was used in the subsequent step without further purification.

Step c) tert-Butyl 4-(2-bromo-4-(trifluoromethyl)benzylidene)piperidine-1-carboxylate

[0455] A mixture of 2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene (6.9 g, 18.4 mmol) in THF (100 mL) was added NaH (2.21 g, 55.2 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h, then 1-Boc-4-piperidone (7.33 g, 36.8 mmol, CAS RN 79099-07-3) was added and the mixture was stirred at 20 °C for 12 h. The mixture was poured into water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by column chromatography (PE : EA = 100 : 1 to 50 : 1) to yield the desired

compound as off-white solid (4 g, 9.52 mmol, 51.7%). MS (ESI): $m/z = 365.9$ $[M-56+H]^+$.

Step d) *tert*-Butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate

[0456] A mixture of *tert*-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS RN 411235-57-9) and potassium carbonate (1973 mg, 14.3 mmol) in DMF (10 mL) and water (0.5 mL) was stirred at 80 °C for 12 h under nitrogen atmosphere. The mixture was poured into water (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4 and concentrated in vacuum. The residue was purified by prep-HPLC to give the compound as light yellow oil (1020 mg, 56.2% yield) MS (ESI): $m/z = 326.0$ $[M-56+H]^+$.

[0457] Step e) *tert*-Butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate A mixture of *tert*-butyl 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (1000 mg, 2.62 mmol) and PtO_2 (100 mg, 0.440 mmol) in EtOAc (20 mL) was stirred at 20 °C for 12 h under hydrogen atmosphere (1520 mm Hg). Then the mixture was filtered and the filtrate was concentrated to yield the compound as light yellow solid (940 mg, 93.5% yield). MS (ESI): $m/z = 328.2$ $[M+H]^+$.

Method D6

BB92

N-methyl-N-[4-(trifluoromethyl)phenyl]piperidin-4-amine; trifluoroacetate salt

[0458] To a solution of *tert*-butyl 4-[N-methyl-4-(trifluoromethyl)anilino]piperidine-1-carboxylate (150 mg, 0.420 mmol) in DCM (1 mL) was added TFA (0.1 mL) at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated in vacuum. The residue was purified by pre-HPLC (in the presence of TFA) to give the desired product as yellow solid (120 mg, 77.0%). MS (ESI): $m/z = 259.2$ $[M+H]^+$.

Step a) *tert*-Butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate

[0459] To a solution of *p*-trifluoromethylaniline (1.17 mL, 9.31 mmol, CAS RN 455-14-1) in DCM (30 mL) was added AcOH (0.560 g, 9.31 mmol) and 1-BOC-4-piperidone (2.78 g, 14.0 mmol, CAS RN 79099-07-3). Then 1M BH_3 /THF solution (27.9 mL, 27.9 mmol) was added carefully at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at 25 °C for 12 h. The mixture was poured into saturated aqueous NH_4Cl solution (30 mL) and extracted three times with EtOAc. The combined organic layers were washed twice with water H_2O , and then brine, dried over Na_2SO_4 and concentrated in vacuum to afford yellow residue, which was purified by silica gel column eluting with a gradient of PE : EtOAc (20 : 1 to 5 : 1) to give the desired product as white solid (2.0 g, 62.4%). MS (ESI): $m/z = 289.1$ $[M-56+H]^+$.

Step b) *tert*-Butyl 4-[N-methyl-4-(trifluoromethyl)anilino]piperidine-1-carboxylate

[0460] To a solution of NaH (52.3 mg, 60.0% wt%, 1.31 mmol) in DMF (5 mL) was added tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate (300 mg, 0.870 mmol) at 0 °C under nitrogen atmosphere. The mixture was stirred at 0 °C for 15 min, and then iodomethane (371 mg, 2.61 mmol) was added. The reaction mixture was stirred at 80 °C for 12 hrs. The reaction mixture was poured into water (20 mL) and extracted three times with EtOAc, the combined organic layers were washed twice with water and brine, dried over sodium sulfate and concentrated in vacuum to afford light yellow residue, which was purified by silica gel column eluting with a gradient of PE : EtOAc (20 : 1 to 5 : 1) to give the desired product as white solid (160 mg, 51.3%). MS (ESI): $m/z = 303.1$ $[M-56+H]^+$.

BB93

N-methyl-N-(4-(trifluoromethyl)phenyl)azetidin-3-amine (trifluoroacetic acid salt)

[0461] The title compound was prepared in analogy to method D6 from tert-butyl 3-[N-methyl-4-(trifluoromethyl)anilino]azetidine-1-carboxylate (48%). MS (ESI): $m/z = 231.1$ $[M+H]^+$.

Step a) tert-Butyl 3-[4-(trifluoromethyl)anilino]azetidine-1-carboxylate

[0462] To a solution of p-trifluoromethylaniline (0.780 mL, 6.21 mmol, CAS RN 455-14-1), AcOH (1.86 g, 31.0 mmol) and 1-BOC-3-azetidinone (2.13 g, 12.4 mmol, CAS RN 398489-26-4) in EtOH (10 mL) was added NaBH₃CN (1.95 g, 31.0 mmol) at 25 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was poured into saturated aqueous NH₄Cl solution (20 mL) and extracted twice with EtOAc. The combined organic layers were washed twice with H₂O and brine, dried over sodium sulfate and concentrated in vacuum to afford yellow residue, which was purified by silica gel column eluting with a gradient of PE : EtOAc (10 : 1 to 5 : 1) to give the desired product as white solid (340 mg, 17.3%). MS (ESI): $m/z = 261.1$ $[M-56+H]^+$.

Step b) tert-Butyl 3-[N-methyl-4-(trifluoromethyl)anilino]azetidine-1-carboxylate

[0463] To a solution of tert-butyl 3-[4-(trifluoromethyl)anilino]azetidine-1-carboxylate (300 mg, 0.950 mmol) in DMF (5 mL) was added NaH (45.5 mg, 60% wt%, 1.14 mmol) at 0 °C. The mixture was stirred for 15 min, and then iodomethane (404 mg, 2.85 mmol) was added. The reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was poured into H₂O (20 mL) and extracted twice with EtOAc. The combined organic layers were washed three times with H₂O and brine, dried over Na₂SO₄ and concentrated in vacuum to afford yellow residue. The residue was purified by silica gel column eluting with a gradient of PE : EtOAc (10 : 1 to 5 : 1) to give the desired product as white solid (310 mg, 98.9%). MS (ESI): $m/z = 275.2$ $[M-56+H]^+$.

Method D7

BB94

N-methyl-N-(piperidin-4-yl)-2-(3-(trifluoromethyl)phenyl)acetamide hydrochloride

[0464] To a solution of *tert*-butyl 4-[methyl-[2-[3-(trifluoromethyl)phenyl]acetyl]amino] piperidine-1-carboxylate (0.080 g, 200 μ mol) in DCM (1 mL) was added a 2 M HCl solution in diethyl ether (999 μ L, 2 mmol). The reaction mixture was stirred at RT overnight and then concentrated in vacuo to afford the title compound (67 mg, 199 μ mol) as an off-white solid. MS (ESI): m/z = 301.2 $[M+H]^+$.

Step a) *tert*-Butyl 4-[methyl-[2-[3-(trifluoromethyl)phenyl]acetyl]amino]piperidine-1-carboxylate

[0465] To a stirred mixture of 2-(3-(trifluoromethyl)phenyl)acetic acid (105 mg, 513 μ mol, CAS RN 351-35-9) in DMF (5 mL) was added HATU (195 mg, 513 μ mol) and DIPEA (181 mg, 244 μ L, 1.4 mmol). After 15 min. stirring, *tert*-butyl 4-(methylamino)piperidine-1-carboxylate (0.100 g, 467 μ mol, CAS RN 147539-41-1) was added and the reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with DCM and washed with H₂O. The org. phase was concentrated to give a crude product which was purified by flash chromatography on a 20 g SiO₂ column, using an eluent mixture of *n*-heptane and EtOAc (0% to 100%) to afford the desired compound as a light yellow oil (85 mg, 213 μ mol). MS (ESI): m/z = 459.259 $[M+CH_3CN+NH_4]^+$.

Method D8

BB194

3-(4-Chloro-3-cyclopropylphenoxy)azetidine

[0466] To a solution of *tert*-butyl 3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate (0.023 g, 0.057 mmol) in DCM (1 mL) was added TFA (0.088 mL, 1.14 mmol) and the reaction mixture stirred at room temperature for 18 hours. The mixture was diluted with DCM, poured into a sat. aq. NaHCO₃ solution and extracted with DCM. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and evaporated to dryness to yield the crude title compound (0.007 g, 35%) as a colorless oil. MS (ESI): m/z = 224.1 $[M+H]^+$.

Step a) *tert*-Butyl 3-(3-bromo-4-chlorophenoxy)azetidine-1-carboxylate

[0467] In a sealed tube, 3-bromo-4-chlorophenol (0.1 mg, 0.482 mmol) and *tert*-butyl 3-hydroxyazetidine-1-carboxylate (0.083 g, 0.482 mmol) were dissolved in toluene (1.5 mL). The vial was degassed with argon, then (tributylphosphoranylidene)acetonitrile (CAS RN 157141-27-0, 0.195 mL, 0.723 mmol) was added and the reaction mixture heated to 100°C for 30 minutes. The mixture was diluted with EtOAc, poured into sat. aq. NaHCO₃ solution and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography eluting with a 0 to 20% EtOAc/heptane gradient to give the title compound (0.116 g, 53%) as a yellow oil. MS (ESI): m/z = 308.1 $[M-56+H]^+$.

Step b) *tert*-Butyl 3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate

[0468] In a microwave vial, *tert*-butyl 3-(3-bromo-4-chlorophenoxy)azetidine-1-carboxylate (0.075 g, 0.165 mmol), cyclopropylboronic acid (0.021 g, 0.248 mmol) and K₂CO₃ (0.046 g, 0.331 mmol) were mixed in dioxane (1.6 mL). Then, water (0.4 mL) was added followed by bis(triphenylphosphine)palladium (II) chloride (0.012 g, 0.016 mmol) and the reaction mixture heated at 130°C under microwave irradiation for 1 hour. The reaction mixture was diluted with EtOAc, poured into water and extracted with EtOAc. The organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography, eluting with a 0 to 10% EtOAc/heptane gradient to give the title compound (0.023 g, 43%) as a colorless oil. MS (ESI): *m/z* = 268.2 [M-56+H]⁺.

Method D9

BB197

3-(2-Chloro-3-cyclopropylphenoxy)azetidine, trifluoroacetate salt

[0469] To a solution of *tert*-butyl 3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carboxylate (0.1 g, 0.310 mmol) in DCM (2.5 mL) was added TFA (0.25 mL) and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated *in vacuo* to give the crude title compound (0.083 g, 80% yield) as a dark brown oil. MS (ESI): *m/z* = 224.6 [M +H]⁺.

Step a) *tert*-Butyl 3-(3-bromo-2-chloro-phenoxy)azetidine-1-carboxylate

[0470] To a solution of *tert*-butyl 3-hydroxyazetidine-1-carboxylate (0.5 g, 2.89 mmol) and 3-bromo-2-chlorophenol (0.5 g, 2.41 mmol) in THF (10 mL) were added PPh₃ (0.948 g, 3.62 mmol) followed by diethyl azodicarboxylate (0.47 mL, 3.62 mmol) and the reaction mixture was stirred at room temperature for 12 hours. The mixture was purified by reversed phase HPLC to give the title product (0.4 g, 46%) as a light yellow oil. MS (ESI): *m/z* = 308.3 [M-56 +H]⁺.

Step b) *tert*-Butyl 3-(2-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate

[0471] In a sealed tube, cyclopropylboronic acid (0.071 g, 0.830 mmol), *tert*-butyl 3-(3-bromo-2-chlorophenoxy)azetidine-1-carboxylate (0.2 g, 0.550 mmol) and Na₂CO₃ (0.117 g, 1.1 mmol) were mixed in 1,4-dioxane (5 mL) and water (1 mL). Then, Pd(dppf)Cl₂ (0.040 g, 0.060 mmol) was added and the mixture was stirred to 110 °C for 12 hours. The mixture was purified by reversed phase HPLC to give the title compound (0.12 g, 67%) as a light yellow oil. MS (ESI): *m/z* = 268.1 [M-56 +H]⁺.

Method D10

BB202

5-(4-Piperidyloxy)-2-(trifluoromethyl)benzonitrile, trifluoroacetate

[0472] To a solution of *tert*-butyl 4-[3-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (0.05 g, 0.140 mmol) in DCM (1.5 mL) was added TFA (0.2 mL) and the reaction mixture stirred at room temperature for 12 hours. The mixture was concentrated *in vacuo* to give the crude title compound (0.051 g, 98%) as a light brown oil. MS (ESI): $m/z = 271.6$ $[M+H]^+$.

Step a) *tert*-Butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0473] To a solution of 3-bromo-4-(trifluoromethyl)phenol (0.5 g, 2.54 mmol) and 1-Boc-4-hydroxypiperidine (0.512 g, 2.54 mmol) in THF (8.5 mL) were added PPh_3 (1 g, 3.82 mmol) followed by diethyl azodicarboxylate (0.665 g, 3.82 mmol) and the reaction mixture was stirred at room temperature for 12 hours. The mixture was purified by silica gel flash chromatography, eluting with with PE:EtOAc 5:1 to give the title compound (0.5 g, 47%) as a light yellow oil. MS (ESI): $m/z = 370.2$ $[M-56 + H]^+$.


Step b) *tert*-Butyl 4-[3-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0474] In a sealed tube, *tert*-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (0.2 g, 0.470 mmol), $Zn(CN)_2$ (0.111 g, 0.940 mmol), CuI (0.09 g, 0.470 mmol) were mixed in DMF (10 mL). Then, $Pd(PPh_3)_4$ (0.109 g, 0.090 mmol) was added and the reaction mixture stirred to 130 °C for 16 hours. The mixture was purified by reversed phase HPLC to give the title product (0.05 g, 29%) as a colorless oil. MS (ESI): $m/z = 315.5$ $[M-56+H]^+$.

Method E**Example 263**

(+)-5-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]oxy-2-(trifluoromethyl)benzonitrile

[0475]



[0476] In a sealed tube, (+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB 205, 0.2 g, 0.420 mmol), $Zn(CN)_2$ (0.098 g, 0.840 mmol), Zn (0.027 g, 0.420 mmol), dppf (0.232 g, 0.420 mmol), Hünig's base (0.108 g, 0.840 mmol) were mixed in DMA (10 mL) and the mixture was degassed. Then, $Pd_2(dba)_3$ (76.59 mg, 0.080 mmol) was


added and the reaction mixture was stirred at 130°C for 16 h. The mixture was purified by reversed phase HPLC to give the title compound (0.055 g, 30%) as a light yellow solid. MS (ESI): $m/z = 425.3$ $[M+H]^+$.

Method F

Example 265

(+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro [3.3] heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b] [1,4] oxazin-3-one

[0477]




[0478] In a sealed tube, (+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB203, 0.2 g, 0.420 mmol), 2-azaspiro[3.3]heptane (CAS RN 665-04-03, 0.117 g, 0.630 mmol), BINAP (0.052 g, 0.080 mmol) and K_2CO_3 (0.173 g, 1.25 mmol) were mixed in DMF (10 mL) and the mixture was degassed. Then, $Pd_2(dba)_3$ (76.59 mg, 0.080 mmol) was added and the reaction mixture was stirred to 110 °C for 16 hours. The reaction mixture was filtered off, the filtrate diluted with water (50 mL) and extracted with EtOAc (3 x 20 mL). Combined organics were washed with brine, dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was purified by reversed phase HPLC to give the title compound (0.06 g, 29%) as a white solid. MS (ESI): $m/z = 495.1$ $[M+H]^+$.

Method G

Example 293

(4aR,8aS)-6-(3-(4-Hydroxy-2-(trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one




[0479]












[0480] Boron tribromide (11.3 mg, 4.29 μ L, 45.3 μ mol) was added to an ice cooled solution of (4aR,8aS)-6-(3-(4-methoxy-2-(trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one


(Example 216, 20 mg, 45.3 μmol) in DCM (0.5 mL). The reaction mixture was stirred at ambient temperature for 3 h. A saturated solution of aqueous NaHCO_3 was added and the mixture was extracted with AcOEt. The layers were separated, the organic layer was dried over Na_2SO_4 , filtered and the solvent removed under reduced pressure. The crude product was purified by prep. HPLC to give the title compound (19%) as colorless solid. MS (ESI): $m/z = 427.2$ $[\text{M}+\text{H}]^+$.

[0481] The following examples listed in the table below were prepared in analogy to the procedure described for the preparation of Example 265 by using the indicated intermediates and/or commercially available compounds and using the mentioned purification method such as reversed-phase HPLC or silica gel flash chromatography.

Ex	Systematic Name / Structure	Intermediates	MS, m/z
266	(+)-(4aR,8aS)-6-[3-[3-(3-Methylazetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB203 BH66 and 3-Methylazetidine hydrochloride (CAS RN 935669-28-6)	469.2 $[\text{M}+\text{H}]^+$
			
267	(+)-(4aR,8aS)-6-[3-[3-(3,3-Difluoroazetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB203 and Difluoroazetidine hydrochloride (CAS RN 288315-03-7)	491.2 $[\text{M}+\text{H}]^+$
			
268	(+)-(4aR,8aS)-6-[3-[3-(3-Fluoro-3-methyl-azetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB203 and 3-Fluoro-3-methylazetidine hydrochloride (CAS RN 1427379-42-7)	487.3 $[\text{M}+\text{H}]^+$
			
269	(+)-(4aR,8aS)-6-[3-[3-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB203 and 6,6-Difluoro-2-azaspiro[3.3]heptane (CAS RN 1354952-05-8)	531.1 $[\text{M}+\text{H}]^+$
			

Ex	Systematic Name / Structure	Intermediates	MS, m/z
			
270	(+)-(4aR,8aS)-6-[3-[3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB203 and 5-Oxa-2-azaspiro[3.5]nonane (CAS RN 138387-19-6)	525.3 [M+H] ⁺
			
271	(+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 258 and 2-Azaspiro[3.3]heptane (CAS RN 665-04-03)	461.1 [M+H] ⁺
			
272	(+)-(4aR,8aS)-6-[3-[2-Chloro-3-(3-methylazetidin-1-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 258 and 3-Methylazetidine hydrochloride (CAS RN 935669-28-6)	435.1 [M+H] ⁺
			
273	(+)-(4aR,8aS)-6-[3-[2-Chloro-3-(3-fluoro-3-methylazetidin-1-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 258 and 3-Fluoro-3-methylazetidinehydrochloride (CAS RN 1427379-42-7)	453.2 [M+H] ⁺
			

Ex	Systematic Name / Structure	Intermediates	MS, m/z
274	(+)-(4aR,8aS)-6-(3-(3-(3-(tert-Butoxy)azetidin-1-yl)-2-chlorophenoxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one	Example 258 and 3- <i>tert</i> -Butoxyazetidine (CAS RN 1147530-63-9)	493.2 [M+H] ⁺
			
275	(+)-(4aR,8aS)-6-[3-[2-Chloro-3-(5-oxa-2-azaspiro[3.4]octan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 258 and 5-Oxa-2-azaspiro[3.4]octane (CAS RN 145309-24-6)	477.2 [M+H] ⁺
			
276	(+)-(4aR, 8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	Example 258 and 5-Oxa-2-azaspiro[3.5]nonane (CAS RN 138387-19-6)	491.2 [M+H] ⁺
			
277	(+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-5-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB204 and 2-Azaspiro[3.3]heptane (CAS RN 665-04-03)	461.3 [M+H] ⁺
			
278	(+)-(4aR,8aS)-6-[3-(3-Chloro-5-pyrrolidin-1-yl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one	BB204 and Pyrrolidine	435.3 [M+H] ⁺

Ex	Systematic Name / Structure	Intermediates	MS, m/z
			

[0482] In analogy to the methods described herein above, the following building blocks were prepared from the respective starting material indicated in the table below.

BB No.	Systematic Name	Starting material	Method	MS, m/z
BB47	3-[(2-Chlorophenoxy)methyl]pyrrolidine; hydrochloride salt	tert-Butyl 3-[(2-chlorophenoxy)methyl]pyrrolidine-1-carboxylate BB47a	D3	212.1 [M+H] ⁺
BB48	4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine; formic acid salt	tert-Butyl 4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate BB48a	D2	262.1 [M+H] ⁺
BB49	3-[(2-Chlorophenyl)methoxy]pyrrolidine; hydrochloride salt	tert-Butyl 3-[(2-chlorophenyl)methoxy]pyrrolidine-1-carboxylate BB49a	D3	212.1 [M+H] ⁺
BB50	3-[(3-Chlorophenyl)methoxy]pyrrolidine; hydrochloride salt	tert-Butyl 3-[(3-chlorophenyl)methoxy]pyrrolidine-1-carboxylate BB50a	D3	212.1 [M+H] ⁺
BB52	3-[(4-Chlorophenoxy)methyl]pyrrolidine; hydrochloride salt	tert-Butyl 3-[(4-chlorophenoxy)methyl]pyrrolidine-1-carboxylate BB52a	D3	212.1 [M+H] ⁺
BB53	3-[(4-Chlorophenyl)methoxy]pyrrolidine formic acid salt	tert-Butyl 3-[(4-chlorophenyl)methoxy]pyrrolidine-1-carboxylate BB53a	D2	Used without further purification
BB54	4-[[2-Methyl-4-(trifluoromethyl)phenyl]methyl]piperidine; formic acid salt	tert-Butyl 4-[[2-methyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate BB54a	D2	258.2 [M+H] ⁺
BB55	4-[[2-Chloro-4-(trifluoromethyl)phenyl]methyl]piperidine; trifluoroacetate salt	tert-Butyl 4-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate BB55a	D1	278.0 [M+H] ⁺
BB71	4-[4-Chloro-3-(trifluoromethyl)phenoxy]piperidine; hydrochloride salt	tert-Butyl 4-[4-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carboxylate BB71a	D3	280.0 [M+H] ⁺
BB72	4-(4-Chloro-3-cyclopropylphenoxy) piperidine; trifluoroacetate salt	tert-Butyl 4-(4-chloro-3-cyclopropylphenoxy)piperidine-1-carboxylate BB72a	D1	Used without further purification
BB73	4-[2-Chloro-5-(4-piperidyloxy)phenyl] morpholine hydrochloride	tert-Butyl 4-(4-chloro-3-morpholino-phenoxy)piperidine-1-carboxylate BB73a	D3	Used without further purification
BB74	4-[2-Methyl-4-(trifluoromethyl)phenoxy]piperidine; trifluoroacetate salt	tert-Butyl 4-[2-methyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate BB74a	D1	260.2 [M+H] ⁺

BB No.	Systematic Name	Starting material	Method	MS, m/z
BB75	2-(4-Piperidyloxy)-5-(trifluoromethyl)benzonitrile	tert-Butyl 4-[2-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate BB75a	D4	271.1 [M+H] ⁺
BB76	2-(4-Piperidylmethyl)oxazolo[5,4-c]pyridine; trifluoroacetate salt	tert-Butyl 4-(oxazolo[5,4-c]pyridin-2-ylmethyl)piperidine-1-carboxylate BB76a	D1	218.1 [M+H] ⁺
BB89	3-[(3-Chlorophenoxy)methyl]pyrrolidine; hydrochloride salt	tert-Butyl 3-[(3-chlorophenoxy)methyl]pyrrolidine-1-carboxylate BB89a	D3	212.1 [M+H] ⁺
BB192	4-[2-Fluoro-4-(trifluoromethyl)phenoxy]piperidine; hydrochloride salt	tert-Butyl 4-hydroxypiperidine-1-carboxylate	D3	264.2 [M+H] ⁺
BB193	4-[3-Chloro-4-(trifluoromethyl)phenoxy]piperidine; hydrochloride salt	tert-Butyl 4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate	D3	280.1 [M+H] ⁺
BB195	4-[2-Chloro-3-(trifluoromethyl)phenoxy]piperidine; hydrochloride salt	tert-Butyl 4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carboxylate	D8	280.1 [M+H] ⁺
BB196	3-(3-Bromo-2-chlorophenoxy)azetidine; trifluoroacetate salt	tert-Butyl 3-(3-bromo-2-chlorophenoxy)azetidine-1-carboxylate	D1	263.0 [M+H] ⁺
BB198	3-[3-Bromo-4-(trifluoromethyl)phenoxy]azetidine; trifluoroacetate salt	tert-Butyl 3-[3-bromo-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate	D9	296.4 [M+H] ⁺
BB199	3-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]azetidine; trifluoroacetate salt	tert-Butyl 3-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate	D9	258.1 [M+H] ⁺
BB200	3-[3-Chloro-4-(trifluoromethyl)phenoxy]azetidine; trifluoroacetate salt	tert-Butyl 3-[3-chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate	D1	252.5 [M+H] ⁺
BB201	3-(3-Bromo-5-chlorophenoxy)azetidine; trifluoroacetate salt	tert-Butyl 3-(3-bromo-5-chlorophenoxy)azetidine-1-carboxylate	D1	263.9 [M+H] ⁺
BB205	3-(3-Bromo-4-chlorophenoxy)azetidine; trifluoroacetate salt	tert-Butyl 3-(3-bromo-4-chlorophenoxy)azetidine-1-carboxylate	D1	263.9 [M+H] ⁺

BB91

4-[[2-Pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine; formic acid salt

[0483] A solution of tert-butyl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate (500 mg, 1.21 mmol) in 6 M HCl in MeOH solution (10.0 mL) was stirred at 20 °C for 1 h. The mixture was concentrated under vacuum, purified by reversed phase column to give the title compound as an orange oil (84.4 mg, 21.8% yield). MS (ESI): m/z = 313.2 [M+H]⁺.

Step a) *Tert-butyl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate*

[0484] To a solution of *tert-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate* (800 mg, 1.90 mmol; BB51, step c), pyrrolidine (163 mg, 2.28 mmol), Ruphos (4.25 mg, 0.010 mmol) and potassium *tert*-butoxide (320 mg, 2.86 mmol) in toluene (15 mL) was added palladium(II) acetate (1.28 mg, 0.010 mmol). The mixture was stirred at 80 °C for 15 h under N₂ atmosphere. The mixture was filtered and concentrated under vacuum to remove toluene. The mixture was diluted with H₂O (40 mL) and extracted three times with EtOAc (40 mL each). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography (PE / EtOAc = 1:0 to 8:1) to give the compound as light yellow oil (552 mg, 1.34 mmol, 36.7%) MS (ESI): *m/z* = 411.1 [M+H]⁺.

Step b) *Tert-butyl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate*

[0485] To a solution of *tert-butyl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate* (525 mg, 0.660 mmol) in MeOH (20 mL) was added wet Pd/C (~52 mg) and the mixture was stirred at 20 °C under H₂ atmosphere (balloon) for 1 h. The mixture was filtered and concentrated under vacuum to give the desired compound as colorless oil (500 mg) which was used in the next step without further purification.

BB95

3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine 4-methylbenzenesulfonate

[0486] To an solution of 3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate (50 mg, 144 μmol, Eq: 1) in EtOAc (0.8 mL) was added 4-methylbenzenesulfonic acid monohydrate (29.7 mg, 173 μmol, Eq: 1.2) and the mixture was heated at reflux for 1.5 hours. The clear, colorless solution was allowed to cool down to RT. No precipitation occurred. The solution was evaporated to give the desired product as a colorless foam. MS (ESI): *m/z* = 248.1 [M-TsOH+H]⁺.

Step a) *tert-butyl 3-[(E)-2-[2-fluoro-6-(trifluoromethyl)phenyl]ethenyl]azetidine-1-carboxylate*

[0487] To an ice-cold solution of diethyl (2-fluoro-4-(trifluoromethyl)benzyl)phosphonate (300 mg, 955 μmol) in THF (2 mL) was added sodium hydride 55% in mineral oil (41.7 mg, 955 μmol) and the mixture was stirred at this temperature for 30 minutes. To the light brown mixture was added dropwise a solution of *tert*-butyl 3-formylazetidine-1-carboxylate (177 mg, 955 μmol) in THF (1 mL). This led to an immediate discolouration of the reaction mixture. Stirring was continued for 1 hours at ice-bath temperature followed by stirring at RT for 1.5 hours. The reaction mixture was poured into water and ethyl acetate and the layers were separated. The aqueous layer was extracted twice with ethyl acetate. The organic layers were washed once with brine, dried over MgSO₄, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 12 g column using an MPLC system eluting with a gradient of *n*-heptane : ethyl acetate (100 : 0 to 25 : 75) to get the desired compound as a colorless solid (0.108 g; 32.8%). MS (ESI): *m/z* = 290.2 [M-56+H]⁺.

Step b) *tert-butyl 3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate*

[0488] To a solution of tert-butyl (E)-3-(2-fluoro-4-(trifluoromethyl)styryl)azetidine-1-carboxylate (105 mg, 304 μmol) in MeOH (1 mL) and Ethyl acetate (1 mL) was added Pd/C 10% (11 mg, 304 μmol) and the mixture was stirred under a hydrogen atmosphere at 1.7 bar and RT for 30 minutes. The suspension was filtered. The filtrate was evaporated to get the desired compound as a colorless oil (0.104 g; 98.5%). MS (ESI): m/z = 292.2 $[\text{M}-56+\text{H}]^+$.

BB96

4-((2-chloro-4-fluorophenoxy)methyl)azepane hydrochloride

[0489] To a solution of tert-butyl 4-((2-chloro-4-fluorophenoxy)methyl)azepane-1-carboxylate (620 mg, 1.73 mmol) in DCM (7.5 ml) was added HCl in ether 2M (10 ml, 20 mmol) and the reaction mixture was stirred overnight at rt. The mixture was concentrated in vacuo, the crude material collected as a white solid (490 mg, 1.67 mmol, 96.1 %) and used directly on the next step. LC-MS (ESI): m/z : 258.2 $[\text{M}+\text{H}]^+$

Step a) tert-butyl 4-((2-chloro-4-fluorophenoxy)methyl)azepane-1-carboxylate

[0490] In a 25ml four-necked sulphonation flask under argon, tert-butyl 4-(hydroxymethyl)azepane-1-carboxylate (480 mg, 2.09 mmol) was dissolved in THF (10 ml). Subsequently, 2-chloro-4-fluorophenol (337 mg, 251 μl , 2.3 mmol) and triphenylphosphine (604 mg, 2.3 mmol) were added and the clear solution was stirred for 5 min at rt.. The mixture was cooled to 0°C and DEAD (401 mg, 365 μl , 2.3 mmol) was added in portions over 10min. The mixture was stirred for 1 hr at 0°C, then overnight at rt. The mixture was taken up into EtOAc (50 ml), washed with water (2x25 ml), organic phase washed with 1M NaOH (3x25 ml), brine (20 ml), dried with Na₂SO₄, filtered and concentrated in vacuo. Residue was dissolved in n-Heptane/diethylether and the mixture stirred for 30 min, the TPPO precipitate filtered and the crude concentrated in vacuo. The crude material was adsorbed on Isolute[®] and purified by flash column chromatography (0 - 30% EtOAc/Heptane) over silica gel (50 g) to afford the desired product (630 mg, 1.76 mmol, 84.1%) as a yellow oil. LC-MS (ESI): m/z : 302.1 $[\text{M}-56+\text{H}]^+$

BB97

4-[[4-(trifluoromethyl)phenyl]methyl]azepane hydrochloride

[0491] To a solution of tert-butyl 4-(4-(trifluoromethyl)benzyl)azepane-1-carboxylate (88 mg, 246 μmol , Eq: 1) in DCM (1.5 ml) was added HCl in ether 2M (3.08 ml, 6.16 mmol) and the reaction mixture was stirred overnight at room temperature. The mixture was concentrated in vacuo, the crude material collected as a white solid (71 mg, 0.24 mmol, 98.2 %) and used directly on the next step. LC-MS (ESI): m/z : 258.2 $[\text{M}+\text{H}]^+$

Step a: Triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide

[0492] Triphenylphosphine (1.84 g, 7 mmol) and 1-(bromomethyl)-4-(trifluoromethyl)benzene (1.61 g, 6.74

mmol) were dissolved in xylene (35 ml). The reaction mixture was heated to reflux at 155 °C for 3.5 h and then cooled to room temperature. The precipitated white crystalline solid was collected by filtration, washed with diethyl ether and dried *in vacuo*. The final compound (3.30 g, 6.58 mmol, 97.7 % yield) was obtained as a white powder and directly used on the next step. LC-MS (ESI): *m/z*: 421.2 [M+H]⁺

Step b: *tert*-butyl (E)-4-(4-(trifluoromethyl)benzylidene)azepane-1-carboxylate

[0493] A suspension of sodium hydride (88.6 mg, 2.22 mmol) in DMF (7.5 ml) was cooled in an ice bath, then triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide (1.11 g, 2.22 mmol) was added. The suspension was stirred at 0 °C for 5 min. then for 25 min at rt. *tert*-butyl 4-oxoazepane-1-carboxylate (315 mg, 1.48 mmol) was added and the resulting mixture was stirred at 80 °C for 28 h. The mixture was concentrated in vacuo, diluted with water (50 ml) and EtOAc (40 ml) and extracted EtOAc (3x 30ml). The combined organic fractions were washed with water, 10% LiCl solution, dried with Na₂SO₄ and concentrated in vacuo. The residual oil was treated with Et₂O in order to precipitate the triphenylphosphoxide that was filtered off. The solution was concentrated in vacuo and the residue was purified by flash column chromatography (0 - 35% EtOAc/Heptane) over silica gel (50 g) to afford the desired product (92 mg, 259 μmol, 17.5 % yield) as a yellow oil. LC-MS (ESI): *m/z*: 300.2 [M-56+H]⁺

Step c: *tert*-butyl 4-(4-(trifluoromethyl)benzyl)azepane-1-carboxylate

[0494] A solution of *tert*-butyl (E)-4-(4-(trifluoromethyl)benzylidene)azepane-1-carboxylate (90 mg, 253 μmol) was dissolved in MeOH (2.5 ml). The reaction vessel was evacuated and back-filled with argon 5 times. Under argon, Pd-C (13.5 mg, 12.7 μmol) was added and the atmosphere was replaced with hydrogen three times. The reaction was stirred under a hydrogen atmosphere at 1 bar for 24h. The atmosphere was replaced with argon and the reaction mixture was filtered over a pad of Dicalite. The filter cake was washed with methanol. The filtrate was concentrated in vacuo to give the desired product (89 mg, 249 μmol, 98.3 % yield) as a colorless oil which was used without further purification. LC-MS (ESI): *m/z*: 302.2 [M-56+H]⁺

BB98

3-((2-Chloro-4-(trifluoromethyl)phenyl)thio)azetidine 2,2,2-trifluoroacetate

[0495] *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate (110 mg, 299 μmol) was dissolved in DCM (2 mL) and TFA (273 mg, 184 μL, 2.39 mmol) was added. The reaction mixture was stirred at RT for 3 h. Volatiles were removed in vacuo to yield 110 mg of a light yellow solid (96%). MS (ESI): *m/z* = 268.1 [M+H]⁺.

Step a) *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate

[0496] In a 20 mL glastube, a solution of 2-chloro-4-(trifluoromethyl)benzenethiol (440 mg, 2.07 mmol) in dry THF (6 mL) was added potassium *tert*-butoxide 1M solution in THF (2.17 ml, 2.17 mmol) and the yellow reaction mixture was stirred at RT for 15 min followed by addition of *tert*-butyl 3-bromoazetidine-1-carboxylate (489 mg, 2.07 mmol). The reaction mixture was then stirred at RT for 5 h and over night at 70°C. The crude reaction was diluted with EtOAc and extracted with H₂O, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na₂SO₄ and evaporated

down to dryness. The residue was purified by chromatography (SiO₂, n-heptane / EtOAc (0 to 40% over 40 min) yielded the product as a viscous oil (467 mg, 61%). MS (ESI): m/z = 312.1 [M-56]⁺.

BB99

3-((2-Chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine 2,2,2-trifluoroacetate

[0497] *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine-1-carboxylate (100 mg, 250 μ mol) was dissolved in DCM and TFA (228 mg, 154 μ L, 2 mmol) was added. The reaction mixture was stirred at RT for 8 h. Volatiles were removed in vacuo to yield the desired compound as light yellow solid (102 mg, 98%). MS (ESI): m/z = 300.0 [M+H]⁺.

Step a) *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate

[0498] In a 20 mL glass tube, a solution of 2-chloro-4-(trifluoromethyl)benzenethiol (440 mg, 2.07 mmol) in dry THF (6 mL) was added potassium *tert*-butoxide 1M solution in THF (2.17 mL, 2.17 mmol) and the yellow reaction mixture was stirred at r.t for 15 min followed by addition of *tert*-butyl 3-bromoazetidine-1-carboxylate (489 mg, 2.07 mmol). The reaction mixture was then stirred at r.t for 5 h and over night at 70°C. The crude reaction was diluted with EtOAc and extracted with H₂O, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na₂SO₄ and evaporated down to dryness. The residue was purified by column chromatography (SiO₂, n-heptane / EtOAc (0 to 40% over 40 min) to yield the desired product as a viscous oil (467 mg, 61%). MS (ESI): m/z = 312.1 [M-56+H]⁺.

[0499] Step b) *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine-1-carboxylate mCPBA (347 mg, 1.41 mmol) was added in one portion to a stirred solution of *tert*-butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate (345 mg, 938 μ mol) in DCM (6 mL) in an ice bath. The reaction was stirred at RT for 20 min. The reaction mixture was poured into 5 mL saturated Na₂CO₃ solution and extracted twice with DCM (20 mL each). The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by preparative HPLC (YMC-Triart C18, ACN / H₂O+0.1% HCOOH) to furnish the product as a white powder (253 mg, 67.5%) MS (ESI): m/z = 344.0 [M-56+H]⁺.

BB100

3-((2-Chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine 2,2,2-trifluoroacetate

[0500] *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine-1-carboxylate (50 mg, 130 μ mol) was dissolved in DCM (1.5 mL), TFA (149 mg, 100 μ L, 1.3 mmol) was added and the reaction mixture was stirred at RT for 8 h. Volatiles were removed in vacuo to yield the compound as white solid (51 mg, 98%). MS (ESI): m/z = 284.1 [M+H]⁺.

Step a) *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate

[0501] The compound was prepared in analogy to BB99, step a, and used in the next step without further purification.

Step b) *tert*-Butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine-1-carboxylate

[0502] The sulfoxide intermediate was isolated from the the synthesis of the according sulfone building block BB99, step b. The product was obtained as a white lyophilized powder (50 mg, 13.9%) MS (ESI): $m/z = 328.1$ $[M-56+H]^+$.

BB101

3-(((2-Chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine 2,2,2-trifluoroacetate

[0503] To a solution of *tert*-butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine-1-carboxylate (0.200 g, 524 μ mol) in DCM (3 mL) was added TFA (478 mg, 323 μ L, 4.19 mmol) and the reaction mixture was stirred at RT for 3 h. Volatiles were removed in vacuo to yield the compound as light yellow oil that was used in the next step without further purification (267 mg). MS (ESI): $m/z = 282.2$ $[M+H]^+$.

Step a) *tert*-Butyl 3-[[2-chloro-4-(trifluoromethyl)phenyl]sulfonylmethyl]azetidine-1-carboxylate

[0504] To a solution of 2-chloro-4-(trifluoromethyl)benzenethiol (0.400 g, 1.88 mmol) in dry THF (6 mL) was added potassium *tert*-butoxide 1M solution in THF (1.98 mL, 1.98 mmol) and the turbid reaction mixture was stirred at RT for 15min followed by addition of *tert*-butyl 3-(bromomethyl)azetidine-1-carboxylate (471 mg, 1.88 mmol). The reaction mixture was then stirred at RT for 19 h. The crude reaction was diluted with EtOAc and extracted with aq. 1 M NaHCO_3 solution, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na_2SO_4 and evaporated down to dryness to yield the crude product which was used in the next step without further purification (762 mg). MS (ESI): $m/z = 326.1$ $[M-56+H]^+$.

BB102

3-((2-Fluoro-6-(trifluoromethyl)benzyl)sulfonyl)azetidine 2,2,2-trifluoroacetate

[0505] *tert*-Butyl 3-((2-fluoro-6-(trifluoromethyl)phenyl)methylsulfonyl)azetidine-1-carboxylate (0.047 g, 118 μ mol) was dissolved in DCM (0.5 mL) and TFA (108 mg, 72.9 μ L, 946 μ mol) was added. The reaction mixture was stirred at RT for 2 h. Volatiles were removed in vacuo to yield the compound as a yellow oil (56 mg) that was used in the next step without further purification. MS (ESI): $m/z = 298.2$ $[M+H]^+$.

tep a) *tert*-Butyl 3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate

[0506] To a solution of tert-butyl 3-mercaptoazetidine-1-carboxylate (0.400 g, 2.11 mmol) in dry THF (5 mL) was added potassium tert-butoxide 1M solution in THF (2.22 mL, 2.22 mmol) and the reaction mixture was stirred at RT for 15 min followed by addition of 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene (CAS RN 239087-08-2). The reaction mixture was then stirred at RT for 14 h. The crude reaction was diluted with EtOAc and extracted with aq. 1 M NaHCO₃ solution, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO₄ and evaporated down to dryness to yield the crude product (805 mg) which was used in the next step without further purification. MS (ESI): $m/z = 310.2$ [M-56+H]⁺.

Step b) tert-Butyl 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfonyl]azetidine-1-carboxylate

[0507] 3-Chlorobenzoperoxoic acid (283 mg, 1.64 mmol) was added in portion to a stirred solution of tert-butyl 3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate (0.300 g, 821 μ mol) in DCM (5 mL) in an ice bath. The reaction mixture was stirred at RT for 15 min and poured into 5 mL saturated aqueous NaHCO₃ solution and extracted twice with DCM (10 mL each). The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash column chromatography (silica gel, 20 g, 0% to 100% EtOAc in n-heptane) to furnish the desired product as a colorless oil (47 mg, 15%). MS (ESI): $m/z = 415.1$ [M+NH₄]⁺.

BB103

3-((2-Fluoro-6-(trifluoromethyl)benzyl)sulfinyl)azetidine 2,2,2-trifluoroacetate

[0508] tert-Butyl 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfinyl]azetidine-1-carboxylate (0.086 g, 225 μ mol) was dissolved in DCM (1 mL) and TFA (206 mg, 139 μ L, 1.8 mmol) was added. The reaction mixture was stirred at RT for 2 h. Volatiles were removed *in vacuo* to yield the compound as a yellow oil (93 mg) that was used in the next step without further purification. MS (ESI): $m/z = 282.2$ [M+H]⁺.

Step a) tert-Butyl 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfonyl]azetidine-1-carboxylate

[0509] The sulfoxide intermediate was isolated from the synthesis of BB102, step b, as a colorless oil (86 mg, 28%). MS (ESI): $m/z = 404.1$ [M+Na]⁺.

BB104

3-(((2-Chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine 2,2,2-trifluoroacetate

[0510] tert-Butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine-1-carboxylate (0.145 g, 350 μ mol) was dissolved in DCM (2 mL) and TFA (320 mg, 216 μ L, 2.8 mmol) was added. The reaction mixture was stirred at RT for 2 h. Volatiles were removed *in vacuo* to yield the compound as a yellow oil (181 mg) that was used in the next step without further purification. MS (ESI): $m/z = 314.1$ [M+H]⁺.

Step a) tert-Butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine-1-carboxylate

[0511] 3-Chlorobenzoperoxoic acid (352 mg, 1.57 mmol) was added in portions to a stirred solution of tert-butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine-1-carboxylate (BB101, step a) (0.300 g, 786 μ mol) in DCM (5 mL) in an ice bath. The reaction mixture was stirred at RT for 15 min and poured into 5 mL saturated aqueous NaHCO₃ solution and extracted twice with DCM (10 mL each). The organic layers were combined, washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in n-heptane) to provide the desired product as a colorless oil (145 mg, 45%). MS (ESI): m/z = 314.0 [M-56+H]⁺.

BB 105**3-(((2-Chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azetidine 2,2,2-trifluoroacetate**

[0512] tert-Butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azetidine-1-carboxylate (0.086 g, 216 μ mol) was dissolved in DCM (1 mL) and TFA (197 mg, 133 μ L, 1.73 mmol) was added. The reaction mixture was stirred at RT for 2 h. Volatiles were removed *in vacuo* to yield the compound as a yellow oil (99 mg) that was used in the next step without further purification. MS (ESI): m/z = 298.1 [M+H]⁺.

Step a) tert-Butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine-1-carboxylate

[0513] The sulfoxide intermediate was isolated from the synthesis of BB104, step a. The desired product was obtained as a yellow oil (80 mg, 25.6%). MS (ESI): m/z = 398.1 [M+H]⁺.

BB 106**3-((2-Fluoro-4-(trifluoromethyl)benzyl)thio)azetidine 2,2,2-trifluoroacetate**

[0514] To a solution of tert-butyl 3-((2-fluoro-4-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate (0.282 g, 772 μ mol) in DCM (3 mL) was added TFA (880 mg, 595 μ L, 7.72 mmol) and the reaction mixture was stirred at RT for 3 h. Volatiles were removed *in vacuo* to yield the desired compound as a colorless oil (302 mg) that was used in the next step without further purification. MS (ESI): m/z = 266.2 [M+H]⁺.

Step a) tert-Butyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methylsulfanyl]azetidine-1-carboxylate

[0515] To a solution of tert-butyl 3-mercaptoazetidine-1-carboxylate (0.200 g, 1.06 mmol) in dry THF (2 mL) was added potassium tert-butoxide 1M solution in THF (1.11 mL, 1.11 mmol) and the reaction mixture was stirred at RT for 15 min followed by addition of 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene (272 mg, 1.06 mmol, CAS RN 239087-07-1). The reaction mixture was then stirred at RT for 14 h. The crude reaction was diluted with EtOAc and extracted with aq. 1 M NaHCO₃ solution, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO₄ and

evaporated down to dryness and purified by flash chromatography (silica gel, 20 g, 0% to 80% EtOAc in n-heptane) to furnish the desired product as a colorless oil (288 mg, 75%). MS (ESI): $m/z = 310.2$ $[M-56+H]^+$.

[0516] In analogy to BB84, the following intermediates were prepared from the respective commercially available starting materials.

BB No.	Systematic Name	Starting material	MS, m/z
BB 107	3-[2-(2,6-Dichlorophenyl)ethynyl]azetidine	1,3-Dichloro-2-iodobenzene	226.1 $[M+H]^+$
BB 108	3-[2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethynyl]azetidine	1-Bromo-2-fluoro-4-(trifluoromethyl)benzene	244.2 $[M+H]^+$
BB 109	3-[2-(2,6-Difluorophenyl)ethynyl]azetidine	1,3-Difluoro-2-iodobenzene	194.2 $[M+H]^+$
BB110	3-[2-[3-Chloro-4-(trifluoromethyl)phenyl]ethynyl]azetidine	4-Bromo-2-chloro-1-(trifluoromethyl)benzene	260.2 $[M+H]^+$
BB111	3-[2-(2-Chloro-6-fluorophenyl)ethynyl]azetidine	2-Bromo-1-chloro-3-fluorobenzene	210.1 $[M+H]^+$
BB112	3-[2-(2-Chloro-4-cyclopropylphenyl)ethynyl]azetidine	1-Bromo-2-chloro-4-cyclopropylbenzene	232.2 $[M+H]^+$
BB113	3-[2-(2-Methoxyphenyl)ethynyl]azetidine	1-Bromo-2-methoxybenzene	188.2 $[M+H]^+$
BB114	3-[2-[4-Chloro-2-(trifluoromethyl)phenyl]ethynyl]azetidine	4-Chloro-1-iodo-2-(trifluoromethyl)benzene	260.1 $[M+H]^+$
BB115	3-[2-(3-Chlorophenyl)ethynyl]azetidine	1-Bromo-3-chlorobenzene	192.1 $[M+H]^+$
BB116	3-[2-[4-(Trifluoromethoxy)phenyl]ethynyl]azetidine	1-bromo-4-(Trifluoromethoxy)benzene	242.2 $[M+H]^+$
BB117	3-[2-[4-(Trifluoromethyl)phenyl]ethynyl]azetidine	1-Bromo-4-(trifluoromethyl)benzene	226.2 $[M+H]^+$
BB118	3-[2-(3-Fluoro-2-methylphenyl)ethynyl]azetidine	1-Bromo-3-fluoro-2-methylbenzene	190.2 $[M+H]^+$
BB119	3-[2-(2,6-Dimethylphenyl)ethynyl]azetidine	2-Iodo-1,3-dimethylbenzene	186.2 $[M+H]^+$
BB120	3-[2-[2-(Trifluoromethoxy)phenyl]ethynyl]azetidine	1-Bromo-2-(trifluoromethoxy)benzene	242.2 $[M+H]^+$
BB121	3-[2-(2-Bromophenyl)ethynyl]azetidine	1-Bromo-2-iodobenzene	236.1 $[M+H]^+$
BB122	3-[2-(2-Chloro-3-fluorophenyl)ethynyl]azetidine	1-Bromo-2-chloro-3-fluorobenzene	210.1 $[M+H]^+$
BB123	3-[2-(o-Tolyl)ethynyl]azetidine	1-Bromo-2-methylbenzene	172.2 $[M+H]^+$
BB124	3-[2-(4-Chloro-2-fluorophenyl)ethynyl]azetidine	4-Chloro-2-fluoro-1-iodobenzene	210.1 $[M+H]^+$

BB No.	Systematic Name	Starting material	MS, m/z
BB125	3-[2-[2-(Difluoromethoxy)phenyl]ethynyl]azetidine	1-(Difluoromethoxy)-2-iodobenzene	224.2 [M+H] ⁺
BB126	2-[2-(Azetidin-3-yl)ethynyl]-3-chloro-benzonitrile	2-Bromo-3-chlorobenzonitrile	217.2 [M+H] ⁺
BB127	3-[2-[4-(Difluoromethoxy)phenyl]ethynyl]azetidine	1-(Difluoromethoxy)-4-iodobenzene	224.2 [M+H] ⁺
BB128	1-[4-[2-(Azetidin-3-yl)ethynyl]phenyl]cyclopropanecarbonitrile	1-(4-Bromophenyl)cyclopropane-1-carbonitrile	223.2 [M+H] ⁺
BB129	3-[2-(4-Cyclopropylphenyl)prop-1-ynyl]azetidine	1-Bromo-4-cyclopropyl-benzene	198.2 [M+H] ⁺
BB130	1-[4-[2-(Azetidin-3-yl)ethynyl]phenyl]cyclopropanol	1-(4-Bromophenyl)cyclopropanol	214.2 [M+H] ⁺
BB131	3-[2-(3-Methoxyphenyl)ethynyl]azetidine	1-Iodo-3-methoxybenzene	188.2 [M+H] ⁺
BB132	3-[2-[2-(Difluoromethyl)phenyl]ethynyl]azetidine	1-Bromo-2-(difluoromethyl)benzene	208.2 [M+H] ⁺
BB133	3-[2-(3-Methoxy-2-methylphenyl)ethynyl]azetidine	1-Iodo-3-methoxy-2-methylbenzene	202.2 [M+H] ⁺
BB134	3-[2-(2-Chloro-6-methylphenyl)ethynyl]azetidine	1-Chloro-2-iodo-3-methylbenzene	206.1 [M+H] ⁺
BB135	3-[2-(2-Chloro-5-fluorophenyl)ethynyl]azetidine	2-Bromo-1-chloro-4-fluorobenzene	210.1 [M+H] ⁺
BB136	3-[2-(4-Methylsulfonylphenyl)ethynyl]azetidine	1-Bromo-4-methylsulfonyl-benzene	236.2 [M+H] ⁺
BB137	3-[2-(5-Chloro-2-thienyl)ethynyl]azetidine	2-Bromo-5-chlorothiophene	198.1 [M+H] ⁺
BB138	3-[2-(5-Chloro-3-thienyl)ethynyl]azetidine	4-Bromo-2-chlorothiophene	198.1 [M+H] ⁺
B 139	3-[2-[2-Chloro-6-fluoro-4-(trifluoromethyl)phenyl]ethynyl]azetidine	2-Bromo-1-chloro-3-fluoro-5-(trifluoromethyl)benzene	278.1 [M+H] ⁺
BB140	3-[2-(2-Chlorophenyl)ethynyl]azetidin-3-ol	Chloro-2-iodobenzene	208.1 [M+H] ⁺
		and	
		<i>tert</i> -butyl 3-ethynyl-3-hydroxyazetidine-1-carboxylate (CAS RN 1259034-35-9)	
BB141	3-[2-[2-(Methoxymethyl)phenyl]ethynyl]azetidine	1-Iodo-2-(methoxymethyl)benzene	202.2 [M+H] ⁺
BB142	3-[2-[2-Chloro-4-(trifluoromethyl)phenyl]ethynyl]azetidine	2-Chloro-1-iodo-4-(trifluoromethyl)benzene	260.2 [M+H] ⁺

[0517] In analogy to BB18, the following intermediates were prepared from the respective commercially available starting materials.

BB No.	Systematic Name	Starting material	MS, m/z
BB143	4-[2-[2-(Trifluoromethyl)phenyl]ethynyl]piperidine	1-Bromo-2-(trifluoromethyl)benzene	254.3 [M+H] ⁺
BB144	4-[2-(2-Methoxyphenyl)ethynyl]piperidine	1-Bromo-2-methoxybenzene	216.3 [M+H] ⁺
BB145	4-[2-(o-Tolyl)ethynyl]piperidine	1-Bromo-2-methylbenzene	200.3 [M+H] ⁺
BB146	4-[2-(2,6-Dimethylphenyl)ethynyl]piperidine	2-Iodo-1,3-dimethylbenzene	214.3 [M+H] ⁺
BB147	4-[2-(2,4-Dichlorophenyl)ethynyl]-4-methyl-piperidine	Bromo-2,4-dichlorobenzene	268.2 [M+H] ⁺
		and	
		<i>tert</i> -Butyl 4-ethynyl-4-methylpiperidine-1-carboxylate (CAS RN 1363383-17-8)	
BB148	4-[2-(2-Chloro-4-fluorophenyl)ethynyl]-4-methyl-piperidine	2-Chloro-4-fluoro-1-iodobenzene	252.2 [M+H] ⁺
		and	
		<i>tert</i> -Butyl 4-ethynyl-4-methylpiperidine-1-carboxylate (CAS RN 1363383-17-8)	

BB149

1-[2-(Azetidin-3-yl)ethynyl]cyclopentanol hydrochloride

[0518] To a solution of *tert*-butyl 3-[2-(1-hydroxycyclopentyl)ethynyl]azetidine-1-carboxylate (0.02 g, 0.075 mmol) in dioxane (0.5 mL) was added 4 M HCl in dioxane (0.094 mL, 0.377 mmol) and the reaction mixture was stirred at RT for 18 h. The mixture was evaporated to dryness and the residue triturated in diisopropyl ether, filtered off and further dried under high vacuum to give the title compound as a white solid as the hydrochloride salt (0.013 g, 87%). MS (ESI): m/z = 166.1 [M+H]⁺.

Step a) *tert*-Butyl 3-[2-(1-hydroxycyclopentyl)ethynyl]azetidine-1-carboxylate

[0519] To a solution of *tert*-butyl 3-ethynylazetidine-1-carboxylate (0.2 g, 1.1 mmol) in THF (6.5 mL) at -78°C was added *n*BuLi (0.759 mL, 1.21 mmol) dropwise and the reaction mixture was stirred at this temperature for 1 h. Then, cyclopentanone (0.107 mL, 1.21 mmol) in THF (3 mL) was added dropwise to the mixture which was stirred at -78°C for 2 h. The mixture was allowed to warm up to 0°C, poured into a sat. NH₄OH aqueous solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel flash chromatography, eluting with a gradient of EtOAc : n-heptane (0 to 100%) to yield the title compound as a light yellow oil (0.020 g, 7%). MS (ESI): m/z = 192.2 [M-56-18+H]⁺.

BB150

4-[3-Pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine formate

[0520] A mixture of tert-butyl 4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (400.0 mg, 0.970 mmol) and TFA (1.0 mL, 0.970 mmol) in DCM (10 mL) was stirred at 20 °C for 12 h. The mixture was purified by prep-HPLC (ACN and water containing 0.225% v/v FA) to give the desired product (300 mg, 94.4%) as colorless gum. MS (ESI): $m/z = 312.1$ $[M+H]^+$.

Step a: tert-Butyl 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0521] To a solution of 3-bromo-5-(trifluoromethyl)phenol (2.0 g, 8.3 mmol), 1-BOC-4-hydroxypiperidine (1.84 g, 9.13 mmol, CAS RN 106-52-5) and PPh_3 (2.61 g, 9.96 mmol) in THF (32.6 mL) was added diisopropyl azodicarboxylate (1.96 mL, 9.96 mmol) and the mixture was stirred at 20 °C for 15 h. The mixture was concentrated under vacuum. The residue was purified by prep-HPLC (ACN and water containing 0.225% v/v FA) and concentrated under vacuum to give the desired product (2.6 g, 73.9% yield) as light yellow oil. MS (ESI): $m/z = 367.9$ $[M-56+H]^+$.

Step b) tert-Butyl 4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0522] A mixture of tert-butyl 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (500.0 mg, 1.18 mmol), pyrazole (160.47 mg, 2.36 mmol), CuI (22.37 mg, 0.120 mmol), cesium carbonate (1152 mg, 3.54 mmol) and N,N'-dimethylethylenediamine (519.15 mg, 5.89 mmol) in DMF (5 mL) was stirred at 110 °C for 12 h. The mixture was poured into H₂O water (30 mL) and extracted three times with EtOAc (50 mL). The combined organic layer was washed with ammonia (10 mL), brine (50 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give the desired product (400 mg, 82.5% yield) as light yellow oil. MS (ESI): $m/z = 356.2$ $[M-56+H]^+$.

BB151**4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine**

[0523] A mixture of 4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]piperidine (250.0 mg, 0.740 mmol) and Pd/C (50.0 mg, wt.10%) in THF (10 mL) was stirred at 20 °C for 12 h under H₂ (1520 mmHg). The mixture was filtered and concentrated under vacuum to give the desired compound (240 mg, 95.4%) as light brown gum. MS (ESI): $m/z = 342.1$ $[M+H]^+$.

Step a) tert-Butyl 4-(p-tolylsulfonylhydrazono)piperidine-1-carboxylate

[0524] To a solution of 4-methylbenzenesulfonylhydrazide (9.35 g, 50.19 mmol, CAS RN 1576-35-8) in MeOH (100 mL) was added 1-BOC-4-piperidone (10.0 g, 50.19 mmol, CAS RN 17502-28-8) and the mixture was stirred at 25 °C for 12 h. The mixture was concentrated to give the desired product (18.4 g, 99.8%) as off-white solid. MS (ESI): $m/z = 368.2$ $[M+H]^+$.

Step b) 2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde

[0525] A mixture of NaH (187.39 mg, 60% dispersion in mineral oil, 4.68 mmol,) in 2,2,2-trifluoroethanol (16.67 mL, 228.74 mmol, CAS RN75-89-8) was stirred at 0 °C. The cooling bath was removed and the mixture was stirred at 20 °C for 2 h, and then 2-fluoro-4-(trifluoromethyl)benzaldehyde (1.0 g, 5.21 mmol, CAS RN 763-93-9) was added and the mixture was stirred at 20 °C for 12 h. The mixture was poured into H₂O (30 mL) and extracted twice with EtOAc (30 mL each). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give the desired product (1.2 g, 84.7%) as light yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.44 - 10.34 (m, 1H), 7.93 (d, *J*=8.1 Hz, 1H), 7.75 (s, 1H), 7.55 (d, *J*=8.1 Hz, 1H), 5.11 (q, *J*=8.7 Hz, 2H).

Step c) tert-Butyl 4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carboxylate

[0526] A mixture of 2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde (1000.0 mg, 3.67 mmol), tert-butyl 4-(p-tolylsulfonylhydrazono)piperidine-1-carboxylate (1350.3 mg, 3.67 mmol) and cesium carbonate (1795.9 mg, 5.51 mmol) in 1,4-dioxane (30 mL) was stirred at 110 °C for 12 h under N₂ atmosphere. The mixture was poured into H₂O (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and the residue was purified by prep-HPLC (MeCN and water containing 0.225% v/v FA) to give the desired product (980 mg, 58.6%) as light yellow gum. MS (ESI): *m/z* = 400.1 [M-56+H]⁺.

Step d) tert-Butyl 4-[hydroxy-2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate

[0527] To a solution of tert-butyl 4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carboxylate (900.0 mg, 1.98 mmol) in MeOH (45 mL) was added NaBH₄ (149.54 mg, 3.95 mmol) at 0 °C and the mixture was stirred at 20 °C for 12 h. The mixture was purified by prep-HPLC (MeCN and water containing 0.225% v/v FA) (650 mg, 71.9%) as light yellow oil. MS (ESI): *m/z* = 384.0 [M-56-OH+H]⁺.

Step e) 4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]piperidine

[0528] A mixture of tert-butyl 4-[hydroxy-2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl] methyl]piperidine-1-carboxylate (400.0 mg, 0.870 mmol) and MsOH (840.43 mg, 8.74 mmol) in DCM (4 mL) was stirred at 40 °C for 24 h. The mixture was poured into saturated aqueous Na₂CO₃ solution (5 mL) and extracted three times with EtOAc (10 mL each). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give the desired compound as light yellow oil (260 mg, 76.2%). MS (ESI): *m/z* = 340.1 [M+H]⁺.

BB152**4-[3-(1,2,4-Triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine trifluoroacetate**

[0529] To a mixture of tert-butyl 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (240.0 mg, 0.580 mmol) in DCM (10 mL) was added TFA (1.0 mL). The mixture was stirred at 20 °C for 12 h and then concentrated under vacuum to give 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine 2,2,2-trifluoroacetic acid salt (240 mg, 96.7%) as light yellow gum. MS (ESI): $m/z = 313.1$ $[M+H]^+$.

Step a) tert-Butyl 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0530] A mixture of tert-butyl 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (500.0 mg, 1.18 mmol, BB98, intermediate a), 1,2,4-triazole (162.8 mg, 2.36 mmol) and CuI (22.37 mg, 0.120 mmol) in DMF (5 mL) was stirred at 110 °C for 12 h. The mixture was poured into H₂O (20 mL) and extracted three times with EtOAc (30 mL each). The combined organic layers were washed with ammonia (20 mL), brine (20 mL, three times), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and the residue was purified by column chromatography (PE : EA = 50 : 1 ~ 3 : 1) to give the desired product (240 mg, 49.4%) as light yellow solid. MS (ESI): $m/z = 357.1$ $[M-56+H]^+$.

BB153

3-[4-Chloro-3-(trifluoromethyl)phenoxy]azetidine trifluoroacetate

[0531] To a solution of tert-butyl 3-[4-chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carboxylate (300.0 mg, 0.530 mmol) in DCM (7.5 mL) was added TFA (1.04 mL) at 0 °C and the mixture was stirred at 20 °C for 2 h. The mixture was concentrated to give the title compound as yellow oil (280 mg, 97%). MS (ESI): $m/z = 252.0$ $[M+H]^+$.

Step a) tert-Butyl 3-[4-chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carboxylate

[0532] To a solution of 2-chloro-5-hydroxybenzotrifluoride (1 g, 5.1 mmol CAS RN 6294-93-5), tert-butyl 3-hydroxyazetidine-1-carboxylate (0.97 g, 5.6 mmol CAS RN 141699-55-0) and triphenylphosphine (1.6 g, 6.11 mmol) in THF (20 mL) was added diisopropyl azodicarboxylate (1.2 mL, 6.11 mmol) and the mixture was stirred at 20 °C for 15 h. The mixture was concentrated and purified by reversed phase chromatography (MeCN and water containing 0.225% v/v FA) to give the title compound (820 mg, 28.7%) as brown solid. MS (ESI): $m/z = 295.9$ $[M-56+H]^+$.

BB154

4-(4-Chloro-3-pyrazol-1-yl-phenoxy)piperidine trifluoroacetate

[0533] To a solution of tert-butyl 4-(4-chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carboxylate (260.0 mg, 0.690 mmol) in DCM (5.38 mL) was added TFA (1.34 mL, 17.46 mmol) at 0 °C and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give the title compound as an orange oil (250 mg, 92.7 yield). MS (ESI): $m/z = 278.1$ $[M+H]^+$.

Step a) *tert*-Butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate

[0534] To a solution of 1-BOC-4-hydroxypiperidine (2.04 g, 10.12 mmol, CAS RN 106-52-5), 3-bromo-4-chlorophenol (2.0 g, 9.64 mmol, CAS RN 2402-82-6) and triphenylphosphine (3.03 g, 11.57 mmol) in THF (50 mL) was added diisopropyl azodicarboxylate (2.28 mL, 11.57 mmol) and the mixture was stirred at 20 °C for 15 h. Then the mixture was concentrated and the residue was purified by reversed flash chromatography (MeCN and water containing 0.1% v/v FA) to give the desired product (2.8 g, 74.3%) as light yellow oil. MS (ESI): m/z = 335.9 [M-56+H]⁺.

Step b) *tert*-Butyl 4-(4-chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carboxylate

[0535] To a mixture of *tert*-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (1.0 g, 2.56 mmol), pyrazole (139.4 mg, 2.05 mmol), cesium carbonate (2501.8 mg, 7.68 mmol) and 1,10-phenanthroline (225.49 mg, 2.56 mmol) in DMF (20 mL) was added CuI (48.59 mg, 0.260 mmol) and the mixture was stirred at 110 °C for 12 h under N₂ atmosphere. The mixture was concentrated, diluted with H₂O (20 mL) and extracted three times with EtOAc (10 mL). The combined organic layers were concentrated and the residue purified by reversed phase chromatography (ACN and water containing 0.1% v/v FA) to give the desired product (265 mg, 22.5%, 82% purity) as yellow oil. MS (ESI): m/z = 378.1 [M+H]⁺.

BB155

4-[5-(4-Piperidyloxy)-2-(trifluoromethyl)phenyl]morpholine trifluoroacetate

[0536] To a solution of *tert*-butyl 4-[3-morpholino-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (400.0 mg, 0.93 mmol) in DCM (3 mL) was added TFA (1.0 mL) and the reaction mixture was stirred at 25 °C for 12 h. The reaction was concentrated in vacuum to provide the crude product (300 mg) as yellow oil, which was used in next step without further purification. MS (ESI): m/z = 331.2 [M+H]⁺.

Step a) *tert*-Butyl 4-(3-bromo-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylate

[0537] To a solution of 3-bromo-4-(trifluoromethyl)phenol (500.0 mg, 2.54 mmol, CAS RN1214385-56-4) and 1-BOC-4-hydroxypiperidine (512 mg, 2.54 mmol, CAS RN 106-52-5) in THF (8.5 mL) was added PPh₃ (1000.9 mg, 3.82 mmol) and diethyl azodicarboxylate (664.53 mg, 3.82 mmol) and the mixture was stirred at 25 °C for 12 h. The mixture was purified by silica gel chromatography using PE : EA = 5 : 1 as eluant to provide the desired product (503 mg, 46.6% yield) as light yellow oil. MS (ESI): m/z = 369.2 [M-56+H]⁺.

Step b) *tert*-Butyl 4-(3-morpholino-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylate

[0538] A mixture of *tert*-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (500.0 mg, 1.18 mmol), morpholine (154 mg, 1.77 mmol, CAS RN 110-91-8), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene (146.77 mg, 0.24 mmol, CAS RN 76189-55-4), cesium carbonate (1.15 g, 3.54 mmol) and tris(dibenzylideneacetone)dipalladium(0) (172.47 mg, 0.240 mmol, CAS RN 76971-72-7) in DMF (10 mL)

was stirred at 110 °C for 12 h. The mixture was poured into H₂O and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and the residue was purified by column chromatography (gradient of EtOAc in PE 5% to 33%) to give the desired product (480 mg, 94.6%) as light yellow solid. MS (ESI): m/z = 431.1 [M+H]⁺.

BB156**4-(4-Chloro-3-(1,2,4-triazol-1-yl)phenoxy)piperidine trifluoroacetate**

[0539] To a solution of tert-butyl 4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylate (196.0 mg, 0.520 mmol) in DCM (5 mL) was added TFA (1.01 mL, 13.13 mmol) at 0 °C and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give the title compound (178 mg, 87.6%) as brown oil. MS (ESI): m/z = 279.1 [M+H]⁺.

Step a) tert-Butyl 4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylate

[0540] A mixture of tert-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500.0 mg, 1.28 mmol, BB102, intermediate a), 1,2,4-triazole (176.8 mg, 2.56 mmol), CuI (24.3 mg, 0.130 mmol) and cesium carbonate (1250.9 mg, 3.84 mmol) and dimethyl glycine (1.0 mL, 1.28 mmol) in DMF (10 mL) was stirred at 120 °C for 12 h. The mixture was concentrated to remove the DMF, diluted with H₂O (50 mL) and extracted three times with EtOAc (20 mL each). The combined organic layers were evaporated and the residue purified by reverse phase flash chromatography (ACN and water containing 0.1% v/v FA) to give the title compound (196 mg, 37.1%) as colorless oil. MS (ESI): m/z = 323.0 [M-56+H]⁺.

BB157**4-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine trifluoroacetate**

[0541] To a mixture of tert-butyl 4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (360.0 mg, 0.930 mmol) in DCM (18 mL) was added TFA (1.8 mL). The mixture was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum to provide the desired compound as light yellow gum (370 mg, 99.2%). MS (ESI): m/z = 286.2 [M+H]⁺.

Step a) tert-Butyl 4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0542] A mixture of tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (500.0 mg, 1.18 mmol, BB103, intermediate b), cyclopropylboronic acid (151.86 mg, 1.77 mmol), Na₂CO₃ (374.74 mg, 3.54 mmol) and Pd(PPh₃)₄ (13.6 mg, 0.010 mmol) in 1,4-dioxane (10 mL) and H₂O (1 mL) was stirred at 95 °C for 12 h. The mixture was poured into H₂O (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and purified by column chromatography (PE : EtOAc = 20 : 1~ 5 : 1) to give the desired product (380 mg, 83.7%) as colorless gum. MS (ESI): m/z = 330.1 [M-56+H]⁺.

BB158

4-[3-Pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine trifluoroacetate

[0543] To a solution of tert-butyl 4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (180.0 mg, 0.440 mmol) in DCM (5 mL) was added TFA (0.5 mL). The mixture was stirred at 25 °C for 12 h and then concentrated under vacuum to give the desired product (180 mg, 96.7%) as light yellow gum. MS (ESI): m/z = 312.1 $[M+H]^+$.

Step a) tert-Butyl 4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate

[0544] A mixture of tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (500.0 mg, 1.18 mmol, BB103, intermediate b), pyrazole (120.35 mg, 1.77 mmol), CuI (22.37 mg, 0.120 mmol), N,N'-dimethylethylenediamine (519.45 mg, 5.89 mmol) and Cs₂CO₃ (767.99 mg, 2.36 mmol) in DMF (10 mL) was stirred at 110 °C for 12 h. The mixture was poured into H₂O (30 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with ammonia (20 mL), brine (50 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated and the crude product was purified by prep-TLC (PE : EA = 5 : 1) to give the desired product (190 mg, 39.2%) as colorless oil. MS (ESI): m/z = 356.1 $[M-56+H]^+$.

BB159

4-[[2,6-Difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine trifluoroacetate

[0545] To a solution of tert-butyl 4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate (70.0 mg, 0.180 mmol) in DCM (1 mL) was added TFA (0.2 mL) and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give the title compound (50 mg, 68.9%) as brown oil. MS (ESI): m/z = 280.1 $[M+H]^+$.

Step a) 2-(Diethoxyphosphorylmethyl)-1,3-difluoro-5-(trifluoromethyl)benzene

[0546] A solution of 2-(bromomethyl)-1,3-difluoro-5-(trifluoromethyl)benzene (1.29 mL, 3.27 mmol, CAS RN 493038-91-8) in triethyl phosphite (5.44 g, 32.73 mmol) was stirred at 160 °C for 5 h. The mixture was concentrated under vacuum to provide the title compound (600 mg, 55.2%; colorless oil) which was used in the next step without further purification.

Step b) tert-Butyl 4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate

[0547] A mixture of 2-(diethoxyphosphorylmethyl)-1,3-difluoro-5-(trifluoromethyl)benzene (400.0 mg, 1.2 mmol) in THF (4 mL) was added to sodium hydride (144.49 mg, 3.61 mmol) in THF (4 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h, and then 1-BOC-4-piperidone (479.83 mg, 2.41 mmol, CAS RN 79099-07-3) was added to the above mixture. The mixture was stirred at 20 °C for 12 h. The mixture was poured into H₂O (50 mL) and

extracted three times with EtOAc (20 mL each). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by column chromatography (PE : EA = 1 : 0 to 2 : 1) to give the title compound (100 mg, 22.0%) as colorless oil. MS (ESI): m/z = 322.0 [M-56+H]⁺.

Step c) *tert*-Butyl 4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate

[0548] To a solution of *tert*-butyl 4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate (100.0 mg, 0.270 mmol) in MeOH (8 mL) was added Pd/C (10.0 mg, wt 10%). The mixture was stirred at 20 °C for 1 h under H₂ atmosphere, then filtered and concentrated to give the title compound as colorless oil (70 mg, 69.6%). MS (ESI): m/z = 324.1 [M-56+H]⁺.

BB160

4- [4-Chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy] piperidine trifluoroacetate

[0549] To a mixture of *tert*-butyl 4-[4-chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carboxylate (145.0 mg, 0.330 mmol) in DCM (10 mL) was added TFA (1.0 mL). The mixture was stirred at 20 °C for 5 h. The mixture was concentrated under vacuum to give the desired product (149 mg, 99.6%) as light brown gum. MS (ESI): m/z = 340.1 [M+H]⁺.

Step a) 1-Chloro-2-(4-chlorophenyl)-3-fluoro-4-methoxy-benzene

[0550] A mixture of 4-bromochlorobenzene (1.41 g, 7.34 mmol, CAS RN 106-39-8), (6-chloro-2-fluoro-3-methoxy-phenyl) boronic acid (1.0 g, 4.89 mmol, CAS RN 867333-04-8) and K₂CO₃ (2.03 g, 14.68 mmol) in 1,4-dioxane (15 mL) and H₂O (1.5 mL) was stirred under N₂ atmosphere at 110 °C for 1 h in a microwave oven. The mixture was poured into H₂O (20 mL) and extracted three times with EtOAc (20 mL each). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and the residue was purified by column chromatography using PE as eluant to give the desired product (110 mg, 8.3%) as colorless oil which was used in the next step without further purification.

Step b) 4-chloro-3-(4-chlorophenyl)-2-fluoro-phenol

[0551] To a mixture of 1-chloro-2-(4-chlorophenyl)-3-fluoro-4-methoxy-benzene (215.0 mg, 0.790 mmol) in DCM (7 mL) was added a solution of BBr₃ (993.36 mg, 3.97 mmol) in DCM (7 mL) drop wise at -78 °C. The mixture was stirred at 20 °C for 12 h. The reaction was quenched by adding MeOH (1 mL) followed by water (10 mL), and the mixture was extracted three times with DCM (10 mL each). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give the desired product (120 mg, 57.5%) as light brown solid which was used in the next step without further purification.

Step c) *tert*-Butyl 4-[4-chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carboxylate

[0552] A mixture of 4-chloro-3-(4-chlorophenyl)-2-fluoro-phenol (120.0 mg, 0.470 mmol), 1-BOC-4-hydroxypiperidine (187.88 mg, 0.930 mmol, CAS RN 106-52-5), PPh₃ (244.85 mg, 0.930 mmol) and DIAD (0.18 mL, 0.930 mmol) in THF (12 mL) was stirred at 20 °C for 12 h. The mixture was poured into H₂O and extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum and the residue purified by column chromatography (PE : EA = 1 : 0~20 : 1) to give the desired product as light yellow gum (150 mg, 73%). MS (ESI): m/z = 384.0 [M-56+H]⁺.

BB161

3-[2-Chloro-4-(Trifluoromethyl)phenoxy]azetidine trifluoroacetate

[0553] To a solution of tert-butyl 3-[2-chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate (400.0 mg, 1.14 mmol) in DCM (10 mL) was added TFA (2.0 mL) at 20 °C. After stirring for 2 h the mixture was concentrated to give the crude product (410 mg, 98.6%) as light yellow oil which was used in the next step without further purification.

Step a) tert-Butyl 3-[2-chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate

[0554] To a solution of 2-chloro-4-(trifluoromethyl)phenol (1000.0 mg, 5.09 mmol, CAS RN 35852-58-5) and tert-butyl 3-hydroxyazetidine-1-carboxylate (1057.5 mg, 6.11 mmol, CAS RN 141699-55-0) in THF (20 mL) was added PPh₃ (1999.49 mg, 7.63 mmol) and diethyl azodicarboxylate (1329.05 mg, 7.63 mmol), the mixture was stirred at 25 °C for 12 h. The reaction mixture solution was evaporated in vacuum, the residue was purified by reverse-phase flash (0.1% v/v FA) to afford the desired product (800 mg, 2.27 mmol, 44.7% yield) as light yellow oil. MS (ESI): m/z = 296.0 [M-56+H]⁺.

BB162

3-((2-Fluoro-6-(trifluoromethyl)benzyl)oxy)azetidine trifluoroacetate

[0555] To a solution of tert-butyl 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate (400.0 mg, 1.15 mmol) in dry DCM (10 mL) was added TFA (2.0 mL) at 25 °C and the mixture was stirred at 25 °C for 12 h. The solvent was stripped off and the residue was dried under vacuum to afford the desired compound as yellow oil (300 mg, 22%). MS (ESI): m/z = 250.0 [M+H]⁺.

Step a) tert-Butyl 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate

[0556] To a solution of 2-fluoro-6-(trifluoromethyl)benzyl bromide (1000.0 mg, 3.89 mmol, CAS RN 239087-08-2) and tert-butyl 3-hydroxyazetidine-1-carboxylate (673.92 mg, 3.89 mmol, CAS RN 141699-55-0) in dry THF (10 mL) at 25 °C, was added t-BuOK (5.84 mL, 5.84 mmol; 1.0 M in dry THF) and the mixture was stirred at 25 °C for 12 h. The mixture was poured into H₂O (10 mL) and extracted three times with EA (20 mL each). The combined organic layers were combined, dried over anhydrous Na₂SO₄ and filtered. The filtrate was

concentrated under reduced pressure, purified by flash chromatography on silica gel (gradient PE : EA = 10 : 1 to 2 : 8) to give the title compound as colorless oil (1100 mg, 80.9%). MS (ESI): m/z = 294.0 $[M-56+H]^+$.

BB163

3-[2-(2-Fluoro-4-methyl-phenyl)ethyl]azetidine trifluoroacetate

[0557] To a solution of tert-butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate (350.0 mg, 1.19 mmol) in dry DCM (10 mL) at 25 °C, was added TFA (1.0 mL, 1.19 mmol) and the mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated by reduced pressure and the residue was dried in vacuum to provide the desired compound as colorless oil (260 mg, 70.9%). MS (ESI): m/z = 194.0 $[M+H]^+$.

Step a) tert-Butyl 3-(2-trimethylsilylethynyl)azetidine-1-carboxylate

[0558] To a solution of trimethylsilylacetylene (9.97 g, 101.55 mmol, CAS RN 1066-54-2) in dry THF (200 mL) at 25 °C, was added i-PrMgCl (48.57 mL, 97.14 mmol; 1.0 M in dry THF) and the mixture was stirred at 25 °C for 15 mins. Then a solution of 1-BOC-3-iodoazetidine (25.0 g, 88.3 mmol, CAS RN 254454-54-1) was added followed by FeCl₂ (0.34 g, 2.65 mmol) in dry DMF (606 mL) and the mixture was stirred at 25 °C for 12 hrs. The mixture was poured into saturated aq. NH₄Cl solution (200 mL) and extracted three times with EtOAc (150 mL each). The organic layers were combined, dried with anhydrous Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (PE : EA = 20 : 1 to 10 : 1) to give the desired product as black oil (18 g, 80.4%).

[0559] ¹H NMR (400MHz, CHLOROFORM-d) δ = 4.11 (t, J=8.4 Hz, 2H), 3.92 (dd, J=6.5, 8.1 Hz, 2H), 3.51 - 3.17 (m, 1H), 1.44 (s, 10H), 0.16 (s, 9H).

Step b) tert-Butyl 3-ethynylazetidine-1-carboxylate

[0560] To a solution of tert-butyl 3-(2-trimethylsilylethynyl)azetidine-1-carboxylate (6243 mg, 24.64 mmol) in dry MeOH (40 mL) was added potassium carbonate (1700 mg, 12.32 mmol) at 25 °C and the reaction mixture was stirred at 25 °C for 2 h. The mixture was filtered, the filtrate was poured into saturated aq. NH₄Cl solution (100 mL) and extracted with EA (100 mL three times). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (PE : EA = 50 : 1 to 15 : 1) to afford the title compound as light yellow oil (4100 mg, 91.8%). ¹H NMR (400 MHz, CHLOROFORM-d) δ = 4.16 - 4.11 (m, 2H), 3.93 (dd, J=6.5, 8.2 Hz, 2H), 3.37 - 3.20 (m, 1H), 2.28 (d, J=2.4 Hz, 1H), 1.43 (s, 9H).

Step c) tert-Butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate

[0561] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate (1000.0 mg, 5.52 mmol) and 4-bromo-3-fluorotoluene (1251.58 mg, 6.62 mmol, CAS RN 452-74-4) in dry THF (20 mL) were added Pd(PPh₃)₄ (530.63 mg, 0.460 mmol), CuI (87.83 mg, 0.460 mmol) and TEA (4644.2 mg, 46.0 mmol) at 25 °C. The mixture was purged with N₂ for 1 min and then stirred at 60 °C under N₂ atmosphere for 12 h. The mixture was poured into saturated aq. NH₄Cl solution (50 mL) and extracted three times with EtOAc (30 mL each). The combined

organic layers were dried with anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (PE : EA = 20 : 1 to 10 : 1) to provide the desired compound as colorless oil (650 mg, 40.7%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ = 7.33 - 7.28 (m, 1H), 6.94 - 6.85 (m, 2H), 4.26 - 4.19 (m, 2H), 4.05 (dd, *J* = 6.4, 8.1 Hz, 2H), 3.66 - 3.49 (m, 1H), 2.36 (s, 3H), 1.46 (s, 9H).

Step d) *tert*-Butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate

[0562] Batch a: To a solution of *tert*-butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate (50.0 mg, 0.170 mmol, 1 eq) in EtOAc (5 mL) was added Pd/C (50.0 mg, wt.10%) at 25 °C. The mixture was stirred at 40 °C under a balloon of hydrogen gas for 12 h. LCMS analysis found 79.8% of desired product.

[0563] Batch b: To a solution of *tert*-butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate (500.0 mg, 1.73 mmol) in EtOAc (10 mL) was added Pd/C (250.0 mg, wt.10%) at 25 °C and the mixture was stirred at 40 °C under a balloon of hydrogen gas for 6 h. LCMS found 80.4% of desired product. Batch a and b were combined, the reaction mixture was filtered through a pad of celite, the filtrate was concentrated under reduced pressure and the residue was dried in vacuum to give the compound as colorless oil (350 mg, 69.0%). MS (ESI): *m/z* = 238.1 [M-56+H]⁺.

BB164

3-[2-[4-Methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine trifluoroacetate

[0564] To a solution of *tert*-butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate (180.0 mg, 0.5 mmol) in dry DCM (10 mL) was added TFA (1.0 mL, 1.19 mmol) at 25 °C and the mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure and the residue was dried in vacuum to give the title compound (150 mg, 80.2%) as colorless oil. MS (ESI): *m/z* = 260.1 [M+H]⁺.

Step a) *tert*-Butyl 3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate

[0565] To a solution of *tert*-butyl 3-ethynylazetidine-1-carboxylate (800.0 mg, 4.41 mmol, BB111, intermediate b) and 3-trifluoromethyl-4-bromoanisole (1350.9 mg, 5.3 mmol, CAS RN 400-72-6) in dry THF (30 mL) at 25 °C, was added Pd(PPh₃)₄ (509.41 mg, 0.440 mmol), CuI (84.31 mg, 0.440 mmol) and TEA (4458.42 mg, 44.14 mmol). The mixture was purged with N₂ for 1 min and then stirred at 60 °C under N₂ atmosphere for 12 h. The mixture was poured into saturated aq. NH₄Cl solution (100 mL) and extracted three times with EtOAc (50 mL each). The organic layers were combined, dried with anhydrous Na₂SO₄, filtered, the filtrate was concentrated with reduced pressure. The residue was purified by flash chromatography on silica gel (PE : EA = 20 : 1 to 10 : 1) to provide the product as colorless oil (160 mg, 8.2%). MS (ESI): *m/z* = 300.1 [M-56+H]⁺.

Step b) *tert*-Butyl 3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0566] To a solution of *tert*-butyl 3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate (230.0 mg, 0.65 mmol) in EtOAc (10 mL) at 25 °C, was added Pd/C (150.0 mg, wt.10%), the mixture was stirred at 40 °C under a balloon of H₂ (about 15 psi) for 12 h. The reaction mixture was filtered through a pad of celite and the filtrate

was concentrated under reduced pressure. The residue was dried under vacuum to furnish the desired compound as colorless oil (180 mg, 77.4%). MS (ESI): $m/z = 304.1$ $[M-56+H]^+$.

BB165**3-[[4-Methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine trifluoroacetate**

[0567] To a solution of tert-butyl 3-[[4-methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate (130.0 mg, 0.380 mmol) in DCM (6.5 mL) was added TFA (1.3 mL, 16.87 mmol) and the reaction was stirred at 20 °C. After 12 h the mixture was evaporated to give the desired crude product as light brown oil (130 mg, 96.1%). MS (ESI): $m/z = 246.5$ $[M+H]^+$.

Step a) 4-Bromo-1-(Bromomethyl)-2-(trifluoromethyl)benzene

[0568] The solution of 5-bromo-2-methylbenzotrifluoride (2000 mg, 8.37 mmol, CAS RN 86845-27-4), N-bromosuccinimide (1489 mg, 8.37 mmol, CAS RN 128-08-5) and benzoyl peroxide (101.34 mg, 0.420 mmol, CAS RN 2685-64-5) in carbon tetrachloride (30 mL) was stirred at 90 °C for 12 h. The mixture was evaporated and the residue was purified by silica gel column chromatography (100% PE) to give the desired product as light brown oil (690 mg, 25.9%) which was used in the next step without further purification.

Step b) tert-Butyl 3-[[4-bromo-2-(Trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate

[0569] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (337.5 mg, 1.95 mmol, CAS RN 22214-30-8) in THF (9 mL) was added t-BuOK (1.95 mL, 1.95 mmol), then 4-bromo-1-(bromomethyl)-2-(trifluoromethyl)benzene (590.0 mg, 1.86 mmol) was added and the mixture was stirred at 20 °C for 12 h. The mixture was poured into aq. NH_4Cl solution (200 mL) and extracted three times with EtOAc (50 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated. The residue was purified by prep-HPLC (ACN and water containing 0.225% v/v FA) to give the desired product as light brown oil (300 mg, 39.4%). MS (ESI): $m/z = 356.3$ $[M-56+H]^+$.

Step c) tert-Butyl 3-[[4-Methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate

[0570] To a solution of tert-butyl 3-[[4-bromo-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate (250.0 mg, 0.610 mmol), trimethylboroxine (114.8 mg, 0.910 mmol), K_2CO_3 (168.5 mg, 1.22 mmol) in 1,4-dioxane (10 mL) and H_2O (2.5 mL) was added $Pd(dppf)Cl_2$ (89.18 mg, 0.120 mmol). The reaction was stirred at 100 °C for 12 h. The mixture was filtered, concentrated, and the residue was purified by reversed flash chromatography (ACN and water containing 0.1% v/v FA) to give the desired product as light brown oil (146 mg, 69.4%). MS (ESI): $m/z = 290.4$ $[M-56+H]^+$.

BB166**3-[2-[2-Methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine trifluoroacetate**

[0571] To a solution of tert-butyl 3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate (300.0 mg, 0.830 mmol) in DCM (5 mL), TFA (1.0 mL) was added and stirred at 25 °C for 1 h. The reaction mixture was evaporated under reduced pressure to give the desired product (300 mg, 96.3%) as colorless oil. MS (ESI): m/z = 260.1 $[M+H]^+$.

Step a) tert-Butyl 3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate

[0572] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate (710.6 mg, 3.92 mmol, B111, intermediate b) and 2-bromo-1-methoxy-3-(trifluoromethyl)benzene (500.0 mg, 1.96 mmol) in dry DMSO (17.5 mL) at 25 °C, was added Pd(PPh₃)₂Cl₂ (137.6 mg, 0.200 mmol) and Cs₂CO₃ (1278 mg, 3.92 mmol). The mixture was purged with N₂ for 1 min and then stirred at 110 °C under N₂ atmosphere for 12 h. The mixture was filtered, the filtrate was concentrated and the residue was purified by silica gel (PE : EtOAc = 20 : 1) to give the desired product as light yellow oil (600 mg, 86.1%) that was used in the next step without further purification.

Step b) tert-Butyl 3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate

[0573] To a solution of tert-butyl 3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate (400.0 mg, 1.13 mmol) in EtOAc (20 mL), wet Pd/C (50 mg, 10 wt.%) was added. The mixture was purged with H₂ 3 times and then stirred at 40 °C under H₂ atmosphere (balloon) for 12 h. The mixture was filtered and the filtrate was concentrated to give the desired product as light yellow oil (300 mg, 74.2% yield) which was used in the next step without further purification.

BB167

3- [2- [4-Methyl-2-(trifluoromethyl)phenyl] ethyl] azetidine trifluoroacetate

[0574] To a solution of tert-butyl 3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate (100.0 mg, 0.290 mmol) in DCM (4 mL) was added TFA (0.5 mL) and the mixture was stirred at 20 °C for 12 h. The reaction mixture was evaporated under reduced pressure to give the desired product as yellow oil (98 mg, 94.2%). MS (ESI): m/z = 244.1 $[M+H]^+$.

Step a) tert-Butyl 3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate

[0575] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate (606.6 mg, 3.35 mmol) and 2-bromo-5-methylbenzotrifluoride (400.0 mg, 1.67 mmol) in dry DMSO (14.9 mL) at 25 °C, was added Pd(PPh₃)₂Cl₂ (117.46 mg, 0.170 mmol) and Cs₂CO₃ (1091 mg, 3.35 mmol). The mixture was purged with N₂ for 1 min and then stirred at 110 °C under N₂ atmosphere for 12 h. The reaction mixture was poured into H₂O and extracted with EtOAc. The organic layer was evaporated and the residue was purified by silica gel column chromatography (PE : EtOAc = 20 : 1) to give the desired compound as a yellow oil (390 mg, 68.7% yield). MS (ESI): m/z = 284.1 $[M-56+H]^+$.

Step b) tert-Butyl 3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0576] To a solution of tert-butyl 3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate (390.0 mg, 1.15 mmol) in EtOAc (19.5 mL), wet Pd/C (150 mg, 10 wt.%) was added, the mixture was purged 3 times with H₂ and stirred at 40 °C under H₂ atmosphere (balloon) for 12 h. The mixture was filtered and the filtrate was concentrated to give the desired product as light yellow oil (295 mg, 72.9% yield). MS (ESI): m/z = 288.1 [M-56+H]⁺.

BB168

1-[2-[2-(Azetidin-3-yl)ethyl]-5-(trifluoromethyl)phenyl]ethanone trifluoroacetate

[0577] To a solution of tert-butyl 3-[2-[2-acetyl-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate (50.0 mg, 0.130 mmol) in DCM (1 mL) was added TFA (0.2 mL) and the solution was stirred at 20 °C for 12 h. The mixture was concentrated to give the desired product as light brown oil (50 mg, 96.4% yield). MS (ESI): m/z = 272.1 [M+H]⁺.

Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene

[0578] To a solution of [2-bromo-4-(trifluoromethyl)phenyl]methanol (500.0 mg, 1.96 mmol, CAS RN 497959-33-8) and PPh₃ (770.5 mg, 2.94 mmol) in THF (10 mL) was added carbon tetrabromide (975.3 mg, 2.94 mmol), and the mixture was stirred at 25 °C for 12 h. The reaction was concentrated in vacuum and the residue was purified by silica gel column chromatography (PE : EA = 0 : 1~20 : 1) to yield the desired product as colorless oil (600 mg, 96.3% yield). ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.78 (s, 1H), 7.55 - 7.46 (m, 2H), 4.53 (s, 2H).

Step b) 2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene

[0579] A solution of 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (600.0 mg, 1.89 mmol) in triethyl phosphite (3136 mg, 18.87 mmol) was stirred at 160 °C for 5 h. The mixture was concentrated at 100 °C under reduced pressure to remove most of the triethyl phosphite to give the crude product (700 mg) as light yellow oil. MS (ESI): m/z = 375.2 [M+H]⁺.

Step c) tert-Butyl 3-[(E)-2-[2-bromo-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate

[0580] A mixture of 2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene (600.0 mg, 1.6 mmol) in THF (10 mL) was added to another suspension of NaH (191.9 mg, 4.8 mmol, 60% dispersion in mineral oil) in THF (10 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h. Then tert-butyl 3-formylazetidine-1-carboxylate (296.3 mg, 1.6 mmol) was added and the mixture was stirred at 20 °C for 11 h. The reaction mixture was poured into aq. NH₄Cl solution (100 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column chromatography (PE : EtOAc = 20 : 1) to give the desired product as light yellow oil (450 mg, 69.3%). MS (ESI): m/z = 352.0 [M56+H]⁺. ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.74

(d, $J = 0.8$ Hz, 1H), 7.58 - 7.51 (m, 1H), 7.49 - 7.41 (m, 1H), 6.71 (d, $J = 15.8$ Hz, 1H), 6.36 (dd, $J = 8.4, 15.8$ Hz, 1H), 4.13 (t, $J = 8.5$ Hz, 2H), 3.78 (dd, $J = 5.8, 8.6$ Hz, 2H), 3.44 - 3.31 (m, 1H), 1.39 (s, 9H).

Step d) *tert*-Butyl 3-[(E)-2-[2-acetyl-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate

[0581] A solution of tributyl(1-ethoxyvinyl)tin (426.7 mg, 1.18 mmol), *tert*-butyl 3-[(E)-2-[2-bromo-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate (400.0 mg, 0.980 mmol) and $\text{Pd}(\text{Ph}_3\text{P})_2\text{Cl}_2$ (138.2 mg, 0.200 mmol) in THF (16 mL) was stirred at 80 °C under N_2 atmosphere for 4 h. The mixture was cooled down to room temperature and aq. KF solution (10 mL) was added. The mixture was stirred for 10 mins, extracted three times with EtOAc (20 mL each) and the combined organic layers were concentrated. The residue was dissolved in THF (20 mL) and aq. HCl (0.6 N, 20 mL) was added. The mixture was stirred at 20 °C for 0.5 h, extracted three times with EtOAc (20 mL each) and the combined organic layers were concentrated. The residue was purified by silica gel column chromatography (PE : EtOAc = 20 : 1) to give the desired product (280 mg, 77% yield) as light yellow oil. MS (ESI): $m/z = 314.1$ $[\text{M}-56+\text{H}]^+$.

Step e) *tert*-Butyl 3-[2-[2-acetyl-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0582] To a solution of *tert*-butyl 3-[(E)-2-[2-acetyl-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate (50.0 mg, 0.140 mmol) in EtOAc (5 mL) was added wet Pd/C (20.0 mg, 10 wt.%) and the mixture was stirred at 20 °C under H_2 (balloon) atmosphere for 12 h. The reaction was then warmed up to 50 °C and stirred for another 12 h. The mixture was filtered and the filtrate was concentrated to give the desired product (50 mg, 99.5%) as light yellow oil. MS (ESI): $m/z = 316.2$ $[\text{M}-56+\text{H}]^+$.

BB169

3-[2-[2-Bromo-4-(trifluoromethyl)phenyl] ethyl] azetidine trifluoroacetate

[0583] To a solution of *tert*-butyl 3-[2-[2-bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate (400.0 mg, 0.980 mmol) in DCM (10 mL) was added TFA (1.0 mL) and the mixture was stirred at 20 °C for 12 h. The reaction mixture was evaporated under reduced pressure to give the desired product (413 mg, 99.8% yield) as yellow oil. MS (ESI): $m/z = 308.1$ $[\text{M}+\text{H}]^+$.

Step a) *tert*-Butyl 3-[2-[2-bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0584] To a suspension of *tert*-butyl 3-[(E)-2-[2-bromo-4-(trifluoromethyl) phenyl]vinyl]azetidine-1-carboxylate (600.0 mg, 1.48 mmol, BB116, intermediate c) and MgO (118.1 mg, 2.95 mmol) in EtOAc (20 mL) was added Pd/C (300.0 mg, 10wt.%), the mixture was stirred at 25 °C under H_2 atmosphere (balloon) for 1 h. The reaction mixture was filtered and the filtrate was evaporated under reduced pressure to give the desired product (500 mg, 82.9%) as light yellow oil. MS (ESI): $m/z = 352.0$ $[\text{M}-56+\text{H}]^+$.

BB174

2-(Azetidin-3-ylmethoxy)-5-(trifluoromethyl)pyridine 2,2,2-trifluoroacetate

Synthesis of BB174 was performed in analogy to BB57, starting from tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate and 2-bromo-5-(trifluoromethyl)pyridine. MS (ESI): $m/z = 233.1$ $[M+H]^+$.

BB175

3-Methyl-5-[[rac-(3R,4R)-3-methyl-4-piperidyl]methoxy]-2-(trifluoromethyl)pyridine dihydrochloride

[0585] tert-Butyl (rac-3R,4R)-3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate (198 mg, 510 μ mol) was dissolved in DCM (2 mL) and HCl 2M in ether (1.53 mL, 3.06 mmol) was added. The reaction mixture was stirred at RT for 8 h. The reaction mixture was concentrated in vacuo to yield 180 mg of desired product as white solid (98%) MS (ESI): $m/z = 289.3$ $[M+H]^+$.

a) tert-Butyl (rac-3R,4R)-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate

[0586] To a stirred solution of cis-N-BOC-3-methylpiperidine-4-carboxylic acid methyl ester (2 g, 7.77 mmol) in THF (10 mL) was added lithium borohydride (5.83 mL, 11.7 mmol) at 2-5°C. The reaction mixture was then heated at reflux for 3 h and then cooled to 2-5°C. Water was added and the aqueous layer was extracted twice with EtOAc (30 mL each). The organic layer was washed with water, NaHCO₃ and brine, the layers were separated, and the organics dried over Na₂SO₄ and concentrated in vacuum. Purification by flash chromatography (gradient of EtOAc in n-heptane, 0 to 65%) provided the product as a colorless oil (930 mg, 50%). MS (ESI): $m/z = 174.1$ $[M-56+H]^+$.

b) tert-Butyl (rac-3R, 4R)-3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate

[0587] tert-butyl (3R,4R)-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate (239 mg, 1.04 mmol) was dissolved in DMF (4.17 mL) and NaH in mineral oil (60%, 45.8 mg, 1.15 mmol) was added at RT. The reaction was stirred for 20 min, then 5-bromo-3-methyl-2-(trifluoromethyl)pyridine (250 mg, 167 μ L, 1.04 mmol) was added and stirring continued for 12 h at RT. The reaction was quenched with 10 mL sat. NH₄Cl solution and extracted three times with water/EtOAc. The organic phases were combined and dried over MgSO₄ and the solvent was removed *in vacuo*. Flash chromatography (gradient of EtOAc in n-heptane, 0 to 50%) yielded the product as white solid (148 mg, 49%). MS (ESI): $m/z = 333.2$ $[M-56+H]^+$.

BB176

3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine 2,2,2-trifluoroacetate

[0588] To a solution of tert-butyl 3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine-1-carboxylate (0.265 g, 729 μ mol) in DCM (4 mL) was added TFA (832 mg, 562 μ L, 7.29 mmol). The resultant reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated to give the title compound as a colorless oil. The crude product was used without further purification. MS (ESI): m/z = 264.2 $[M+H]^+$.

Step a) [2-Fluoro-4-(trifluoromethyl)phenyl]methyl methanesulfonate

[0589] To an ice-cold solution of (2-fluoro-4-(trifluoromethyl)phenyl)methanol (840 mg, 4.33 mmol) and triethylamine (1.31 g, 1.81 mL, 13 mmol) in DCM (8 mL) was added dropwise methanesulfonyl chloride (496 mg, 337 μ L, 4.33 mmol) and the mixture was stirred at 0°C for 1 h. The reaction mixture was poured on saturated aqueous NaHCO₃ solution (10 mL) and DCM (20 mL) and the layers were separated. The aqueous layer was extracted once with DCM (20 mL). The organic layers were washed once with brine, dried over MgSO₄, filtered and evaporated to yield the desired compound as a yellow oil (1.13 g, 96%).

Step b) tert-Butyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carboxylate

[0590] To an ice-cold solution of tert-butyl 3-hydroxy-2-methylazetidine-1-carboxylate (250 mg, 1.34 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 58.7 mg, 1.47 mmol) in portions and the mixture was stirred at ice-bath temperature for 5 min followed by stirring at RT for 40 min. A solution of 2-fluoro-4-(trifluoromethyl)benzyl methanesulfonate (436 mg, 1.6 mmol) in DMF (1 mL) was added dropwise to the mixture at RT. Stirring of the slurry was continued at RT for 16 h. The reaction mixture was poured on saturated aqueous NH₄Cl solution (10 mL) and EtOAc (20 mL) and the layers were separated. The aqueous layer was extracted once with EtOAc (50 mL). The organic layers were washed twice with water, dried over Na₂SO₄, filtered, and concentrated. The crude compound was purified by silica gel chromatography (gradient of n-heptane : EtOAc 100 : 0 to 0 : 100) to get tert-butyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carboxylate as a colorless oil (0.265 g, 54.6 % yield). MS (ESI): m/z = 308.2 $[M-56+H]^+$.

BB 177

2-(Azetidin-3-ylmethoxy)-4,5-bis(trifluoromethyl)pyridine 2,2,2-trifluoroacetate

[0591] Synthesis of BB177 was performed in analogy to BB57, starting from tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate and 2-chloro-4,5-bis(trifluoromethyl)pyridine. MS (ESI): m/z = 301.2 $[M+H]^+$.

BB179

3-((4-Chloro-2-phenoxybenzyl)oxy)azetidine 2,2,2-trifluoroacetate

[0592] Synthesis of BB179 was done in analogy to BB39, starting from tert-butyl 3-hydroxyazetidine-1-carboxylate and 1-(bromomethyl)-4-chloro-2-phenoxybenzene (synthesis described below). MS (ESI): m/z = 290.2 $[M+H]^+$.

1-(Bromomethyl)-4-chloro-2-phenoxybenzene**[0593]**

1. i) In a 10 mL round-bottomed flask, methyl 4-chloro-2-phenoxybenzoate (547 mg, 2.08 mmol) was diluted in toluene (3.82 mL) and the reaction mixture was cooled in an ice bath. Sodium bis(2-methoxyethoxy)aluminum hydride 70% in toluene (649 mg, 637 μ L, 2.25 mmol) was added dropwise slowly at max. 15°C to give a light yellow solution. The reaction mixture was stirred at r.t. for 30 min. The crude reaction mixture, containing the product (4-chloro-2-phenoxyphenyl)methanol was used directly in the next step.
2. ii) In a 25 mL round-bottomed flask, hydrobromic acid 48% in H₂O (6.49 g, 4.35 mL, 38.5 mmol) was cooled in an ice bath. Then 4-chloro-2-phenoxyphenyl)methanol (crude, 488 mg, 2.08 mmol) was added dropwise slowly and the mixture was stirred at 50°C for 2 h. Hydrobromic acid 48% in H₂O (6.25 g, 2.18 mL, 19.25 mmol) was added and the mixture was stirred at 60°C for 1 h, then cooled to RT. The aqueous phase was separated, the organic phase was washed four times with H₂O and evaporated. The crude material was purified by flash column chromatography (gradient 0% to 25% EtOAc in hexanes) and was used in the next step without further purification. Yield: 85%.

BB 181**3-((1-(2,4-Dichlorophenyl)cyclopropyl)methoxy)azetidine 2,2,2-trifluoroacetate**

[0594] To a solution of tert-Butyl 3-((1-(2,4-dichlorophenyl)cyclopropyl)methoxy)azetidine-1-carboxylate (165 mg, 443 μ mol) in DCM (2 mL) was added TFA (202 mg, 137 μ L, 1.77 mmol) and the reaction stirred at RT for 8 h. The mixture was concentrated in vacuo (azeotrop with toluene, EtOAc and n-heptane) to provide the compound as a colorless oil (170 mg, 99%). MS (ESI): m/z = 272.2 [M+H]⁺.

Step a) 1-(2,4-Dichlorophenyl)cyclopropyl)methanol

[0595] In a 50 mL three-necked flask, 1-(2,4-dichlorophenyl)cyclopropane-1-carboxylic acid (1 g, 4.33 mmol) was combined with THF (20 mL) to give a colorless solution. At 0°C, borane tetrahydrofuran complex solution 1.0 M in THF (6.49 mL, 6.49 mmol) was added dropwise over a period of 15 min. The reaction was stirred at RT for 2 h. MeOH (2 mL) was added dropwise followed by 1M aq. HCl solution and stirred for 30 min. The reaction mixture was extracted twice with EtOAc (40 mL each) and the organic layers were washed with 10% aq Na₂CO₃ solution (40 mL) followed by brine (40 mL). The organic fractions were combined and dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by flash column chromatography (gradient EtOAc in n-heptane, 0% to 30%) to yield the compound as colorless oil (90%) MS (ESI): m/z = 201.0 [M-16+H]⁺.

Step b) 1-(2,4-Dichlorophenyl)cyclopropyl)methyl methanesulfonate

[0596] To an ice-cold solution of (1-(2,4-dichlorophenyl)cyclopropyl)methanol (350 mg, 1.61 mmol) and TEA

(326 mg, 449 μ L, 3.22 mmol) in DCM (6 mL) was added dropwise methanesulfonyl chloride (185 mg, 126 μ L, 1.61 mmol) and the mixture was stirred at 0°C for 1 h, then at RT overnight. The reaction mixture was poured on saturated aqueous NaHCO₃ solution (10 mL) and DCM (10 mL) and the layers were separated. The aqueous layer was extracted once with DCM (10 mL). The organic layers were washed with brine, dried over MgSO₄, filtered and evaporated to furnish the desired intermediate mesylate compound as a yellow oil (435 mg, 91%). MS (ESI): m/z = 201.0 [M-mesyl+H]⁺.

Step c) *tert*-Butyl 3-((1-(2, 4-dichlorophenyl)cyclopropyl)methoxy)azetidine-1-carboxylate

[0597] To an ice-cold solution of *tert*-butyl 3-hydroxyazetidine-1-carboxylate (220 mg, 1.27 mmol) in DMF (4 mL) was added sodium hydride in mineral oil (60%, 61 mg, 1.52 mmol) in portions and the mixture was stirred at ice-bath temperature for 5 min followed by stirring at RT for 40 min. A solution of 1-(2,4-dichlorophenyl)cyclopropyl)methyl methanesulfonate (431 mg, 1.46 mmol) was dissolved in DMF (1 mL) and added dropwise to the mixture at RT. Stirring of the slurry was continued at RT for 16 h, then at 55°C for 2.5 h. The reaction mixture was poured on saturated aqueous NH₄Cl solution (10 mL) and EtOAc (20 mL) and the layers were separated. The aqueous layer was extracted once with EtOAc (50 mL). The organic layers were washed twice with water, dried over MgSO₄, filtered and evaporated. Flash Chromatography (gradient of EtOAc in *n*-heptane 0 to 40%) yielded the product as colorless oil (165 mg, 35%) MS (ESI): m/z = 316.2 [M-56+H]⁺.

BB182

2-((Azetidin-3-yloxy)methyl)-6-(4-fluorophenoxy)-4-(trifluoromethyl)pyridine 4-methylbenzenesulfonate

[0598] *Tert*-butyl 3-((6-(4-fluorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxylate (150mg, 339 μ mol) was dissolved under argon in EtOAc (2 mL), *p*-toluenesulfonic acid monohydrate (77.4 mg, 407 μ mol) was added and the mixture was stirred at RT for 5 min, then for 80°C 3 h at and at RT over night. The reaction mixture was evaporated to provide the compound as 180 mg of a yellow oil which was used in the next step without further purification. MS (ESI): m/z = 343.2 [M+H]⁺.

Step a) *tert*-Butyl 3-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxylate

[0599] To a solution of *tert*-butyl 3-hydroxyazetidine-1-carboxylate (272 mg, 1.57 mmol) in dry THF (8 mL) was added potassium *tert*-butoxide 1M in THF (1.57 mL, 1.57 mmol) and the turbid reaction mixture was stirred at RT for 30 min. 2-Bromo-6-(bromomethyl)-4-(trifluoromethyl)pyridine (500 mg, 1.57 mmol) was added at 0 - 2°C and the reaction stirred at 0 - 2°C for 20 min. The reaction mixture was then stirred at RT for 16 h. The reaction mixture was diluted with EtOAc, extracted with water, the organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic layers were dried over sodium sulfate and evaporated down to dryness. The crude material was purified by flash column chromatography (gradient of EtOAc in *n*-heptane, 0% to 40%) to provide the product as light yellow oil (41%) MS (ESI): m/z = 355.1 [M-56+H]⁺.

Step b) *tert*-Butyl 3-[[6-(4-fluorophenoxy)-4-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-carboxylate

[0600] *tert*-Butyl 3-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxylate (260 mg, 632

μmol) and 4-fluorophenol (70.9 mg, 632 μmol) were dissolved in DMF (2 mL), then K_2CO_3 (131 mg, 948 μmol) was added and the mixture was stirred at 80° for 30 h. The reaction mixture was evaporated under vacuum and the residue was dissolved in EtOAc and extracted with water and brine. The organic layers were dried over MgSO_4 , filtered and the solvent was removed under vacuum. The residue was purified by flash chromatography (gradient of EtOAc in n-heptane, 0 to 30%) to yield the product as a light yellow oil (93%). MS (ESI): $m/z = 443.4$ $[\text{M}+\text{H}]^+$.

BB183

6-((Azetidin-3-yloxy)methyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridine 4-methylbenzenesulfonate

[0601] tert-Butyl 3-((6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxylate (170 mg, 384 μmol) was dissolved under argon atmosphere in EtOAc (2.27 mL) and p-toluenesulfonic acid monohydrate (87.7 mg, 461 μmol) was added. The reaction was stirred at RT for 5 min, then at 80°C for 3 h and stirred at RT over night. The reaction mixture was evaporated under reduced pressure to dryness to provide the desired product as light yellow oil (89%) MS (ESI): $m/z = 343.2$ $[\text{M}+\text{H}]^+$.

Step a) Methyl 6-(4-fluorophenoxy)-5-(trifluoromethyl)picolinate

[0602] Methyl 6-chloro-5-(trifluoromethyl)picolinate (800 mg, 3.34 mmol), 4-fluorophenol (412 mg, 3.67 mmol) and K_2CO_3 (692 mg, 5.01 mmol) were dissolved in DMF (6 mL) and stirred at 80°C for 6 h. The reaction mixture was cooled to RT and extracted three times with water (20 mL each), twice with EtOAc (30 mL each), brine (20mL), dried over MgSO_4 , filtered and evaporated in vacuo. The crude residue was purified by flash column chromatography (gradient of EtOAc in n-heptane, 0 to 50%) to provide the product as white solid (67%). MS (ESI): $m/z = 316.1$ $[\text{M}+\text{H}]^+$.

Step b) (6-(4-Fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methanol

[0603] To a stirred solution of methyl 6-(4-fluorophenoxy)-5-(trifluoromethyl)picolinate (705 mg, 2.24 mmol) in THF (8 mL) was added lithium borohydride 2M in THF (1.34 mL, 2.68 mmol) at 2-5°C. The reaction mixture was stirred at RT for 3 h and then cooled to 2-4°C and quenched with 10 mL water (slowly added). The aqueous layer was extracted twice with EtOAc (30 mL each) and the combined organic layers were washed with water, 10 mL NaHCO_3 solution and 10 mL brine. The organic layer was dried over Na_2SO_4 and concentrated in vacuum. Purification by flash column chromatography (gradient of EtOAc in n-heptane, 0 to 50%) yielded the product as a colorless solid (95%). MS (ESI): $m/z = 288.2$ $[\text{M}+\text{H}]^+$.

Step c) 6-(Bromomethyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridine

[0604] To a solution of (6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methanol (330 mg, 1.15 mmol) in dry DCM (5 mL) was added tetrabromomethane (457 mg, 1.38 mmol). The mixture was cooled to 0-3°C and over 10 min triphenylphosphine (392 mg, 1.49 mmol) in 1 mL dry DCM was added. The mixture was stirred 1 hr at 2-4°C, then 20mL DCM and silica gel was added. The solvent was removed in vacuo and the residue subjected to column flash chromatography (gradient of EtOAc in n-heptane, 0 to 40%) to yield the desired

product as a colorless oil (94%). MS (ESI): $m/z = 350.0$ $[M+H]^+$.

Step d) *tert-Butyl 3-((6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxylate*

[0605] To a solution of *tert-butyl 3-hydroxyazetidine-1-carboxylate* (183 mg, 1.06 mmol) in dry THF (5 mL) was added potassium *tert*-butoxide 1M in THF (1.11 mL, 1.11 mmol) and the reaction mixture was stirred at RT for 15 min. Then, 6-(bromomethyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridine (370 mg, 1.06 mmol) was added. The reaction mixture was stirred at RT for 1 h and then diluted with EtOAc and extracted with 1M aq. NaHCO_3 solution. The organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over sodium sulfate and evaporated down to dryness. The residue was purified by column flash chromatography (gradient of EtOAc in *n*-heptane, 0 to 30%) to furnish the product as a colorless oil (34%). MS (ESI): $m/z = 387.2$ $[M-56+H]^+$.

BB184

2-((Azetidin-3-yloxy)methyl)-4-(4-fluorophenyl)thiazole 2,2,2-trifluoroacetate

[0606] To a solution of *tert-butyl 3-((4-(4-fluorophenyl)thiazol-2-yl)methoxy)azetidine-1-carboxylate* (150 mg, 412 μmol) in dry DCM (1.5 mL) under argon atmosphere was added TFA (282 mg, 190 μL , 2.47 mmol) and the solution was stirred at RT for 8 h. The reaction mixture was concentrated in vacuo (azeotrop with toluene, EtOAc and heptane) to yield the desired product as a yellow solid (98%). MS (ESI): $m/z = 265.2$ $[M+H]^+$.

Step a) *(4-(4-Fluorophenyl)thiazol-2-yl)methanol*

[0607] To a stirred solution of ethyl 4-(4-fluorophenyl)thiazole-2-carboxylate (835 mg, 3.32 mmol) in dry THF (10 mL) was added lithium borohydride 2M in THF (1.99 mL, 3.99 mmol) at -2 – -5°C . The reaction mixture was stirred at RT for 3h, then cooled to -2 – -4°C and quenched with water (10 mL slowly added). The aqueous layer was extracted twice with EtOAc (30 mL each) and the organic layers were washed with water, 10 mL NaHCO_3 solution and 10 mL brine. The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum. The residue was purified by column flash chromatography (gradient of EtOAc in *n*-heptane, 0 to 60%) to yield the desired product as a white solid (94%) MS (ESI): $m/z = 210.1$ $[M+H]^+$.

Step b) *2-(Bromomethyl)-4-(4-fluorophenyl)thiazole*

[0608] To a solution of (4-(4-fluorophenyl)thiazol-2-yl)methanol (400 mg, 1.91 mmol) in dry DCM (7 mL) was added tetrabromomethane (761 mg, 2.29 mmol), the solution was cooled to 0 – 3°C and triphenylphosphine (652 mg, 2.49 mmol) in 1 mL dry DCM was added over 10 min. The mixture was stirred at -2 – -4°C for 1 h, then 20 mL DCM were added. The reaction mixture was extracted with water, saturated NH_4Cl solution and brine. The organic phase was dried over MgSO_4 , filtered and evaporated. The residue was purified by flash chromatography (gradient of EtOAc in *n*-heptane, 0 to 40%) to provide 480 mg of the title compound as a light yellow oil (83%). MS (ESI): $m/z = 273.9$ $[M+H]^+$.

Step c) *tert-Butyl 3-((4-(4-fluorophenyl)thiazol-2-yl)methoxy)azetidine-1-carboxylate*

[0609] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (293 mg, 1.69 mmol) in dry THF (6 mL) was added potassium tert-butoxide 1M in THF (1.77 mL, 1.77 mmol) and the reaction mixture was stirred at RT for 15 min. After cooling down to 2-4°C 2-(bromomethyl)-4-(4-fluorophenyl)thiazole (460 mg, 1.69 mmol) in 1mL THF was added. The reaction mixture was stirred at RT for 1h, diluted with EtOAc and extracted with 1M aq. NaHCO₃ solution. The organic phase was collected and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na₂SO₄ and evaporated down to dryness. The residue was purified by column flash chromatography (gradient of EtOAc in n-heptane, 0 to 40%) to furnish the desired product as a light yellow solid (89%). MS (ESI): m/z = 365.2 [M+H]⁺.

BB186**rac-(2R,3S)-3-(2-Bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine 2,2,2-trifluoroacetate**

[0610] To a solution of rac-tert-butyl (2R,3S)-3-(2-bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine-1-carboxylate (225mg, 530 µmol) in dry DCM (2 mL) under argon atmosphere was added TFA (242 mg, 163 µL, 2.12 mmol) and the solution was stirred at RT over night. The reaction mixture was concentrated in vacuo to dryness (azeotrop with n-heptane) to provide 233 mg of the title compound as a colorless oil (97%). MS (ESI): m/z = 324.1 [M+H]⁺.

Step a) rac-tert-Butyl (2R,3S)-3-(2-bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine-1-carboxylate

[0611] To a solution of rac-tert-butyl (2R,3 S)-3-hydroxy-2-methylpyrrolidine-1-carboxylate (CAS:1807941-04-3, 150 mg, 745 µmol) in dry THF (4 mL) under argon atmosphere was added potassium tert-butoxide 1M in THF (783 µL, 783 µmol). The mixture was stirred at RT for 15 min, then cooled down to 2-4°C and a solution of 1-bromo-2-fluoro-4-(trifluoromethyl)benzene (181 mg, 745 µmol) in 0.5mL dry THF was added slowly. The mixture was stirred at RT for 2 h and then extracted with EtOAc and aqueous 5% NaHCO₃ solution followed by water and brine. The organic phase was dried over MgSO₄, filtered off and evaporated to dryness. The residue was purified by column flash chromatography (gradient of EtOAc in n-heptane, 0 to 40%) to yield the product as light yellow oil (71%). MS (ESI): m/z = 368 [M-56+H]⁺.

[0612] The following intermediates were synthesized from 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB7a) and the suitable building blocks in analogy to the reaction methods described herein.

BB No.	Building block(s)	MS, m/z	Method
BB203	BB198	480.1 [M+H] ⁺	A10 without DMAP
BB204	BB201	445.1 [M+H] ⁺	A10 without DMAP

BB206**3- [2- [2-Fluoro-4-(trifluoromethyl)phenyl] ethyl] azetidine; 4-methylbenzenesulfonic acid**

[0613] The compound was prepared in analogy to BB95 from tert-butyl 3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carboxylate and 4-methylbenzenesulfonic acid monohydrate. Upon cooling a suspension formed which was filtered. The filter cake was washed with a small volume of EtOAc to provide the desired product as a colorless solid (71.6%). MS (ESI): $m/z = 248.2$ $[M+H]^+$.

Step a) Diethyl (2-fluoro-4-(trifluoromethyl)benzyl)phosphonate

[0614] The compound was prepared in analogy to BB159, step a, from 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and triethyl phosphite. Colorless oil (83.4%). MS (ESI): $m/z = 315.2$ $[M+H]^+$.

Step b) tert-Butyl 3-[(E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate

[0615] The compound was prepared in analogy to BB95, step a, from diethyl (2-fluoro-4-(trifluoromethyl)benzyl)phosphonate and tert-butyl 3-formylazetidine-1-carboxylate to yield the compound as a colorless oil (69.9%). MS (ESI): $m/z = 290.1$ $[M-56+H]^+$.

Step c) tert-Butyl 3-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0616] The compound was prepared in analogy to BB95, step b, from tert-butyl 3-[(E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate. Colorless oil (92.0%). MS (ESI): $m/z = 292.2$ $[M-56+H]^+$.

BB208

3-[2,2-Difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine; 4-methylbenzenesulfonic acid

[0617] The compound was prepared in analogy to BB95 from tert-butyl 3-(2,2-difluoro-2-(4-(trifluoromethyl)phenyl)ethyl)azetidine-1-carboxylate and 4-methylbenzenesulfonic acid monohydrate and using the material isolated from the filtrate after evaporation, which was used without further purification (30%). MS (ESI): $m/z = 266.2$ $[M+H]^+$.

Step a) tert-Butyl 3-[2-[methoxy(methyl)amino]-2-oxo-ethyl]azetidine-1-carboxylate

[0618] To a suspension of 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (2 g, 9.29 mmol) and HATU (3.89 g, 10.2 mmol) in DCM (65 mL) was added DIPEA (2.64 g, 3.57 mL, 20.4 mmol) and the mixture was stirred at RT for 30 min before N,O-dimethylhydroxylamine hydrochloride (906 mg, 9.29 mmol) was added. Stirring was continued at RT overnight. The reaction mixture was poured on saturated aqueous NH_4Cl solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water, dried over $MgSO_4$, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 25 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) to furnish the desired compound as a colorless oil (100%) which was used

in the next step without further purification. MS (ESI): $m/z = 203.2$ $[M-56+H]^+$.

Step b) *tert*-Butyl 3-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate

[0619] To an ice-cold solution of *tert*-butyl 3-(2-(methoxy(methyl)amino)-2-oxoethyl)azetidine-1-carboxylate (0.8 g, 3.1 mmol) in THF (5 mL) in an argon-flushed and heat-dried 2-neck flask was added dropwise a turbid solution of (4-(trifluoromethyl)phenyl)magnesium bromide 2.22 M in THF (1.95 mL, 4.34 mmol). The brown solution was stirred in an ice-bath for 2.5 h allowing the temperature to rise to RT. The reaction mixture was poured on saturated aqueous NH_4Cl solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over $MgSO_4$, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 25 g column using an MPLC system eluting with a gradient of *n*-heptane : EtOAc (100 : 0 to 0 : 100) to provide the desired compound as a colorless solid (25.9%). MS (ESI): $m/z = 342.3$ $[M-H]^-$.

[0620] Step c) *tert*-Butyl 3-[2,2-difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate To a solution of *tert*-butyl 3-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)azetidine-1-carboxylate (50 mg, 146 μ mol) in toluene (0.3 mL) under argon was added bis(2-methoxyethyl)aminosulphur trifluoride (50% solution in THF, 387 mg, 379 μ L, 874 μ mol) and the mixture was stirred at 80°C for 19 h. The dark mixture was allowed to cool down and another batch of bis(2-methoxyethyl)aminosulphur trifluoride (50% solution in THF, 387 mg, 379 μ L, 874 μ mol) was added. Heating was continued at 80°C for another 4 h. The reaction mixture was poured on saturated aqueous $NaHCO_3$ solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over $MgSO_4$, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 4 g column using an MPLC system eluting with a gradient of *n*-heptane : EtOAc (100 : 0 to 50 : 50) to yield the desired compound as a light brown oil (45.1%). MS (ESI): $m/z = 266.1$ $[M+H]^+$.

BB209

3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine;4-methylbenzenesulfonic acid

[0621] The compound was prepared in analogy to BB95 from *tert*-butyl 3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate. Colorless oil which was used in the next step without further purification. MS (ESI): $m/z = 250.1$ $[M+H]^+$.

Step a) *tert*-Butyl 3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate

[0622] To a solution of 2-fluoro-5-(trifluoromethyl)phenol (321 mg, 1.78 mmol), *tert*-butyl 3-hydroxypyrrolidine-1-carboxylate (334 mg, 1.78 mmol; CAS RN: 103057-44-9) and triphenylphosphine (467 mg, 1.78 mmol) in THF (5 mL) was added (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (450 mg, 1.78 mmol, CAS RN 10465-81-3) in portions and the mixture was stirred at RT for 40 h. Silica gel was added to the suspension and it was evaporated. The compound was purified by silica gel chromatography on a 24 g column using an MPLC (ISCO) system eluting with a gradient of *n*-heptane : EtOAc (100 : 0 to 75 : 25) to provide the desired compound as a colorless oil (8.3%) which was used in the next step without further purification. MS (ESI): $m/z = 294.1$ $[M-56+H]^+$.

BB210

3-[2-Chloro-5-(trifluoromethyl)phenoxy]pyrrolidine;4-methylbenzenesulfonic acid

[0623] The compound was prepared in analogy to BB95 from tert-butyl 3-[2-chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate. Colorless oil. MS (ESI): $m/z = 266.1$ $[M+H]^+$.

Step a) *tert-Butyl 3-[2-chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate*

[0624] The compound was prepared in analogy to BB209, step a, from 2-chloro-5-(trifluoromethyl)phenol and tert-butyl 3-hydroxypyrrolidine-1-carboxylate. Colorless solid which was used after chromatography without further purification. MS (ESI): $m/z = 310.1$ $[M-56+H]^+$.

BB211

3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine;4-methylbenzenesulfonic acid

[0625] The compound was prepared in analogy to BB95 from tert-butyl 3-[(E)-2-(2-fluoro-4-methylphenyl)vinyl]azetidine-1-carboxylate and 4-methylbenzenesulfonic acid monohydrate. Colorless solid (87%). MS (ESI): $m/z = 192.2$ $[M+H]^+$.

Step a) *1-(Diethoxyphosphorylmethyl)-2-fluoro-4-methyl-benzene*

[0626] The compound was prepared in analogy to BB206, step a, from 1-(bromomethyl)-2-fluoro-4-methylbenzene and triethyl phosphite followed by silica gel chromatography on a 40 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless liquid (85%). MS (ESI): $m/z = 261.1$ $[M+H]^+$.

Step b) *tert-Butyl 3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carboxylate*

[0627] The compound was prepared in analogy to example BB206, step b, from tert-butyl 3-formylazetidine-1-carboxylate and 1-(diethoxyphosphorylmethyl)-2-fluoro-4-methyl-benzene. Colorless oil (7%). MS (ESI): $m/z = 236.2$ $[M-56+H]^+$.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2005066187A](#) [0170] [0172]
- [WO20110059118A](#) [0172]
- [WO2016185279A](#) [0172]
- [WO2013179024A](#) [0319]
- [WO2015179559A](#) [0319]
- [US201159118A1](#) [0341]

Non-patent literature cited in the description


- IANNOTTI, F.A. et al. Progress in lipid research, 2016, vol. 62, 107-28 [0002]
- NOMURA, D.K. et al. Science, 2011, vol. 334, 809- [0002] [0004] [0005]
- CHANDA, P.K. et al. Molecular pharmacology, 2010, vol. 78, 996- [0002]
- VIADER, A. et al. Cell reports, 2015, vol. 12, 798- [0002]
- LLEO A. Cell Mol Life Sci., 2007, vol. 64, 1403- [0004]
- LONG, J.Z et al. Nature chemical biology, 2009, vol. 5, 37 [0005]
- IGNATOWSKA-JANKOWSKA B. et al. J. Pharmacol. Exp. Ther., 2015, vol. 353, 424- [0006]
- ZHONG P. et al. Neuropsychopharmacology, 2014, vol. 39, 1763- [0006]
- BERNAL-CHICO, A et al. Glia, 2015, vol. 63, 163- [0007]
- ALPAR, A. et al. Nature communications, 2014, vol. 5, 4421- [0007]
- FELIU A. et al. Journal of Neuroscience, 2017, vol. 37, 358385- [0007]
- QIN, H. et al. Cell Biochem. Biophys., 2014, vol. 70, 33- [0008]
- NOMURA DK et al. Cell, 2009, vol. 140, 149-61 [0008]
- NOMURA DK et al. Chem. Biol., 2011, vol. 18, 1846-857 [0008]
- HIGUCHISTELLA Pro-drugs as Novel Delivery Systems A.C.S. Symposium Series, vol. 14, [0044]
- Bioreversible Carriers in Drug Design American Pharmaceutical Association and Pergamon Press 1987 0000 [0044]
- T. W. GREENE P. G. M. WUTTS Protective Groups in Organic Chemistry John Wiley & Sons 2014 0000 [0046] [0159]
- G. SARTORI et al. Green Chemistry, 2000, vol. 2, 140- [0047] [0167]
- BARANYR. B. MERRIFIELD J. Am. Chem. Soc., 1977, vol. 99, 7363- [0161]
- H. WALDMANN et al. Angew. Chem. Int. Ed. Engl., 1996, vol. 35, 2056- [0161]
- RICHARD C. LAROCK. Comprehensive Organic Transformations: A Guide to Functional Group Preparations John Wiley & Sons 1999 0000 [0163]
- Z. RAFINSKI et al. J. Org. Chem., 2015, vol. 80, 7468- [0170]
- S. DUGAR et al. Synthesis, 2015, vol. 47, 5712- [0170]
- T.W. GREENE P.G.M. WUTTS Protective Groups in Organic Chemistry Wiley 2006 0000 [0171] [0178] [0182]
- H. J. CRISTAUF. PLÉNAT PATAI'S Chemistry of Functional Groups, 2006, [0174]
- Chem. Rev., 1984, vol. 84, 577- [0175]
- Current Org. Chem., 2015, vol. 19, 9744- [0176]

- Chem. Rev., 1989, vol. 89, 4863- [\[0176\]](#)
- Org. React., 1977, vol. 25, 73- [\[0176\]](#)
- Liebigs Ann./Recueil, 1997, vol. 1283, [\[0176\]](#)
- Acc. Chem. Res., 1983, vol. 16, 411- [\[0176\]](#)
- Org. Chem. Front.20150000vol. 2, 739- [\[0189\]](#)
- Chem. Rev., 2009, vol. 109, 62551- [\[0189\]](#) [\[0211\]](#) [\[0216\]](#)
- Org. Chem. Front., 2015, vol. 2, 739- [\[0211\]](#) [\[0216\]](#)
- **G.G. MUCCIOLIG. LABARD.M. LAMBERT**Chem. Bio. Chem., 2008, vol. 9, 2704-2710 [\[0240\]](#)
- CHEMICAL ABSTRACTS, 32315-10-9 [\[0294\]](#)
- CHEMICAL ABSTRACTS, 333987-57-8 [\[0294\]](#)
- CHEMICAL ABSTRACTS, 28033-37-6 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 192990-03-7 [\[0319\]](#) [\[0319\]](#) [\[0333\]](#)
- CHEMICAL ABSTRACTS, 1239730-22-3 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 23145-88-2 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 681482-50-8 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 614731-39-4 [\[0319\]](#) [\[0319\]](#)
- CHEMICAL ABSTRACTS, 36938-76-8 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 937614-88-5 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 337912-66-0 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 35852-58-5 [\[0319\]](#) [\[0319\]](#) [\[0407\]](#) [\[0554\]](#)
- CHEMICAL ABSTRACTS, 946680-87-1 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 1580795-67-0 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 914299-54-0 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 957988-84-4 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 63843-53-8 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 1354963-49-7 [\[0319\]](#)
- CHEMICAL ABSTRACTS, 142253-56-3 [\[0321\]](#) [\[0326\]](#) [\[0365\]](#)
- CHEMICAL ABSTRACTS, 39890-98-7 [\[0321\]](#)
- CHEMICAL ABSTRACTS, 55304-75-1 [\[0326\]](#)
- CHEMICAL ABSTRACTS, 7693-46-1 [\[0333\]](#)
- CHEMICAL ABSTRACTS, 57260-71-6 [\[0336\]](#)
- CHEMICAL ABSTRACTS, N63614-86-8 [\[0337\]](#)
- CHEMICAL ABSTRACTS, 1000773-62-5 [\[0339\]](#)
- CHEMICAL ABSTRACTS, 280-64-8 [\[0339\]](#)
- CHEMICAL ABSTRACTS, 159635-49-1 [\[0339\]](#) [\[0424\]](#)
- CHEMICAL ABSTRACTS, 72287-26-4 [\[0339\]](#)
- CHEMICAL ABSTRACTS, 127-09-3 [\[0341\]](#)
- CHEMICAL ABSTRACTS, 79-04-9 [\[0341\]](#)
- CHEMICAL ABSTRACTS, 1334492-54-4 [\[0345\]](#)
- CHEMICAL ABSTRACTS, 603-35-0 [\[0345\]](#)
- CHEMICAL ABSTRACTS, 79099-07-3 [\[0346\]](#) [\[0459\]](#) [\[0547\]](#)
- CHEMICAL ABSTRACTS, 6457-49-4 [\[0354\]](#)
- CHEMICAL ABSTRACTS, 158407-04-6 [\[0356\]](#) [\[0363\]](#) [\[0371\]](#)
- CHEMICAL ABSTRACTS, 1016731-24-0 [\[0380\]](#)
- CHEMICAL ABSTRACTS, 398489-42-4 [\[0405\]](#)
- CHEMICAL ABSTRACTS, 1104083-23-9 [\[0405\]](#)
- CHEMICAL ABSTRACTS, 248262-29-5 [\[0405\]](#) [\[0407\]](#)
- CHEMICAL ABSTRACTS, 77227-78-2 [\[0406\]](#) [\[0407\]](#)
- CHEMICAL ABSTRACTS, 1996-41-4 [\[0406\]](#) [\[0406\]](#)
- CHEMICAL ABSTRACTS, 1126650-66-5 [\[0406\]](#)
- CHEMICAL ABSTRACTS, 130047-19-7 [\[0407\]](#)
- CHEMICAL ABSTRACTS, 91407-41-9 [\[0407\]](#)

- CHEMICAL ABSTRACTS, 452-72-2 [\[0407\]](#)
- CHEMICAL ABSTRACTS, 870987-63-6 [\[0413\]](#)
- CHEMICAL ABSTRACTS, 72914-19-3 [\[0413\]](#)
- CHEMICAL ABSTRACTS, 1873-77-4 [\[0413\]](#)
- CHEMICAL ABSTRACTS, 14221-01-3 [\[0418\]](#)
- CHEMICAL ABSTRACTS, 287192-97-6 [\[0423\]](#)
- CHEMICAL ABSTRACTS, 40161-54-4 [\[0424\]](#)
- CHEMICAL ABSTRACTS, 128-08-5 [\[0426\]](#) [\[0453\]](#)
- CHEMICAL ABSTRACTS, 411235-57-9 [\[0429\]](#)
- CHEMICAL ABSTRACTS, 275387-83-2 [\[0444\]](#)
- CHEMICAL ABSTRACTS, 147539-41-1 [\[0465\]](#)
- CHEMICAL ABSTRACTS, 157141-27-0 [\[0467\]](#)
- CHEMICAL ABSTRACTS, 665-04-03 [\[0478\]](#) [\[0481\]](#) [\[0481\]](#)
- CHEMICAL ABSTRACTS, 935669-28-6 [\[0481\]](#) [\[0481\]](#)
- CHEMICAL ABSTRACTS, 288315-03-7 [\[0481\]](#)
- CHEMICAL ABSTRACTS, 1427379-42-7 [\[0481\]](#) [\[0481\]](#)
- CHEMICAL ABSTRACTS, 1354952-05-8 [\[0481\]](#)
- CHEMICAL ABSTRACTS, 138387-19-6 [\[0481\]](#) [\[0481\]](#)
- CHEMICAL ABSTRACTS, 1147530-63-9 [\[0481\]](#)
- CHEMICAL ABSTRACTS, 145309-24-6 [\[0481\]](#)
- CHEMICAL ABSTRACTS, 239087-08-2 [\[0506\]](#) [\[0556\]](#)
- CHEMICAL ABSTRACTS, 239087-07-1 [\[0515\]](#)
- CHEMICAL ABSTRACTS, 1259034-35-9 [\[0516\]](#)
- CHEMICAL ABSTRACTS, 1363383-17-8 [\[0517\]](#) [\[0517\]](#)
- CHEMICAL ABSTRACTS, 106-52-5 [\[0521\]](#) [\[0537\]](#) [\[0552\]](#)
- CHEMICAL ABSTRACTS, 1576-35-8 [\[0524\]](#)
- CHEMICAL ABSTRACTS, 17502-28-8 [\[0524\]](#)
- CHEMICAL ABSTRACTS, 75-89-8 [\[0525\]](#)
- CHEMICAL ABSTRACTS, 763-93-9 [\[0525\]](#)
- CHEMICAL ABSTRACTS, 141699-55-0 [\[0532\]](#) [\[0554\]](#) [\[0556\]](#)
- CHEMICAL ABSTRACTS, 2402-82-6 [\[0534\]](#)
- CHEMICAL ABSTRACTS, RN1214385-56-4 [\[0537\]](#)
- CHEMICAL ABSTRACTS, 110-91-8 [\[0538\]](#)
- CHEMICAL ABSTRACTS, 76189-55-4 [\[0538\]](#)
- CHEMICAL ABSTRACTS, 76971-72-7 [\[0538\]](#)
- CHEMICAL ABSTRACTS, 493038-91-8 [\[0546\]](#)
- CHEMICAL ABSTRACTS, 106-39-8 [\[0550\]](#)
- CHEMICAL ABSTRACTS, 867333-04-8 [\[0550\]](#)
- CHEMICAL ABSTRACTS, 1066-54-2 [\[0558\]](#)
- CHEMICAL ABSTRACTS, 254454-54-1 [\[0558\]](#)
- CHEMICAL ABSTRACTS, 452-74-4 [\[0561\]](#)
- CHEMICAL ABSTRACTS, 400-72-6 [\[0565\]](#)
- CHEMICAL ABSTRACTS, 86845-27-4 [\[0568\]](#)
- CHEMICAL ABSTRACTS, 22214-30-8 [\[0569\]](#)
- CHEMICAL ABSTRACTS, 497959-33-8 [\[0578\]](#)

PATENTKRAV

1. Forbindelse med formlen (I)



5 eller et farmaceutisk acceptabelt salt deraf,

hvor:

(i) X er CR^3 , m er 0 eller 1, n er valgt blandt 0, 1 og 2, og L er valgt blandt $-(\text{CH}_2)_p-$, $-\text{O}-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{OCH}_2-$, $-\text{CF}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-(\text{CR}^{16}\text{R}^{17})_q-\text{CH}_2\text{O}-$ og $-\text{CH}_2\text{CF}_2-$, eller

(ii) X er N, m er 1, n er 1 eller 2, og L er $-(\text{CH}_2)_p-$ eller $-\text{CF}_2\text{CH}_2-$,

10 p er valgt blandt 1, 2 og 3,

q er 0 eller 1,

A er valgt blandt:

(i) $\text{C}_6\text{-C}_{14}$ -aryl substitueret med R^4 , R^5 og R^6 ,

(ii) 5- til 14-leddet heteroaryl substitueret med R^7 , R^8 og R^9 og

15 (iii) 3- til 14-leddet heteroaryl substitueret med R^{10} , R^{11} og R^{12} ,

R^1 er hydrogen eller C_{1-6} -alkyl,

R^2 er valgt blandt hydrogen, C_{1-6} -alkyl og hydroxy- C_{1-6} -alkyl,

R^3 er valgt blandt hydrogen, halogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkyl og halogen- C_{1-6} -alkyl,

20 hver af R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} og R^{12} er uafhængigt valgt blandt hydrogen, halogen, cyano, hydroxy, C_{1-6} -alkyl, halogen- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkanoyl, halogen- C_{1-5} -alkyl- $\text{CH}(\text{OH})-$, C_{1-6} -alkoxy, halogen- C_{1-6} -alkoxy, SF_5 , CH_3SO_2 , C_{3-10} -cycloalkyl, C_{3-10} -cycloalkyl substitueret med R^{13} , 3- til 14-leddet heterocycloalkyl, 3- til 14-leddet heterocycloalkyl substitueret med R^{14} og R^{15} , 5- til 14-leddet heteroaryl, $\text{C}_6\text{-C}_{14}$ -aryl, 25 $\text{C}_6\text{-C}_{14}$ -aryloxy, halogen- $\text{C}_6\text{-C}_{14}$ -aryl og halogen- $\text{C}_6\text{-C}_{14}$ -aryloxy,

hver af R^{13} , R^{14} og R^{15} er uafhængigt valgt blandt C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen- C_{1-6} -alkyl, halogen- C_{1-6} -alkoxy, halogen og hydroxy, og

R^{16} og R^{17} sammen med det karbonatom, hvortil de er bundet, danner en C_{3-10} -cycloalkyl.

30 2. Forbindelse med formlen I ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, hvor:

(i) X er $C-R^3$, m er 0 eller 1, n er valgt blandt 0, 1 og 2, og L er valgt blandt $-(CH_2)_p-$, $-O-$, $-OCH_2-$, $-CF_2CH_2-$, $-CH=CH-$, $-(CR^{16}R^{17})_q-CH_2O-$ og $-CH_2OCH_2-$, eller

(ii) X er N, både m og n er 1, og L er $-(CH_2)_p-$,

p er 1 eller 2,

5 q er 0 eller 1,

R^2 er hydrogen eller C_{1-6} -alkyl, og

R^3 er valgt blandt hydrogen, halogen, C_{1-6} -alkoxy og halogen- C_{1-6} -alkyl.

3. Forbindelse med formlen I ifølge krav 2, eller et farmaceutisk acceptabelt salt deraf, hvor:

10 X er $C-R^3$,

både m og n er 0, eller

både m og n er 1, og

L er valgt blandt $-(CH_2)_p-$, $-O-$, $-OCH_2-$ og $-CH_2O-$,

p er 2,

15 q er 0,

R^2 er hydrogen eller C_{1-6} -alkyl, og

R^3 er valgt blandt hydrogen, halogen og C_{1-6} -alkyl.

4. Forbindelse med formlen I ifølge krav 3, eller et farmaceutisk acceptabelt salt deraf, hvor:

20 X er $C-R^3$,

både m og n er 0, eller

både m og n er 1, og

L er valgt blandt $-(CH_2)_p-$, $-O-$, $-OCH_2-$ og $-CH_2O-$,

p er 2,

25 q er 0,

R^2 er hydrogen eller metyl, og

R^3 er valgt blandt hydrogen, fluor og metyl.

5. Forbindelse med formlen I ifølge et hvilket som helst af kravene 1-4 eller et farmaceutisk acceptabelt salt deraf, hvor:

30 R^4 er valgt blandt hydrogen, halogen, hydroxy, cyano, C_{1-6} -alkyl, C_{1-6} -alkanoyl, SF_5 , C_{1-6} -alkoxy, halogen- C_{1-6} -alkoxy, halogen- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, 3- til 14-leddet heterocyclyl, 3- til 14-leddet heterocycloalkyl substitueret med R^{14} og R^{15} , 5- til 14-leddet heteroaryl, C_6-C_{14} -aryloxy og halogen- C_6-C_{14} -aryl,

R^5 er valgt blandt hydrogen, cyano, halogen, C_{1-6} -alkyl, halogen- C_{1-6} -alkyl, C_{1-6} -

alkoxy, 3- til 14-leddet heterocycloalkyl, C₃₋₁₀-cycloalkyl, 5- til 14-leddet heteroaryl og halogen-C₆-C₁₄-aryl,

R⁶ er hydrogen eller halogen,

R⁷ er valgt blandt hydrogen, C₁₋₆-alkyl, C₆-C₁₄-aryl, halogen-C₆-C₁₄-aryl, halogen-C₆-

5 C₁₄-aryloxy og halogen-C₁₋₆-alkyl,

R⁸ er valgt blandt hydrogen, halogen, C₁₋₆-alkyl og halogen-C₁₋₆-alkyl,

R⁹ er hydrogen,

R¹⁰ er halogen,

R¹¹ er halogen,

10 R¹² er hydrogen,

R¹⁴ er valgt blandt C₁₋₆-alkyl, C₁₋₆-alkoxy og halogen, og

R¹⁵ er hydrogen eller halogen.

6. Forbindelse med formelen I ifølge krav 5 eller et farmaceutisk acceptabelt salt deraf, hvor A er valgt blandt:

15 (i) C₆-C₁₄-aryl substitueret med R⁴, R⁵ og R⁶ og

(ii) 5- til 14-leddet heteroaryl substitueret med R⁷, R⁸ og R⁹,

R⁴ er valgt blandt halogen, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen-C₁₋₆-alkoxy, halogen-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl og 3- til 14-leddet heterocycloalkyl,

R⁵ er valgt blandt hydrogen, cyano, halogen, C₁₋₆-alkyl, halogen-C₁₋₆-alkyl, 3- til 14-

20 leddet heterocycloalkyl, C₃₋₁₀-cycloalkyl og halogen-C₆-C₁₄-aryl,

R⁶ er hydrogen,

R⁷ er C₁₋₆-alkyl eller halogen-C₁₋₆-alkyl,

R⁸ er hydrogen eller halogen-C₁₋₆-alkyl, og

R⁹ er hydrogen.

25 7. Forbindelse med formelen I ifølge krav 6 eller et farmaceutisk acceptabelt salt deraf, hvor A er valgt blandt:

(i) fenyl substitueret med R⁴, R⁵ og R⁶,

(ii) oxazolyl substitueret med R⁷, R⁸ og R⁹ og

(iii) pyridyl substitueret med R⁷, R⁸ og R⁹,

30 R⁴ er valgt blandt klor, SF₅, metyl, methoxy, OCF₃, CF₃, cyclopropyl og 2-azaspiro[3,3]heptan-2-yl,

R⁵ er valgt blandt hydrogen, cyano, fluor, klor, metyl, CF₃, pyrrolidinyl, cyclopentyl, cyclopropyl og klorfenyl,

R⁶ er hydrogen,

R⁷ er *tert*-butyl eller CF₃,

R⁸ er hydrogen eller CF₃, og

R⁹ er hydrogen.

8. Forbindelse med formlen I ifølge et hvilket som helst af kravene 1-7, eller et
5 farmaceutisk acceptabelt salt deraf, hvor R¹ er hydrogen.

9. Forbindelse med formlen (I) ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, der er valgt blandt:

(+)-(4aR,8aS)-6-(4-((4-(*tert*-butyl)thiazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

10 (+)-(4aR,8aS)-6-(4-((4-(*tert*-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-[4-[(4-*tert*-butylthiazol-2-yl)methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

15 rac-(4aR,8aS)-6-(4-((4-(*tert*-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(-)-(4aS,8aR)-6-(4-((4-(*tert*-butyl)thiazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(-)-(4aS,8aR)-6-(4-((4-(*tert*-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

20 rac-(4aR,8aS)-6-(4-((4-chlor-4-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)-(4aR,8aS)-6-[4-[[4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

25 rac-(4aR,8aS)-6-(4-((4-chlorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-(4-(4-chlorbenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-[4-[[4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

30 (+)- eller (-)-(4aR,8aS)-6-(4-(4-(trifluormethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3 (4H)-on,

rac-(4aR,8aS)-6-(4-(4-(trifluormethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)-(4aS,8aS)-6-(4-(4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-

pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aRS,8aS)-6-[4-(phenoxymethyl)piperidin-1-carbonyl]-4,4a,5,7,8,8a-

hexahydropyrido[4,3-b][1,4]oxazin-3-on,

rac-(4aR,8aS)-6-(4-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)methyl)piperidin-1-

5 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aS,8aS)-6-(4-(4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-(4-((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)piperidin-1-

carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

10 (-)-(4aR,8aR)-6-(4-(4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(-)-(4aS,8aR)-6-[4-[[4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-

4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

rac-(4aR,8aS)-6-(4-(4-(trifluormethyl)benzyl)piperazin-1-carbonyl)hexahydro-2H-

15 pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-(4-(4-chlorbenzyl)piperazin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(-)-(4aS,8aR)-6-(4-((2-chlor-4-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

20 (+)-(4aR,8aS)-6-(4-((2-chlor-4-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-[4-[[5-(trifluormethyl)-2-pyridyl]methyl]piperidin-1-carbonyl]-

4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-(4-((4-(trifluormethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-

25 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-fluorbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

30 (+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aS,8aR)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-(4-(4-(trifluormethoxy)benzyl)piperidin-1-

- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((2,4-difluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(4-chlor-3-fluorbenzyl)piperidin-1-carbonyl)hexahydro-
 5 2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-4-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahidropyrido[4,3-b][1,4]oxazin-6-carbonyl]-4-piperidyl]methyl]benzonitril,
 (+)- eller (-)-(4aR,8aS)-6-(4-(4-chlorbenzyl)piperidin-1-carbonyl)hexahydro-2H-
 pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 10 (+)- eller (-)-(4aR,8aS)-6-[3-[[4-(trifluormethyl)phenyl]methyl]azetidin-1-carbonyl]-
 4,4a,5,7,8,8a-hexahidropyrido[4,3-b][1,4]oxazin-3-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4,4-difluorpiperidin-1-yl)methyl)piperidin-1-
 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((5-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-
 15 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-[4-[(2-fluor-4-methoxyphenoxy)methyl]piperidin-1-
 carbonyl]hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(2-chlor-4-(trifluormethyl)phenoxy)piperidin-1-
 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 20 (+)- eller (-)-(4aS,8aR)-6-(4-(((6-(trifluormethyl)pyridin-3-yl)oxy)methyl)piperidin-1-
 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(((6-(trifluormethyl)pyridin-3-yl)oxy)methyl)piperidin-1-
 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(3-(trifluormethyl)phenoxy)piperidin-1-
 25 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aS,8aR)-6-[4-[[2-chlor-4-(trifluormethoxy)phenoxy]methyl]piperidin-
 1-carbonyl]-4,4a,5,7,8,8a-hexahidropyrido[4,3-b][1,4]oxazin-3-on,
 (+)- eller (-)-(4aR,8aS)-6-[4-[[2-chlor-4-(trifluormethoxy)phenoxy]methyl]piperidin-
 1-carbonyl]-4,4a,5,7,8,8a-hexahidropyrido[4,3-b][1,4]oxazin-3-on,
 30 (+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)phenoxy)methyl)azetidin-1-
 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aS,8aR)-6-[4-[(2-chlor-4-fluor-phenoxy)methyl]-4-methyl-piperidin-1-
 carbonyl]-4,4a,5,7,8,8a-hexahidropyrido[4,3-b][1,4]oxazin-3-on,
 (+)- eller (-)-(4aS,8aR)-6-(4-((2,4-difluorphenoxy)methyl)piperidin-1-

- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4-chlor-2-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4-fluor-2-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 5 (+)- eller (-)-(4aR,8aS)-6-(4-((2-fluor-4-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 10 (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-2-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-6-carbonyl]-4-piperidyl]methoxy]-5-fluor-benzonitril,
 (+)- eller (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluormethyl)benzyl)piperazin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 15 (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-fluorphenoxy)methyl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-[4-[[2-cyclopentyl-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 20 (+)- eller (-)-3-chlor-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazin-6-carbonyl)piperidin-4-yl)methoxy)benzonitril,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4-(trifluormethyl)-1H-imidazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 25 (+)- eller (-)-(4aR,8aS)-6-(4-((4-fluor-2-methylphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-(trifluormethyl)phenoxy)methyl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-fluorphenoxy)methyl)-4-fluorpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 30 (+)- eller (-)-(4aR,8aS)-6-(4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (2R,4aR,8aS)-2-methyl-6-[4-[[4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

- (+)- eller (-)-(4aR,8aS)-6-(4-(benzo[d]oxazol-2-ylmethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (+)- eller (-)-(4aR,8aS)-6-(4-((4',6-dichlor-[1,1'-biphenyl]-3-yl)oxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 5 (+)- eller (-)-(4aR,8aS)-6-(cis-4-((2-chlor-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (+)- eller (-)-(4aR,8aS)-6-(3-((4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 10 (+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethoxy)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-fluorophenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 15 (+)- eller (-)-(4aR,8aS)-6-(4-(2-(1H-pyrazol-4-yl)-4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-[3-[(2,4-dichlorophenyl)methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[3-methoxy-4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-
- 20 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[[5-methyl-6-(trifluormethyl)pyridin-3-yl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[(3-chlorophenoxy)methyl]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 25 (4aR,8aS)-6-[3-[(2-chlorophenoxy)methyl]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[[2-fluor-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[(2-chlorophenyl)methoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-
- 30 hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[(3-chlorophenyl)methoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[[2-cyclopropyl-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[(4-chlorphenoxy)methyl]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[(4-chlorphenyl)methoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

5 (4aR,8aS)-6-[4-[[2-methyl-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[4-[[2-chlor-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[4-(trifluormethyl)phenyl]methyl]pyrrolidin-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[3-fluor-5-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-6-(trifluormethyl)phenyl]methoxymethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

15 (4aR,8aS)-6-[2-methyl-3-[[4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[3-chlor-4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[(2-chlor-4-fluorophenoxy)methyl]-3-fluorazetidin-1-carbonyl]-
20 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxy]-3-(trifluormethyl)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxy]-3-methylazetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

25 (4aR,8aS)-6-[3-[[2,4-difluor-5-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-5-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[3-fluor-4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-
30 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-methoxy-4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[4-chlor-2-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

- (4aR,8aS)-6-[2-methyl-3-[[4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 5 (4aR,8aS)-6-[4-[4-chlor-3-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-(4-chlor-3-cyclopropylphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-(4-chlor-3-morpholin-4-ylphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 10 (4aR,8aS)-6-[4-[2-methyl-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 2-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-6-carbonyl]piperidin-4-yl]oxy-5-(trifluormethyl)benzonitril,
- 15 (4aR,8aS)-6-[4-(oxazolo[5,4-c]pyridin-2-ylmethyl)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[2-fluor-6-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[(2-chlor-4-fluorophenoxy)methyl]azepan-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 20 (4aR,8aS)-6-[4-[[4-(trifluormethyl)phenyl]methyl]azepan-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[3-pyrazol-1-yl-5-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 25 (4aR,8aS)-6-[4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[3-(1,2,4-triazol-1-yl)-5-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[4-chlor-3-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 30 (4aR,8aS)-6-[4-(4-chlor-3-pyrazol-1-yl-phenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-(4-(3-morpholino-4-(trifluormethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

- (4aR,8aS)-6-[4-[4-chlor-3-(1,2,4-triazol-1-yl)phenoxy]piperidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 5 (4aR,8aS)-6-[4-[3-pyrazol-1-yl-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-(4-chlorphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[[2,6-difluor-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[4-chlor-3-(4-chlorphenyl)-2-fluor-phenoxy]piperidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-chlor-4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 15 (4aR,8aS)-6-[3-[[2-fluor-6-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-(2-fluor-4-methyl-phenyl)ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-
20 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[4-methyl-2-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[2-methoxy-6-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 25 (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[2-acetyl-4-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[2-brom-4-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-
30 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[6-fluor-4-(trifluormethyl)-2-pyridyl]oxymethyl]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[6-fluor-5-(trifluormethyl)-2-pyridyl]oxymethyl]azetidin-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[(3,4-dichlorophenyl)methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[(2,5-dichlorophenyl)methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

5 (4aR,8aS)-6-[3-[[3-(trifluormethoxy)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

10 (4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[5-(trifluormethyl)-2-pyridyl]oxymethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

15 (4aR,8aS)-6-[rel-(3R,4R)-3-methyl-4-[[5-methyl-6-(trifluormethyl)-3-pyridyl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[rel-(3S,4S)-3-methyl-4-[[5-methyl-6-(trifluormethyl)-3-pyridyl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

20 (4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxy]-2-methyl-azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[4,5-bis(trifluormethyl)-2-pyridyl]oxymethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

25 (4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxymethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxy]-2-methyl-azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

30 (4aR,8aS)-6-[3-[(4-chlor-2-phenoxy-phenyl)methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[2-fluor-4-(pentafluor-lambda6-sulfanyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(4aR,8aS)-6-[3-[[1-(2,4-dichlorophenyl)cyclopropyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

- (4aR,8aS)-6-[3-[[6-(4-fluorophenoxy)-4-(trifluormethyl)-2-pyridyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[6-(4-fluorophenoxy)-5-(trifluormethyl)-2-pyridyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][4]oxazin-3-on,
- 5 (4aR,8aS)-6-[3-[[4-(4-fluorophenyl)thiazol-2-yl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[2-fluor-4-(trifluormethyl)phenyl]methoxy]-3-(trifluormethyl)pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 10 (4aR,8aS)-6-[rac-(2R,3S)-3-[2-brom-5-(trifluormethyl)phenoxy]-2-methyl-pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[rel-(2R,3S)-3-[2-brom-5-(trifluormethyl)phenoxy]-2-methyl-pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[rel-(2S,3R)-3-[2-brom-5-(trifluormethyl)phenoxy]-2-methyl-pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 15 (+)-(4aR,8aS)-6-[3-[[2,4-bis(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (+)-(4aR,8aS)-6-(3-((2-methyl-3-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 20 (+)-(4aR,8aS)-6-(3-((4-methyl-2-(trifluormethoxy)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluormethoxy)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 25 (+)-(4aR,8aS)-6-[4-[2-fluor-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (+)-(4aR,8aS)-6-[4-[3-chlor-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 30 (+)-(4aR,8aS)-6-[3-(4-chlor-3-cyclopropylphenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (+)-(4aR,8aS)-6-[4-[2-chlor-3-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (+)-(4aR,8aS)-6-[3-(3-brom-2-chlor-phenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-

hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-(2-chlor-3-cyclopropyl-phenoxy)azetidin-1-carbonyl]-

4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-cyclopropyl-4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-

5 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-chlor-4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-

4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-5-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-6-carbonyl]-4-piperidyl]oxy]-2-(trifluormethyl)benzonitril,

10 (+)-5-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-6-carbonyl]azetidin-3-yl]oxy]-2-(trifluormethyl)benzonitril,

(+)-(4aR,8aS)-6-[3-(3-brom-4-chlorphenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-

15 (trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(3-methylazetidin-1-yl)-4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(3,3-difluorazetidin-1-yl)-4-(trifluormethyl)phenoxy]azetidin-

20 1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(3-fluor-3-methyl-azetidin-1-yl)-4-

(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(6,6-difluor-2-azaspiro[3.3]heptan-2-yl)-4-

25 (trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)-4-

(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

30 (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chlor-phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[2-chlor-3-(3-methylazetidin-1-yl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-[3-[2-chlor-3-(3-fluor-3-methyl-azetidin-1-yl)phenoxy]azetidin-1-

- carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (+)-(4aR,8aS)-6-(3-(3-(3-(tert-butoxy)azetidin-1-yl)-2-chlorphenoxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)-(4aR,8aS)-6-[3-[2-chlor-3-(5-oxa-2-azaspiro[3.4]octan-2-yl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 5 (+)-(4aR,8aS)-6-[3-[2-chlor-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-5-chlor-phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 10 (+)-(4aR,8aS)-6-[3-(3-chlor-5-pyrrolidin-1-yl-phenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[3-[2-[2-fluor-4-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[3-[4-fluor-2-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 15 (4aR,8aS)-6-[3-[2,2-difluor-2-[4-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[3-[3-(trifluormethoxy)phenyl]methyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 20 (4aR,8aS)-6-[3-[2-fluor-5-(trifluormethyl)phenoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[3-[2-chlor-5-(trifluormethyl)phenoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[(3R eller 3S)-3-[2-fluor-5-(trifluormethyl)phenoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 25 (4aR,8aS)-6-[(3S eller 3R)-3-[2-fluor-5-(trifluormethyl)phenoxy]pyrrolidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[3-[(E)-2-(2-fluor-4-methyl-phenyl)vinyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 30 (4aR,8aS)-6-(3-((3-fluor-4-(trifluormethoxy)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (4aR,8aS)-6-(3-((E)-2-fluor-6-(trifluormethyl)styryl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (4aR,8aS)-6-(3-((2,3-dimethylbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-

pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(4aR,8aS)-6-(3-((2,4-dimethylbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-

pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(4aR,8aS)-6-(3-((2-methyl-4-(trifluormethyl)benzyl)oxy)azetidin-1-

5 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(4aR,8aS)-6-(3-(4-hydroxy-2-(trifluormethyl)phenethyl)azetidin-1-

carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on og

(4aR,8aS)-6-[3-[[4-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-

4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on.

10 10. Forbindelse med formlen (I) ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, der er valgt blandt:

(+)-(4aR,8aS)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-

carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)-(4aR,8aS)-6-[4-[[4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-

15 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

(+)-(4aR,8aS)-6-(4-((2-chlor-4-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-

2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

rac-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)azetidin-1-

carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

20 (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-fluorbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

25 (+)- eller (-)-(4aR,8aS)-6-(4-(4-(trifluormethoxy)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-(4-(4-chlor-3-fluorbenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-(4-(2-chlor-4-(trifluormethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

30 (+)- eller (-)-(4aR,8aS)-6-(4-(3-(trifluormethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,

(+)- eller (-)-(4aR,8aS)-6-[4-[[2-chlor-4-(trifluormethoxy)phenoxy]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,


(+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)phenoxy)methyl)azetidin-1-

- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4-chlor-2-fluorphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((4-fluor-2-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 5 (+)- eller (-)-(4aR,8aS)-6-(4-((2-fluor-4-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluormethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 10 (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-(trifluormethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-[4-[[2-cyclopentyl-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 15 (+)- eller (-)-3-chlor-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazin-6-carbonyl)piperidin-4-yl)methoxy)benzonitril,
 (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-(trifluormethyl)phenoxy)methyl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-fluorphenoxy)methyl)-4-fluorpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 20 (+)- eller (-)-(4aR,8aS)-6-(4-((4',6-dichlor-[1,1'-biphenyl]-3-yl)oxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(cis-4-((2-chlor-4-fluorphenoxy)methyl)-3-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 25 (+)- eller (-)-(4aR,8aS)-6-(3-((2-chlor-4-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethoxy)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 (+)- eller (-)-(4aR,8aS)-6-(4-((2-chlor-4-fluorphenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
 30 (4aR,8aS)-6-[3-[(2,4-dichlorophenyl)methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
 (4aR,8aS)-6-[4-[[2-fluor-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,

- (4aR,8aS)-6-[4-[[2-cyclopropyl-4-(trifluormethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[[3-chlor-4-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 5 (4aR,8aS)-6-[3-[[2-fluor-5-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-[2-fluor-6-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-(3-(2-fluor-4-(trifluormethyl)phenethyl)azetidin-1-carbonyl)hexahydro-10 2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 6-(3-((2,4-bis(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-[4-[3-chlor-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 15 (4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluormethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-((3,4-dichlorbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-((2,5-dichlorbenzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-20 pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- rac-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-(((4,5-bis(trifluormethyl)pyridin-2-yl)oxy)methyl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 25 rac-(4aR,8aS)-6-(3-((2-fluor-4-(trifluormethyl)benzyl)oxy)-2-methylazetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-((2-fluor-4-(pentafluor-16-sulfaneyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-((4-methyl-2-(trifluormethoxy)benzyl)oxy)azetidin-1-30 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-(2-fluor-4-methyl-phenyl)ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,


- (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluormethyl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 5 (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluormethyl)phenyl]ethyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-(3-((4-methyl-3-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- (4aR,8aS)-6-(3-((2-methyl-3-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on,
- 10 rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluormethoxy)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluormethyl)phenyl]methoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 15 (4aR,8aS)-6-[3-(4-chlor-3-cyclopropylphenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[4-[2-chlor-3-(trifluormethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 20 (4aR,8aS)-6-[3-(2-chlor-3-cyclopropyl-phenoxy)azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chlor-phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-[3-[2-chlor-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- 25 (4aR,8aS)-6-[3-[(E)-2-(2-fluor-4-methyl-phenyl)vinyl]azetidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on,
- (4aR,8aS)-6-(3-((E)-2-fluor-6-(trifluormethyl)styryl)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on og
- 30 (4aR,8aS)-6-(3-((4-methyl-3-(trifluormethyl)benzyl)oxy)azetidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on.

11. Forbindelse med formlen I ifølge krav 1, der er:




eller et farmaceutisk acceptabelt salt deraf.

12. Forbindelse med formlen I ifølge krav 1, der er:




5 eller et farmaceutisk acceptabelt salt deraf.

13. Forbindelse med formlen I ifølge krav 1, der er:



eller et farmaceutisk acceptabelt salt deraf.


14. Forbindelse med formlen I ifølge krav 1, der er:



10

eller et farmaceutisk acceptabelt salt deraf.


15. Forbindelse med formlen I ifølge krav 1, der er:



eller et farmaceutisk acceptabelt salt deraf.

15


16. Forbindelse med formlen I ifølge krav 1, der er:




eller et farmaceutisk acceptabelt salt deraf.

17. Fremgangsmåde til fremstilling af forbindelserne med formlen (I) ifølge et hvilket som helst af kravene 1 til 16 eller farmaceutisk acceptable salte deraf, der omfatter:

5 omsætning af en første amin med formlen 1, hvor R^1 er som beskrevet i et hvilket som helst af kravene 1 til 16,



med en anden amin 2, hvor A, L, m, n, X og R^2 er som beskrevet i et hvilket som helst af kravene 1 til 16,



i nærvær af en base og en urinstofdannende reagens for at danne forbindelsen med formlen (I).

18. Forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 16, eller et farmaceutisk acceptabelt salt deraf, til anvendelse som terapeutisk aktivt stof.

19. Farmaceutisk sammensætning, der omfatter en forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 16, eller et farmaceutisk acceptabelt salt deraf, og en terapeutisk inaktiv bærer.

20. Forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 16, eller et farmaceutisk acceptabelt salt deraf, eller en farmaceutisk sammensætning ifølge krav 19, til anvendelse til behandling eller forebyggelse af neuroinflammation, neurodegenerative sygdomme, smerte, cancer og/eller psykiske lidelser hos et pattedyr.

21. Forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 16, eller et farmaceutisk acceptabelt salt deraf, eller farmaceutisk sammensætning ifølge krav 19, til anvendelse til behandling eller forebyggelse af multipel sklerose, Alzheimers sygdom, Parkinsons sygdom, amyotrofisk lateral sklerose, traumatisk hjerneskade, neurotoksicitet, slagtilfælde, epilepsi, angst, migræne, depression, hepatocellulært karcinom, koloncancer,

ovariecancer, neuropatisk smerte, kemoterapi-induceret neuropati, akut smerte, kronisk smerte og/eller spasticitet forbundet med smerte hos et pattedyr.